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SUMMARY/ZUSAMMENFASSUNG  
 
SUMMARY 
 
Carbohydrates and their binding proteins (Lectins) play important role in all living organisms and 
the development of new analytical technologies in the past few years allowed us to partially 
decipher the significance of carbohydrates in biology. Moreover, the role of lectins in 
pathogenicity was pointed out in the last decade, revealing that lectins play a crucial role in 
bacterial infection through, for example, virulence and adherence to the host as well as in biofilm 
formation. In this work, various biophysical and structural techniques were employed to identify 
anti-biofilm agents for human-opportunistic, Gram-negative bacterium pathogens, such as 
Pseudomonas aeruginosa and Burkholderia cenocepacia, by targeting their lectins and studying 
the binding properties of lectin blockers upon binding on their desired target. Furthermore, a new 
lectin (PllA) from the entomopathogenic bacterium Photorhabdus luminescens was 
characterized; this resulted in a new tool for lectinology and biomedical research, as a probe for 
detecting α-galactoside-terminating glycoconjugates.  
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ZUSAMMENFASSUNG   
 
Kohlenhydrate und dessen Bindeproteine (Lektine) spielen eine wichtige Rolle in allen 
Lebewesen. Durch die Entwicklung von neuen analytischen Verfahren wird die Bedeutsamkeit 
von Kohlenhydraten in der Biologie ersichtlich. Es zeigt sich, dass Lektine bei der Pathogenität 
durch Bakterien in Bezug auf die Virulenz, Haftfestigkeit und deren Eigenschaft zur Biofilmbildung 
eine wesentliche Rolle spielen. In dieser Arbeit wurden verschiedene biophysikalische und 
strukturelle Techniken angewendet, um Biofilm verhindernde Wirkstoffe gegen opportunistische 
Erreger, wie den Gram-negativen Bakterien Pseudomonas aeruginosa und Burkholderia 
cenocepacia, zu erforschen. Dazu wurden die Bindeeigenschaften der Lektinblocker an 
entsprechenden Zielen untersucht. 
Außerdem wurde ein neues Lektin (PIIA) vom entomopathogenen Bakterium Photorhabdus 
luminescens charakterisiert. Es bindet an α-Galactoside und kann zur Erkennung von 
Glykokonjugaten in der Lektinology und in der biomedizinischen Forschung eingesetzt werden. 
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1. INTRODUCTION  
 
1.1. GLYCOBIOLOGY 
  
Glycobiology is the study of the structure, biosynthesis, and function of carbohydrates (glycans) 
in living organisms. Complex glycans are widely distributed in nature and play key roles in many 
biological processes (e.g. cell differentiation, cell–cell recognition, cell signaling, host–pathogen 
interaction during infection, host immune response, and membrane rigidity) (Figure 1).1 
Compared to genome and proteome, the investigation accomplished was less in the 
carbohydrate biology due to the complexity of carbohydrates and to the fact they are not 
encoded in the genome.2 The development of new technologies over the last few years 
has drawn attention to glycobiology and many recent studies have focused on the role of 
glycans in human health and in diseases, particularly cancer and infections. 
Figure 1. The roles of carbohydrates in biological processes. Carbohydrates are involved in cell 
recognition, adhesion, and signalling as well as in immune triggering. This figure was taken from 
http://www.cermav.cnrs.fr/sites/default/files/u1394/infectionen.jpg (28.04.2015).   
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1.2. GLYCOSYLATION AND ITS ROLE IN HUMAN BIOLOGY  
 
Glycosylation refers to the process by which sugar moieties are attached to proteins, lipids, and 
all substances resulting in structures called glycoconjugates. 10 monosaccharide units are the 
building blocks for complex oligosaccharide polymers in mammals (Figure 2). Glycan 
monosaccharides are connected through their anomeric centre to many hydroxyl groups, 
resulting in numerous linkages with linear or branched structures. Furthermore, the anomerization 
at the anomeric centre of each monomer ends with a high number of possible glycan epitopes.3 
Glycosylation is a critical biological process in many living organisms, especially in the folding 
and stabilization of proteins. In eukaryotes, more than 70 % of the proteins are glycosylated, 
whereas in prokaryotes it is still too early to predict the full extent of its protein glycosylation.4 
Protein N-linked (Asn), O-linked (Ser/Thr), and lipid glycosylation are the most common 
glycosylation mechanisms.  
 
Figure 2. The monosaccharide building units of mammalian glycans. Glucose (Glc), galactose (Gal), 
mannose (Man), fucose (Fuc), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), xylose 
(Xyl), glucuronic acid (GlcA), iduronic acid (IdA) and sialic acid (Sia). The more commonly used three-letter 
codes and the symbolic notations used by the consortium for functional glycomics are shown here. This 
figure has been adapted from reference3. 
 
N-linked glycosylation is a very prevalent form of glycosylation and dolichol-linked 
oligosaccharide precursor is required to transfer the sugar chain to the nascent protein using a 
multisubunit protein complex in the endoplasmic reticulum (ER) membrane of eukaryotes, called  
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oligosaccharyltransferase. In this process, a 14 carbohydrate-long common oligosaccharide 
precursor (2 N-acetylglucosamine, 9 mannose, and 3 glucose) is attached to the amide side chain 
of asparagine of the target peptide chain. Upon protein folding in ER, three glucose moieties split 
from the glycan part and then protein transfers to the Golgi apparatus. In the Golgi apparatus, 
further modification may occur through remodelling of sugar moieties with other sugars, such as 
N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), galactose (Gal), fucose (Fuc) 
and sialic acid.2,1 
O-linked glycosylation is simpler since the dolichol-linked oligosaccharide precursor is not 
required. By O-linked glycosylation, GalNAc makes a covalent bond to the hydroxyl of serine or 
threonine of the target peptide chain in the Golgi apparatus via a GalNAc transferase (GalNAcT) 
enzyme. Afterwards, several sugars such as Fuc, Gal, GlcNAc and sialic acid are added to the 
GalNAc and elongate the sugar chain.1 
Lipid glycosylation is carried out by the addition of either glucose or galactose to 1-hydroxy group 
of C-18 ceramide, producing a simple glucosylceramide (GlcCer) or galactosylceramide (GalCer). 
From these building blocks several complex structures can be generated, such as 
lactosylceramide (LacCer), and globotriaosylceramide (Gb3).5,6 
 
Human A, B, and O blood-group antigens represent the essential role of glycosylation among 
human beings. The O antigen (also called the H antigen) consists of three sugar moieties that 
are attached to a ceramide lipid or serine/threonine residue of proteins on the surface of the 
erythrocytes. A and B antigens differ from the O antigen by having an additional α-linked GalNAc 
or Gal on the terminal Gal residue, respectively (Figure 3). All people have enzymes that 
synthesise the O antigen, whereas some with types A, B and AB have, in addition, GalNAc 
transferase or Gal transferase or both transferases, respectively.7  
Another example of a glycosylation difference among mammalians is the so-called α-Gal epitope 
(Gal-⍺-1,3-Gal-β-1,4-GlcNAc). α-Gal is a ubiquitous antigen in non-primate mammals and new-
world monkeys. This epitope is absent in humans and old-world monkeys due to the evolutionary 
loss of the galactosyltransferase gene that is responsible for α-Gal synthesis. The human body  
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has additionally developed antibodies against the α-Gal epitope, which causes a severe immune 
rejection upon xenotransplantation.8,9 
 
Figure 3. The human ABO blood-group antigens. The presence or absence of certain glycosyltransferase 
leads to a different glycosylation pattern for human erythrocytes, resulting in different antigen structures 
and blood groups. 
 
What is the impact of glycosylation on human diseases?  
 
A complex mechanism controls the biosynthesis of N-linked and O-linked glycosylation in ER and 
in the Golgi apparatus through several manifestations of glycosyltransferase and glycosidase, 
resulting in numerous carbohydrate structures, varying in different species, cell types, and tissue 
types. The regulation of this biosynthesis depends on serval parameters, such as the level of 
gene expression, enzyme protein activity and localization, and through substrate and co-factor 
concentrations at the synthesis site.10 
 
Diseases are thus accompanied by a change in the glycosylation pattern where the relative 
proportions of carbohydrate structures are often characteristically different from healthy ones.  
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These changes can also enable us to assess the stage of the disease and to give a diagnosis. In 
liver cirrhosis and hepatitis, transferrin and α-1-acid glycoprotein show a change in their 
glycosylation repertoire, manifested by increased branching or fucosylation.10,11 Contrary to this, 
a reduction in serum IgG galactose content has been reported in rheumatoid arthritis patients due 
to a decrease in Gal transferase activity in the antibody-producing B cell.12  In tumorigenesis, 
glycan is excessively expressed in different forms but they still have the complete or incomplete 
sequence of sugars. In addition to this, some over-expressed glycans may contain a truncated 
form of oligosaccharide. For example, there can be a high level of Tn antigen and LewisX&Y 
expression in breast and lung cancer cells, respectively. By contrast, reduced glycan expression 
has been reported in bladder cancer where the activity of the ABO transferases decreases 
leading to less presentation of the ABO antigens.13 
Some of the mechanisms underlying glycoprotein alterations in disease have recently been 
elucidated and glycans are therefore now regarded as biomarkers for many diseases.14 Hence, 
there is a current need to improve the analytic tools for glycan, which will in turn lead to a more 
accurate diagnosis.   
 
1.3. Glycomics  
 
 
Glycomics describes the complete repertoire of the glycans that are produced under specified 
conditions of time, location, and environment.8 The complexity of glycans which has a bearing on 
glycoconjugates makes their analysis a challenge. Mass spectrometry (MS), high-pressure liquid 
chromatography (HPLC), and lectins are the common tools that are currently used in glycomics.  
Mass spectrometry is the most widely used technique in glycomics to analyze complex glycans. 
The drawback of this technique, however, is the requirement for glycans to be liberated from their 
glycoconjugates, and this slows down the analytical process. Moreover, diverse glycan isomers 
cannot be analyzed by MS. HPLC is another common method for glycan analysis. Here, the 
separation depends on carbohydrate chemistry. The reducing end after N-linked glycan release 
is tagged with different tracers to assess the visualization and to enable a comparison between 
two samples.3 A more specific technique that assigns carbohydrates according to their  
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isomerizations is a lectin microarray. Lectins are carbohydrate-binding proteins that are neither 
enzymes nor antibodies.15 They are ubiquitous in nature and highly specific for sugar moieties. In  
lectin microarrays, the well-defined lectins, mostly plant-derived with different carbohydrate 
specificities, are immobilized onto a solid support and used for profiling complex glycan features 
without the need for the liberation of glycans. This method has been intensely used in medical 
fields for the analysis of disease-related biomarkers, such as when drastic glycosylation changes 
occur along with tumorigenesis and metastasis.16–18 Despite the success of lectin microarrays, 
several issues must still be resolved to make this technology even more useful in glycomics. First, 
most of the characterized lectins are of plant origin with unreliable availability. Second, many 
lectins often have a broader carbohydrate specificity which complicates the interpretation of the 
data by these lectins. Third, less common glycans, such as sulphated glycans, are still lacking a 
lectin probe. There is therefore an urgent need to characterize new lectins, which can be 
recombinantly produced in bacterial cells, or to engineer the existing lectins to improve their 
specificity and affinity to solve the above obstacles.19 
 
  
1.4. Lectins and their role in microbial pathogenicity 
 
 
Lectins play numerous biological roles, for example, cell adhesion and recognition (see figure 1). 
They contain a carbohydrate-recognition domain (CRD) that recognizes and binds their specific 
carbohydrate ligand. 
Lectins are also expressed by microbes, such as viruses, bacteria, fungi, and protozoa, and were 
initially detected based on their tendency to aggregate or to induce the hemagglutination of 
erythrocytes.20 In the 1970’s, Nathan Sharon and colleagues described for the first time how 
lectins facilitate the attachment or adherence of bacteria to host cells, which is a prerequisite for 
bacterial colonization and infection. The trimeric influenza viral hemagglutinin (HA) is an example 
of a viral lectin which binds specifically to the sialic acid on the host cells and mediates 
endocytosis and the pH-dependent fusion of the viral envelope with the endosomal membrane, 
leading to the eventual release of the viral RNA into the cytosol. Parasite invasion to their host  
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cells is also mediated by lectins, such as the erythrocyte-binding antigen-175 (EBA-175) in 
Plasmodium falciparum (malaria). EBA-175-glycan binding triggers the invasion of merozoites  
into red blood cells, where they develop and subsequently release newly formed merozoites into 
the bloodstream. Similar to viral and parasite lectins, bacterial lectins are involved first in cell 
adhesion and then in invasion of host cells (Table.1). In addition to this, some bacterial lectins 
are toxins such as the cholera and Shiga toxins in Vibrio cholera and Shigella dysenteriae, 
respectively. They contain both a CRD and a catalytic domain, where the CRD binds to the 
terminal glycan of the glycolipid which mediates the endocytosis into the host cells and the 
catalytic domain inactivates a crucial function inside the cells, leading to cell death.20 
Moreover, bacterial lectins contribute to bacterial pathogenicity through biofilm formation. LecA 
(also called PA-IL) and LecB (also called PA-IIL) from Pseudomonas aeruginosa (P. aeruginosa) 
and BC2lA,B,C from Burkholderia cenocepacia (B. cenocepacia) play a crucial role in biofilm 
formation, leading to an increase in bacterial resistance to conventional antibiotics.21–23 Thus, the 
targeting of these bacterial lectins constitutes a new strategy to fight bacterial resistance, 
especially in P. aeruginosa.24  
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Table 1. Examples of bacterial lectins and their carbohydrate specificities and sites of infection. This table 
was adapted from reference 20. 
 
Microorganism Lectin Glycan-receptor specificity Site of infection 
Actinomyces 
naeslundii 
fimbriae Gal-β-1,3-GalNAc-β- oral 
Bordetella pertussis filamentous 
hemagglutinin 
(FHA) 
sulfated glycolipids, heparin ciliated epithelium 
in the respiratory 
tract 
Borrelia burgdorferi ErpG protein heparan sulfate endothelium, 
epithelium, and 
extracellular matrix 
Campylobacter jejuni flagella, LPS Fuc-α-1,2-Gal-β-1,4-GlcNAc-β- 
(H-antigen) 
intestinal cells 
Escherichia coli P fimbriae Gal-α-1,4-Gal-β- urinary tract 
S fimbriae gangliosides GM3, GM2 neural 
type-1 fimbriae Man-α-1,3(Man-α-6-Man-α-1,6) 
Man 
urinary tract 
K99 fimbriae gangliosides GM3, Neu5Gc-α-
2,3-Gal-β1,4-Glc 
intestinal cells 
Haemophilus 
influenzae 
HMW1 adhesin Neu5Ac-α-2,3-Gal-β1,4 
GlcNAc-β-, heparan sulfate 
respiratory 
epithelium 
Helicobacter pylori BabA sialyl Lewisx stomach 
 SabA Lewisb stomach and 
stomach 
duodenum 
Mycobacterium 
tuberculosis 
heparin-binding 
hemagglutinin 
adhesin (HBHA) 
heparan sulfate respiratory 
epithelium 
Neisseria gonorrhoeae Opa proteins 
protein 
LacCer; Neu5Ac-α-2,3-Gal-β-
1,4-GlcNAc-β-, syndecans, 
heparan sulfate 
genital tract 
Pseudomonas 
aeruginosa 
type IV pili asialo GM1 and GM2 respiratory tract 
 LecA Gal-α-1,4-Gal-β-1,4-	glucosyl 
ceramide (Gb3) 
 
respiratory tract 
 LecB Fucose and Lewisa respiratory tract 
Staphylococcus 
aureus 
signal peptide of 
panton valentine 
leukocidin 
heparan sulfate connective tissues 
and endothelial 
cells 
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1.5. Pseudomonas aeruginosa lectins  
 
  
P. aeruginosa is a Gram-negative bacterium and one of the ESKAPE pathogens (Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species), which are the leading cause of 
nosocomial infections throughout the world, and most of them are multi-drug resistant.25 P. 
aeruginosa causes serious infections in patients who are immunocompromised or suffer from 
cystic fibrosis (CF). It protects itself from the host immune system and antibiotics by building up 
a biofilm which is a matrix of extracellular polymeric substances (i.e. rhamnolipids, 
exopolysaccharides, extracellular DNA, and several proteins).26 Among the extracellular proteins 
are two soluble lectins, called LecA and LecB, which were briefly mentioned in the previous 
section. 
 
1.5.1. LECA (PA-IL)  
 
 
LecA is one of the P. aeruginosa lectins that are found on bacterial surfaces as well as 
extracellularly. Its crystal structure reveals that LecA contains one calcium ion in each binding 
pocket, mediating the recognition to the carbohydrate ligand, and a hydrophobic region close to 
the carbohydrate recognition domain, which is formed by the amino acids H50 and P51 (Figure 
4 A,B).21,24 The 12.8 kDa LecA specifically binds to D-galactose or its glycoconjugates and it has 
recently been reported that LecA binds to Gb3 sphingolipid, which mediates the bacterial 
engulfment into host cells.27 Like other lectins, LecA shows a low binding affinity to its natural 
ligand D-galactose (1, figure 4C) with Kd of 87.5 μM.28 Several LecA inhibitors have been 
developed, and the most potent monovalent inhibitors are the β-linked galactosides with aromatic 
aglycon, such as naphthyl β-thio-D-galactoside (2, figure 4C) with a Kd value of 6.3 μM.29 This 
improvement in binding affinity is due to the additional CH−π interaction between the aromatic 
ring of the binding ligand and H50 at the binding pocket (Figure 4B).29 In contrast to monovalent 
inhibitors, the multivalent LecA inhibitors show a potent inhibitory effect with Kd values in the 
nano-molar range.24 To date, the most potent divalent LecA inhibitor is compounds 3 which has  
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been designed by Pieters and co-workers where they bridged the space between two binding 
galactose residues by using a rigid spacer, resulting in a high-affinity binder with a Kd of 28 nM 
(Figure 4A,C).30  
 
  
Figure 4. A) Homotetramer of LecA (cartoon coloured by chain, PDB code 4YWA) co-crystalized with 
compound 3 and one Ca2+ ion per binding site (green spheres). B) LecA binding pocket with naphthyl β-
thio-D-galactoside (2, PDB code 4A6S). C) Mono- and multivalent- carbohydrate-based inhibitors of the 
lectin LecA. The Kd values and structure of compound 3 were taken from reference 24. Compound 2 and 3 
are depicted as sticks coloured by the elements (N: blue, O: red, S: yellow, C: grey); LecA amino acids (N: 
blue, O: red, C: marine). 
 
 
1.5.2. LECA ORTHOLOGS IN OTHER PATHOGENIC BACTERIA 
 
 
Only one gene (i.e. plu2096) has been reported as a potential gene that encodes LecA homolog 
protein in the insect pathogen bacterium Photorhabdus luminescens and was later confirmed to 
be a galactose-binding lectin.31,32 
O
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O
HO
HO
OH
HO
S
established its simultaneous binding to two adjacent binding
sites in one LecA tetramer.279 Numerous large dendrimer-based
galactosides with diﬀerent core and linker structures were
synthesized and evaluated for LecA binding and antibioﬁlm
eﬀects on P. aeruginosa (reviewed in refs 280,281). Recently,
Vidal and co-workers reported a thoroughly characterized study
with the calixarene-based ligand 63.282 Despite a very high
aﬃnity of this ligand toward LecA (Kd 176 nM), very high
concentrations of 5 mM were necessary to observe inhibitory
eﬀects in in vitro bioﬁlms and mouse infection models.
Unfortunately, the potent divalent ligand 62 with ideal
positioning of the binding paratopes also showed only modest
activity in an assay testing bacterial viability in a bioﬁlm
experiment.279
The carbohydrate-binding protein LecB (PA-IIL) was ﬁrst
isolated by Gilboa-Garber et al. in 1977.50 The carbohydrate
speciﬁcity of this 11.8 kDa lectin was reported with a preference
for L-fucose over D-mannose and others.261 The crystal
structure of LecB shows the protein as a noncovalent
homotetramer where the C-terminus of each polypeptide
chain is involved in the carbohydrate recognition site of the
neighboring chain (Figure 20A).283 In LecB, two protein-bound
Ca2+-ions mediate the binding to one carbohydrate ligand by
coordination to the 2-, 3-, and 4-hydroxyl groups in fucose. The
relative orientation of the three hydroxyl groups explains the
speciﬁcity of LecB.284 In contrast to its weak ligand D-mannose,
the very high aﬃnities to L-fucose (57, Kd 2.9 μM)
285 or its
methyl glycoside (64, Kd 430 nM)
286 (Figure 21) were
explained with the additional lipophilic interaction of the C-6
methyl group with the protein (Figure 20B). Methyl α-D-
mannoside (56, Kd 71 μM
286) forms an additional hydrogen
bond of the 6-hydroxy group with Ser23 in the crystal
structure.284 Using a glycan array, Imberty and co-workers
identiﬁed the best known monovalent LecB ligand, the natural
trisaccharide Lewisa (65, Kd 212 nM), which forms additional
interactions via its N-acetyl glucosamine moiety (Figure
20C).285 Because the galactose residue in Lewisa has little
contact with the protein, Roy and co-workers developed
truncated disaccharides (e.g., 66)287 and oxazole-substituted
fucosides (67)288 with comparable aﬃnity for LecB as
compared to Lewisa. To further improve their aﬃnity several
divalent,287 oligovalent,285 and dendrimer-based287−290 com-
pounds were designed and evaluated as LecB inhibitors.
Tetravalent glycopeptide 68 (IC50 140 nM) showed a 10-fold
increase in potency per fucose residue compared to its
monovalent glycopeptide epitope and inhibited bioﬁlm
formation and disrupted established bioﬁlms at 50 μM.290
To reduce the potential to aggregate or cross-link bacteria
due to multivalency of inhibitors and lectins and in order to
improve physicochemical properti s for a putative application,
small drug-like molecules with monovalent epitopes could be
beneﬁcial. In addition, multivalent inhibitors with natural
epitopes could interfere with mannose- or fucose-binding
host lectins such as human pathogen-recognition receptors
(PRRs).
By modiﬁcation of the low aﬃnity ligand methyl α-D-
mannoside (56) with amides and sulfonamides, we achieved up
to 20-fold higher aﬃnities with 69 (Kd 18 μM) and 70 (Kd 3.3
μM) (Figure 21).291 Both compounds were shown to inhibit
LecB-mediated bacterial adhesion. The binding mode of
sulfonamide 70 was determined by X-ray crystallography
(Figure 20D) and the binding mode of cinnamide 69, ﬁrst
unclear,291 was recently experimentally veriﬁed.292 In an
extended structure−activity relationship study, more potent
Figure 19. Divalent and multivalent inhibitors of the lectin LecA.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.5b01698
J. Med. Chem. 2016, 59, 5929−5969
5944
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1.5.3. LECB (PA-IIL) 
 
LecB (PA-IIL) is a 11.8 kDa lectin shows a preference for L-fucose over D-mannose and other 
sugars (Figure 5C). The crystal structure of LecB shows that it is a homotetrameric lectin with two 
calcium ions in each CRD (Figure 5A). These ions help the carbohydrate ligand to accommodate 
in the binding pocket by establishing interactions with 2OH, 3OH and 4OH of L-fucose and D-
mannose (Figure 5B).33 Most of LecB present in the cytosol and it was also found extracellularly 
in the biofilm.22 The secretion mechanism of LecB is still unknown and transient N-glycosylation 
of LecB is hypothesized as a key player in the secretion process.34 As mentioned before, LecB is 
involved in biofilm formation: the proof of this concept was demonstrated in 2005 where the LecB 
knock-out P. aeruginosa strain was not able to grow the biofilm.22 Through a sequence analysis 
of more than 200 P. aeruginosa strains originating from natural or clinical isolates, LecB gene 
was found in two main clusters which were assigned as PAO1-like and PA14-like. The sequence 
variation between PAO1 and PA14 was 14 %, whereas the fucose binding pocket is conserved 
in all strains.35 Thus, the targeting of the conserved fucose binding pocket of LecB is currently 
being promoted as a new strategy to inhibit biofilm formation.24,36 Up until now, the natural Lewisa 
(6, figure 5C) is the most potent monovalent LecB inhibitor with a Kd value of 212 nM. More 
improvement in its potency was achieved by designing divalent, oligovalent, and dendrimer-
based inhibitors.24 For instance, tetravalent glycopeptide (7, figure 5C) showed a 10-fold increase 
(IC50 140 nM) in potency per L-fucose compared to its monovalent epitope.37 However, the 
multivalent inhibitors have some drawbacks when using them as a drug since they may mediate 
the aggregation and cross-linking of bacteria and their physicochemical properties also need 
further optimization.38 Then, several monovalent LecB inhibitors were designed, based on L-
fucose or Lewisa disaccharide core (α-Fuc-1,4-GlcNAc), but they failed to reach methyl ⍺-L-
fucoside or Lewisa potency.39,40 Therefore, since 2013 our research group has been focusing on 
designing monovalent drug-like inhibitors for LecB, based on low-affinity D-mannoside. The 
introduction of sulfonamides at C6 of methyl α-D-mannoside (8, figure 5C) showed a remarkable  
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improvement in the Kd value from 71 to 3.3 µM, respectively.41 Then, the hybrid structure (9, figure 
5C) was synthesized with the important features of L-fucose and D-mannose for LecB binding 
and the Kd value was 16 µM.42 A further extension of the hybrid structure was done by adding 
sulfonamides at C6, which led to a further improvement in the Kd value, reaching the nanomolar 
range (e.g. compound 10).43 
Figure 5. A) Homotetramer of LecB (cartoon coloured by chain, ligand not shown, PDB code 1OXC) with 
two Ca2+ ions per binding site (green spheres). B) LecB binding pocket with L-fucose (4, PDB code 1OXC). 
C) Mono - and multivalent- carbohydrate-based inhibitors of the lectin LecB. The Kd values and the structure 
of 6 and 7 were taken from reference 24. Compound 4 is depicted as sticks coloured by the elements (N: 
blue, O: red, C: grey) ; LecB amino acids of chain A (N: blue, O: red, C: marine); LecB amino acids of chain 
B (N: blue, O: red, C: green). 
 
1.5.4. LECB ORTHOLOGS IN OTHER PATHOGENIC BACTERIA 
 
 
LecB-like sequences have been identified in the genomes of some opportunistic bacteria, such 
as Ralstonia solanacearum (R. solanacearum), Chromobacterium violaceum, (C. violaceum) and  
 
O
HOOH
OH
OH
OMe
O
HOOH
OH
OH
O
HOOH
OH
H
N
OMe
S
O O
O
HOOH
OH
H
N
S
O O
S
The ﬂagellar cap protein FliD was shown to be directly
involved in adhesion to mucin glycoproteins.45 Its expression is
controlled by the transcription factor FleQ which is under
direct control of the c-di-GMP regulatory pathway. It was
further demonstrated that FliD binds Lewisx (77) and sialyl-
Lewisx (78) (Figure 22)304 and that FliD-mediated adhesion of
P. aeruginosa to lung epithelial cells is enhanced after TNF-
induced sialyl Lewisx (78) overexpression.305 This hyper-
sialylation in bronchial mucins is an inﬂammatory response in
CF patients.306
The adhesin CdrA is controlled through the c-di-GMP
regulatory system, and the structure of this 220 kDa large
protein was predicted as a β-helix with a sugar-binding site at
the N-terminal tip.47 Elevated expression levels of CdrA were
Figure 21. Natural and synthetic carbohydrate-based inhibitors of the lectin LecB.
Figure 22. Gangliotetraosyl ceramide (asialo GM1) (75) as identiﬁed ligand for the adhesin PilA located on type IV pili. Derivative 76 was shown to
inhibit the P. aeruginosa type IV pili binding to asialo-GM1. Natural carbohydrate ligands Lewisx (77) and sialyl Lewisx (78) of adhesin FliD.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.5b01698
J. Med. Chem. 2016, 59, 5929−5969
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Burkholderia cenocepacia (B. cenocepacia).44–47 Like LecB, RS-IIL from R. solanacearum and 
CV-IIL from C. violaceum share the same tetrameric arrangement of subunits with the presence 
of two calcium ions in the CRD. They show a binding affinity to their ligands in the micromolar 
range and recognize both L-fucose and D-mannose.44,47 In contrast to LecB, BC2L-A from B. 
cenocepacia is a dimeric lectin with two calcium ions in the binding site and shows a high affinity 
to D-mannose over L-fucose.45 As mentioned in subchapter 1.4, BC2L-A is involved in biofilm 
formation; inhibiting this lectin is a current ongoing work to develop potent mono- and multivalent- 
inhibitors.48–50 Another well-characterized B. cenocepacia lectin is the fucose-binding BC2L-C. It 
is a hexameric superlectin with an additional TNF domain binding fucose in addition to the 
mannose-binding LecB domain at the C-terminal.  BC2L-B is also a B. cenocepacia lectin with an 
additional N-terminal domain, but without homology to known domains; this lectin has not been 
characterized yet. 46,51 
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2. AIM OF THE THESIS 
 
 
 
2.1. To find new antibacterial agents for human pathogenic bacteria 
by targeting their lectins 
 
25,000 deaths and extra costs of €900 million in the European Union in 2007 were caused by 
antibiotic-resistant strains in health care units and nosocomial infections.52 Furthermore, the 
number of newly approved antibiotics decreased in the last decades, leading to a huge gap 
between the number of existing antibiotics and the number of antibiotic-resistant strains. There is 
thus an urgent need to speed up the development of new anti-infectives as well as to develop 
new strategies to fight bacterial resistance. The targeting of extracellular lectins is one of the new 
strategies to control infections by Gram-negative bacteria through inhibiting biofilm formation; 
there is here no necessity to overcome the bacterial membrane and resist its efflux pumps. The 
aim of this work is to find more potent or new classes of inhibitors for some Gram-negative human 
pathogen bacterium lectins by screening several natural, semi-synthetic and synthetic libraries. 
 
2.2. To characterize new lectins from pathogenic bacteria 
 
The need for the characterization of new lectins with a sharp specificity has already been 
highlighted in subchapter 1.3, which described the improvement of glycome analysis using lectin 
microarrays. Together with the absence of characterized P. aeruginosa LecA homologs, the 
identification, expression and analysis of LecA homologs from other pathogenic bacteria is the 
second aim of this work. 
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3.1. IDENTIFICATION OF PSEUDOMONAS AERUGINOSA LECB 
INHIBITORS USING A FLUORESCENCE POLARIZATION-BASED 
HIGH-THROUGHPUT ASSAY 
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Introduction 
 
 
Besides the existing approaches for LecB inhibition (see subchapter 1.5.3), we decided to pursue another 
strategy, namely, to explore new classes of LecB inhibitors by screening natural product and semisynthetic 
as well as non-carbohydrate libraries. Natural products are considered by many pharmaceutical companies 
to be a major source of antibiotics and anti-tumour drugs, where the diversity of these compounds makes 
them an attractive source for potential new drugs.1,2 Myxobacteria is one of the best known natural product 
producers for it has a broad spectrum of secondary metabolites that show many bioactivities (e.g. anti-
bacterial, anti-fungal, anti-tumour, anti-biofilm and other bioactivities).3 29 % of myxobacterial metabolites 
demonstrate anti-bacterial activity through targeting different biological processes in other bacteria. For 
instance, etnangien and orallopyronin target DNA and RNA polymerase, respectively, althiomycin inhibits 
protein synthesis, and myxovalargin damages cell membrane. Carolacton is the only myxobacterial 
metabolite that shows an anti-biofilm activity, which was reported in a Gram-positive Streptococcus mutans.4  
 
In this study, we present our strategy for the discovery of LecB inhibitors. The first step in such a screening 
study is the establishment of an appropriate system which allows the identification and characterization of hit 
compounds. We therefore developed a simple but robust fluorescence polarization-based binding assay, 
using a tracer with a red-shifted fluorophore for LecB, and demonstrated its utility for testing several libraries, 
including concentrated natural product extracts. Polarization–based high-throughput assays have been used 
in many studies and have shown a feasibility for high-throughput screening.5–7 Using this assay, a set of ∼1944 compounds (including myxobacterial pure metabolites and semi/full-synthetic compounds) were 
screened. In addition to this, 2200 crude extracts from myxobacteria strains underwent the screening process 
and then one of the active extracts was investigated to find the active compound.  
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Experimental details 
 
Chemicals  
L-fucose and methyl α-L-fucoside (2) were purchased from Dextra Laboratories (UK); SPECS-308, -432, -
387, -605, and -836 from SPECS, Netherlands; OTAVA glycomimetic focused library from OTAVA Ltd. 
(Canada).  
 
LecB and LecA expression and purification 
 
LecBPAO1 and LecAPAO1 were produced according to the previously published protocols.8,9 In short, E. coli 
BL21 (DE3) carrying the plasmid of either LecB or LecA were grown in 1 L of LB medium (supplemented with 
100 μg mL-1 ampicillin) to an OD600 = 0.5-0.6 at 37 °C and 180 rpm. The expression was induced with the 
addition of IPTG to a final concentration of 0.5 mM (LecB) or 0.25 mM (LecA) and the bacteria were then 
further cultured for 4 h at 37 °C (LecB) or 30 °C (LecA) and 180 rpm. The cells were harvested by 
centrifugation (9000 x g, 10 min) and the pellet was washed with TBS/Ca (20 mM Tris, 137 mM NaCl, 2.6 
mM KCl at pH 7.4, supplemented with 100 µM CaCl2). The cells were resuspended in 60 mL TBS/Ca with 
PMSF (1 mM) and lysozyme (0.4 mg mL−1) and subsequently disrupted by 5 cycles in a microfluidic 
homogenizer (Microfluidics Corp., USA). Cell debris was removed by centrifugation (19’000 x g, 60 min) and 
the supernatant was loaded on mannosylated or galactosylated sepharose CL-6B for LecB and LecA, 
respectively.10 The column was washed with TBS/Ca and either LecB or LecA was eluted by 100 mM D-
mannose or D-galactose, respectively. The eluted fractions were extensively dialyzed against distilled water 
and then TBS/Ca buffer. The concentration was determined by UV absorbance at 280 nm using a calculated 
molar extinction coefficient of 6990 or 27960 M−1 cm−1 for LecB and LecA, respectively. 
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Direct binding of the tracer 1 to LecB 
 
10 μL of tracer 1 (20 nM) in TBS/Ca was mixed with 10 μL serial dilutions (234 - 0.014 μM, i.e., a final 
concentration of 117 μM to 0.007 μM) of LecB in TBS/Ca in triplicates in black 384-well microtiter plates 
(Greiner Bio-One, Germany, cat no 781900). After incubation for 4 h at r.t., the blank corrected fluorescence 
intensity was recorded, using a PheraStar FS microplate reader (BMG Labtech GmbH, Germany) with 
excitation filters at 590 nm and emission filters at 675 nm, and fluorescence polarization was calculated. The 
data were analyzed using a four-parameter fit of the MARS Data Analysis Software (BMG Labtech GmbH, 
Germany). A minimum of two independent measurements on two plates was performed. 
 
 
Testing of LecB stability at different concentration of DMSO 
 
Four serial dilutions (666 - 0.085 µM) of methyl ⍺-L-fucoside (2) were prepared in different DMSO 
concentrations (i.e. 0, 2, 4, and 10 %). Thereafter, 10 μL of each serial dilution was added in triplicates to a 
384-well plate (Greiner Bio-One, Germany, cat no 781900). Then, 10 μL of LecB and 1 were added to each 
well at final concentrations of 150 nM and 10 nM, respectively. After incubation for 4 h at r.t., the fluorescence 
polarization was determined using a microplate reader, as described above. The data were analyzed using 
a four-parameter fit of the MARS Data Analysis Software. 
 
 
Screening libraries using polarization–based high-throughput assays 
 
Each analyte was diluted in a TBS/Ca buffer, as shown in table 1. Pre-and fractionated myxobacterial extracts 
were additionally centrifuged for 1 h at 4000 rpm (Hettich® UNIVERSAL 320 R; Hettich 2 X 500 g rotor, cat 
no. 1460, Hettich GmbH & Co. KG, Tuttlingen, Germany) to remove the insoluble  components. 10 µL of 
diluted samples were added in duplicates or triplicates to a 384-well plate (Greiner Bio-One, Germany, cat 
no 781900). Afterwards, 10 µL of either LecB or LecA with Cy5-conjugated α-L-fucoside (1) for LecB or FITC-
conjugated α-D-galactose (9)9 for LecA was added to each well at final concentration of 150 nM (LecB) or 20 
µM (LecA) and 10 nM of tracer. The final concentration of each library is listed in table 1. After incubation for 
4 h or 1 h for LecB or LecA, respectively, at r.t., the blank corrected fluorescence intensity was recorded, 
using a PheraStar FS microplate reader with excitation filters at 590 or 485 nm (for LecB and LecA tracer, 
respectively) and emission filters at 675 nm or 535 nm (for LecB and LecA tracer, respectively), and the 
fluorescence polarization was calculated. The data were analyzed using a four-parameter fit of the MARS 
Data Analysis. 
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The percentage of inhibition for the FP assays was calculated according to equation 1.  
 
 
 
 
 
 
Equation 1. Calculation of the percentage of inhibition of the tested compound. 
 
 
 
Generally, compounds enhancing or quenching the total fluorescence intensity in a dose-dependent manner 
(deviating value of fluorescence intensity > 20 % from the controls) were excluded from further investigation.5 
 
 
 
Calculation of the Z factor 
 
The Z factor is a dimensionless value used to evaluate the quality of the HTS assay, using equation 2: a 
good assay should have a Z factor of between 0.5 and 1.11 
 
 
 
 
 
 
Equation 2. Z factor calculation. SD refers to the standard deviation. 
 
%	#$	%&ℎ%(%)%#& = 	 +,-&	#$	&,.-)%/,	0#&)1#2 − +,-&	#$	4-+52,	+,-&	#$	&,.-)%/,	0#&)1#2 − +,-&	#$	5#4)%/,	0#&)1#2 	6	100 
9 = 	1 − 3;<	#$	4-+52, + 3;<	#$	0#&)1#2|+,-&	#$	4-+52, −+,-&	#$	0#&)1#2| 
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Table 1. All screened libraries with their stock, diluted concentrations and the final concentration 
in the screening assay.  
Library Number of analytes 
Concentration 
of stocks 
 
Dilution 
ratio in 
TBS/Ca 
buffer 
Final 
concentration 
in assay  
Provider/sup-
plier 
Test plate 48 100 X (see table S2) 1:50 1 X 
Prof. Bilitewski 
(HZI) 
Pure 
myxobacterial 
compounds 
259 10 mM (DMSO) 1 mM (DMSO) 
1:10 
1:50 
500 µM 
10 µM 
Prof. Müller 
(HIPS) 
Myxobacterial 
extracts  2200 
100 % of 
methanolic 
crude extract  
1:20 
2.5 % of 
methanolic 
crude extract 
Prof. Müller 
(HIPS) 
Fractionated 
myxobacterial 
extracts  
863 100 % of each fraction 1:20 
2.5 % of each 
fraction 
Prof. Müller 
(HIPS) 
Hydrophilic 
SPECS library  1120 10 mM (DMSO) 1:10 500 µM 
Prof. Bilitewski 
(HZI) 
ExNCL 1-4 340 1 mM (DMSO) 1:25 20 µM Prof. Müller (HIPS) 
OTAVA 
(LecB) 134 10 mM (DMSO) 1:100 50 µM OTAVA Ltd 
OTAVA 
(LecA) 134 10 mM (DMSO) 1:50 100 µM OTAVA Ltd 
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Cultivation and extraction of secondary metabolites of Cystobacter violaceus Cbvi28  
 
 
50 mL of pre-culture of Cystobacter violaceus Cbvi28 strain (C. violaceus Cbvi28) was prepared by 
inoculating 50 mL of the media (Table S3) with a piece of agar that contained C. violaceus Cbvi28 
cells. The pre-culture was incubated for 3 days at 30 °C and 180 rpm. Thereafter, the main-culture 
with 2 % of XAD-16 resin was inoculated by 5 % of its volume with the pre-culture and then incubated 
for 10 days at 30 °C and 180 rpm. Cells were harvested afterwards by centrifugation at 4000 rpm for 
40 min and resuspended in 37.5 % of the main-culture volume with acetone and stirred for 3 h at r.t. 
Then, the whole extract was filtered (3 hw filter paper, Sartorius AG, Germany), and rotatory 
evaporated at 40 °C and 300 mbar. The sample was finally dissolved in 1.1 % of the main-culture 
volume with methanol and stored at - 20 °C for further use. 
 
Small-scale LC-MS fractionation of extract  
All fractionation was performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH (C18, 
100 x 2.1 mm, 1.7 μm) column by the injection of five μL of the methanolic sample. Separation was 
achieved by a linear gradient with (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 550 
μL/min and 45 °C. The gradient was initiated by a 0.27 min isocratic step at 5 % B, followed by an 
increase to 95 % B in 18 min to end up with a 1.5 min flush step at 95 % B before equilibration under 
the initial conditions. Coupling the HPLC to the MS was supported by an Advion Triversa Nanomate 
nano-ESI system attached to a Thermo Scientific Orbitrap. Mass spectra were acquired in a centroid 
mode ranging from 200 – 2000 m/z at a resolution of R = 30000. The flow was split to 500 nL/min 
before entering the ion source. The Nanomate transfers the remaining LC flow into a 96 well plate 
within a time range from 0.6 to 20.6 min. Each well is filled for 10 μL yielding 93 wells in total. The 
well plate is dried using a Genevac centrifugal evaporator (Genevac Ltd., Suffolk, UK) and used for 
bioactivity assay afterwards.  
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Large-scale HPLC fractionation of extract 
The fractionation was performed on a Dionex Ultimate 3000 RSLC system using NUCLEODUR® 
C18 Gravity-SB (C18, 250 X 10 mm, 5 µm) by injection of 1.3 mL of 1:2.6 (H2O:ACN) contains ∼ 50 
mg of dry extract. The separation was achieved by a linear gradient with (A) H2O +0.1% FA to (B) 
ACN + 0.1% FA at flow rate 8 mL/min. The gradient was initiated by 1 min of isocratic step at 5 % of 
B, followed by an increase to 95 % of B in 20 min and remains at 95 % of B for 4 min to end up with 
a 5 min flush step to reach 5 % of B. During this separation, more than 100 fractions in 1.5 - 2 mL 
were collected. The volume of fractions was not equal at the beginning since the collection was 
manually performed but we could then automate this collection process. Afterwards, the fractionated 
samples were dried using a Thermo Savant SpeedVac SPD111V Centrifugal Evaporator 
(ThermoFisher, Germany) and subsequently dissolved in 10 µL of DMSO and transferred into 96 
well plates. The plates were stored at - 20 °C for bioactivity assay afterwards.  
 
 
Molecular Docking  
SPECS-836 was docked into the binding site of LecB using PLANTS v1.1 software.12 The calculation 
of charge and energy minimization of the protein and tested compounds was done using Molecular 
Operating Environment (MOE), 2014.09. Thereafter, the standard docking procedure (PLANTS 
Manual, available at http://www.tcd.uni-konstanz.de/plants download/download/ manual1.1.pdf) was 
validated by removing the D-mannose ligand and redocking it inside the active site of LecB (PDB 
code: 1OUR, RMSD: 0.165 Å). The docking site was limited inside a 13.3 Å radius sphere centred 
in the mass centre (coordination: X = 45.806, Y = 29.194 and Z = 5.333) of the crystallized ligand. 
Ser22, Ser23, Asp96, and Asp99 were set as flexible residues in the input file. 
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Polarimetry 
Optical rotations of SPECS-836 (3 mg mL-1 DMSO) were determined on a P-2000 polarimeter 
(JASCO, Gross- Umstadt, Germany) at 22.5 °C and 589 nm using equation 3. 
 
 
Equation 3. Calculation of optical rotation. α for measured rotation in degrees; T for temperature in degrees 
Celsius; λ for wavelength in nanometers; I for path length in decimeters; C in concentration in g/mL. 
 
 
 
Molecular dynamics  
The molecular dynamics was done using Molecular Operating Environment (MOE), 2014.09. 
Afterwards, the molecular dynamics ran for cis and trans configuration at the tetrahydrothiophene 
ring of SPECS-836 and the dihedral angles were collected each 0.5 sec for 50 sec. Thereafter, the 
calculation of 3J values was done using the average of collected dihedral angles according to 
equation 4.13  
 
                                                    Calculated 3J = 7 - cos(θ) + 5cos(2θ) 
Equation 4. Calculation of 3J from dihedral angles which were recorded from molecular dynamics simulation. 
 
 
 
 
 
 
 
 
[⍺]"# = 	 ⍺& ∗ (	 [⍺])*+)).- = 	 ...)/..-∗....0	 = + 14 
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Results and discussion  
 
Development of a screening assay based on fluorescence polarization technique 
The competitive binding assay, based on fluorescence polarization, has been used before for lectins 
to assign the binding affinity of several inhibitors.8,9,14,15 Instead of using fluorescein-labeled sugar 
as a tracer, we used here Cy5-labeled α-L-fucoside (1). Cy5 is a red-shifted dye, the signal of which 
shows minimal interference with natural products compared to fluorescein in fluorescence based-
assays.5 Cy5-conjugated α-L-fucoside (1) was synthesized by Dirk Hauck and then evaluated by 
direct titration of a constant amount of 1 with different concentrations of LecB (Figure 1). Compound 
1 showed a Kd value of 235 nM, which is in good agreement with the reported Kd of methyl α-L-
fucoside.16  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Determination of the dissociation constant for Cy5-conjugated α-L-fucoside (1) with LecB. 
Dissociation constant was obtained from a four-parameter fitting procedure to the concentration-dependent 
increase in fluorescence polarization (Kd = 235 ± 41 nM). Dissociation constant and standard deviations were 
determined from two independent measurements of triplicates each. 
 
Thereafter, compound 1 was displaced by methyl ⍺-L-fucoside (2) in the presence of different 
quantities of DMSO (0 - 5 %) to check the assay tolerance for DMSO. The IC50 values of compound 
2 corresponded to the reported one without significant effect from DMSO up to 5 % (Table S1).16  
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A test plate that contains several antibiotics and synthetic peptides, were subsequently tested at 1 
% of DMSO stock (see table S2) as the first run. Our screening assay showed a high Z factor value 
(> 0.8), which is considered to be good quality for an HTP screening assay. Moreover, we monitored 
the fluorescence intensity of each compound to eliminate fluorescence enhancer or quencher 
compounds (Figure 2). Here, three hits, namely, Quercetin, WTE: A-A-W-R-A-A-C peptide and 
PD98059, were identified with more than 20 % of inhibition and two of them (Quercetin and WTE: A-
A-W-R-A-A-C peptide) were out of the acceptable range of fluorescence intensity. Then, the 
concentration-dependent inhibition was analyzed; unfortunately, all of these compounds could not 
bind to LecB up to 500 µM for Quercetin and PD98059, and 175 µM for WTE: A-A-W-R-A-A-C 
peptide.  
 
 
Figure 2. Screening of test plate which contains several antibiotics and synthetic peptides against LecB at 1% 
of stocks (see table 2) using a competitive binding assay based on fluorescence polarization. Black columns 
represent the calculated percentage of inhibition; red squares represent the normalized fluorescence intensity 
signals to the signal of positive control. The acceptable fluorescence intensity data should have 0.8 < 
fluorescence intensity < 1.2. Each column and square represent the average of results from three different 
wells. +ve control is L-fucose; -ve control is LecB with tracer 1 and without inhibitors.  
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Screening of the myxobacterial natural product library 
Myxobacteria are a group of Gram-negative soil bacteria that hold a large genome (e.g. ≈ 13 million 
nucleotides in the Myxobacterium sorangium cellulosum strain) and is sub-divided into 7500 strains 
(up to year 2010). At least 100 distinct core structures have been discovered in myxobacterial strains, 
exhibiting various bio-activities.3 Here, 259 myxobacterial secondary metabolites, derived from a 
DZIF natural compound library (Class IV), were screened in duplicate at 500 µM. The results showed 
outlier fluorescence intensity signals, which cannot be considered in our screening assay (Figure 
S1). The inconsistency of fluorescence intensity signals might have come from the poor solubility of 
the tested compounds; the screening was therefore performed again at a lower concentration (10 
µM) to overcome precipitation of the tested compounds (Figure 3). As a result, none of the 
myxobacterial pure compounds was able to block LecB at 10 µM. 
 
Figure 3. Screening of 259 myxobacterial secondary metabolites against LecB at 10 µM. Compounds with % 
of inhibition < zero (with fluorescence polarization > than negative control) are not shown. The dots of the 
scatter plot represent the averaged data of at least two measurements for each compound. 
 
 
Since myxobacteria are producing plenty of secondary metabolites, most of which have not been 
characterized yet, we decided next to explore extracts of myxobacterial strain cultures to find LecB 
inhibitors.3 
2200 myxobacteria extracts were tested at 2.5 % of their methanolic crude extract and interestingly 
a large number of hits were identified (Figure 4).  
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Figure 4. Screening of the myxobacterial extract library against LecB at 2.5 % of methanolic crude extract. 
The dots of the scatter plot represent averaged data from at least duplicates for each extract. Black dots for % 
of inhibition < 60; Green dots for 60 ≥ % of inhibition < 80; Red dots for % of inhibition ≥ 80. 
 
7 extracts showed ≥ 80 % of LecB inhibition and then, to reduce the complexity, we minimized the 
size of the investigated extracts to the top three (Table 2). The extracts of strain A, B, and C were 
chosen according to their result reproducibility and fluorescence intensity, as well as the percentage 
of inhibition of each. 
 
Table 2. The best 7 hits with more than 80% LecB inhibition from the myxobacterial strains’ extract screen and 
their fluorescence intensity deviation from the positive control. SD: standard error and represents three 
independent measurements of at least duplicates each; FI: fluorescence intensity.  
Strain Myxobacteria strain   % of inhibition to +ve 
control ± SD 
 % of FI deviation from 
+ve control ± SD 
A 
"unclassified bacterium" 
NOSO3 (DSM 53667) 82 ± 5 102 ± 4 
B Cystobacter violaceus Cbvi28 82 ± 3 105 ± 6 
C Stigmatella erecta Pde45 83 ± 6  119 ± 8 
D Cystobacter fuscus Cbf33 90 ± 9 137 ± 5 
E Myxococcus virescens Mxv214 65 ± 11 147 ± 9 
F Stigmatella erecta Pde30 82 ± 10 149 ± 7 
G Nannocystis exedens 9237 115 ± 13 221 ± 10 
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They were then fractionated into 93 fractions, using a 96-well plate automated LC-MS fractionation 
procedure, by Rolf Müller’s group and were subsequently evaluated for their binding to LecB. As 
illustrated in figure 5, the binding signals in the investigated fractions mostly came from fraction one 
(Fr.1) in all extracts, whereas extract of strain B showed additional moderate to high active fractions 
at Fr.72 and Fr.73. Thereafter, the concentration-dependent inhibition of all active fractions was 
analyzed (except Fr.72 from strain’s extract B) (Figure S2).  
 
Figure 5. Screening of fractionated extracts from three myxobacterial strains that showed activity to 
LecB in the initial screen. Fractions with % of inhibition < 40 represented by the sky-blue colour; 40 
≥ % of inhibition < 60 by dark blue colour; % of inhibition ≥ 60 by orange colour. C.E. refers to the pre- 
fractionated crude extract. 
 
 
 
As a result, Fr.1 and Fr.73 from extract of strain B are the only ones showing 69 % of inhibition at 3 
% of Fr.1 and an IC50 of 0.05 % of Fr.73. Here, the search for active compounds was narrowed within 
extract of strain B and even more so within Fr.73 since the hydrophilic Fr.1 seems to be sugars from 
the growth medium (see below). The LC-MS spectrum at Fr.73 showed a low MS signal with two 
major peaks, m/z = 371.0994 and 403.1258, which do not match any characterized class in the 
myxobacterial database (Figure S3). The production of compounds in Fr.73 was therefore optimized 
by cultivating the strain B in five different media (Table S3). Besides, cell-free media underwent the 
same cultivation and extraction procedure to be used as a control in further assays. The IC50 values 
of the bacterial extract and of the control were generated and showed the highest binding signals at 
CLF medium either with or without bacterial cells (IC50 = 0.111 and 0.087 % of their methanolic 
extract, respectively) (Figure 6). 
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Figure 6. Optimization of active fractions’ production in extract of strain B by the cultivation strain B in 
different media. The extracts of cultivated cells in each medium and cell-free media were analyzed with LecB 
by generating their concentration-dependent inhibition curves. The solid line refers to extracts of cultivated cell 
in each media; the dash line is for cell-free media extracts. The different colours represent different media.  
 
 
The CLF medium was used in the cultivation of strain B in the previous experiments. Furthermore, 
the extract of the cell-free CLF medium showed an equivalent effect to the cells’ extract, which could 
be due to the skimmed milk that was uniquely present in the CLF medium constituents (Table S3). 
It has been reported that human milk oligosaccharides block P. aeruginosa LecB, but whether 
skimmed milk blocks LecB remains to be investigated.17,18  
At that time, we speculated that the strong signal in the extract of strain B could be acquired from 
polar sugar components inside the medium, in addition to other less polar active metabolites, which 
were identified at Fr.73. We scaled up the cultivation of the strain B in the CLF medium from 200 mL 
to 2 L to improve the amount of the active compounds within Fr.73. Furthermore, a large-scale 
fractionation procedure using a preparative HPLC system was established. Three independent 
batches of strain B extract (2 X 200 mL and 1 X 2 L batches) in addition to the extract of cell-free 
CLF medium were fractionated by preparative HPLC and subsequently examined their inhibitory 
effect to LecB at  2.5% of each fraction (Figure 7).  
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Figure 7. Screening of the fractionated stain B extract from different batches in addition to the control (extract 
from cell-free CLF medium). Fractions with % of inhibition < 40 represented by the sky-blue colour; 40 ≥ % of 
inhibition < 60 by the dark blue colour; % of inhibition ≥ 60 by the orange colour. White colour: no sample. No.1 
and 2 the extracts from different 200 mL batches; No. 3 extracts from a different 2 L batch; Control from a 200 
mL batch; C.E. refers to the unfractionated crude extract. 
 
 
As shown in figure 7, there is a lack of reproducibility of the results from the active fractions with non-
polar property, i.e Fr.78, 79, and 116 in batch No.1. In contrast to this, the high polar active (i.e. Fr.9 
- 11) fractions were present in all fractionated batches, including the extract of the cell-free medium. 
We therefore stopped working with the myxobacterial extracts as the outcome was not reproducible 
and the culture medium contained LecB blockers. 
 
Screening of the natural products library (NxCL) 
The NxCL library is part of the DZIF screening library and contains 340 compounds. These 
compounds are mostly antibiotics, mainly originating from Streptomycetes, fungi, plants, 
Cyanobacteria, etc. The NxCL library was screened at 20 µM and unfortunately none of tested 
compounds showed significant interactions with the LecB at 20 µM (Figure 8).   
Polar&
Non)polar&
Polar&
Non)polar&
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Figure 8.  Screening of the NxCL library against LecB at 20 µM. The dots of the scatter plot represent averaged 
data of at least two measurements for each tested compound. 
 
Screening of the SPECS library 
The SPECS library contains chemically diverse compounds, which have been synthesized and 
brought from more than 2,000 academic sources worldwide. In this study, 1120 hydrophilic 
compounds, which were selected at DZIF, were tested to target the hydrophilic binding pocket in 
LecB. The SPECS compounds were tested at 500 µM and five hits showed more than 20 % of 
inhibition (Figure 9, S4). 
 
 
Figure 9. Screening of SPECS library with LecB at 500 µM. The dots in the scatter plot represent the averaged 
data from screening compounds. The red dots represent hits with more than 20 % of LecB inhibition. 
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All compounds that were identified as hits in the initial screen were then purchased from commercial 
vendors, freshly prepared in DMSO and validated by analysing their concentration-dependent 
inhibitory effect (Figure S5). Only one of the five hits, SPECS-836, showed binding with 60% 
inhibition at 1 mM. To confirm SPECS-836 binding to LecB, we tried to co-crystallize the LecB in a 
complex with SPECS-836 in Anne Imberty’s lab but the compound could not be found in the binding 
pocket. Hence, a molecular docking was carried out afterwards by docking SPECS-836 (in cis/trans 
configuration) into the LecB binding pocket. The best pose showed that the 3-OH at the 
tetrahydrothiophene ring and the carbonyl group in the compound are in the cis configuration and 
coordinate to Ca2+ ions in the same manner as 3-OH and 4-OH in D-mannose (Figure 10B). 
Unfortunately, the structural flexibility at the tetrahydrothiophene ring of SPECS-836 was not given 
by the supplier and a detailed structural characterization for SPECS-836 was therefore carried out 
using NMR spectroscopy, optical polarimetry, and computational methods. The stereochemistry at 
the tetrahydrothiophene ring could not be addressed by NMR and the specific rotation (+14) indicates 
a non-racemic compound (Figure S6). Furthermore, a molecular dynamics study was performed to 
calculate the 3J coupling constant values at the tetrahydrothiophene ring of modelled SPECS-836 in 
cis/trans configurations and then compared to the measured 3J values by 1H NMR (Figure 10C and 
S7). The calculated 3J values at the tetrahydrothiophene ring of cis configuration were marginally 
closer to the experimental data, which supports the binding behavior of SPECS-836 in the previous 
docking study. Nevertheless, further investigations should be performed to confirm the binding of 
SPECS-836 to LecB.  
  33 
RESULTS 
 
 
 
 
Figure 10. A) Chemical structure of SPECS-836 with possible stereochemistry at the tetrahydrothiophene. B) 
Superposition of LecB in a complex with D-mannose (PDB:1OUR) and docked SPECS-836 into the LecB 
binding pocket, using PDB:1OUR. D-mannose and SPECS-836 are depicted as sticks coloured by the 
elements (O: red, C: green) and (N: blue, O: red, S: yellow, C: grey), respectively. Two Ca2+
 
ions in the binding 
site are shown as green spheres. C) Comparison of in-silico calculated and measured 3J values at the 
tetrahydrothiophene ring of SPECS-836. 
 
Screening of a glycomimetic-focused library (OTAVA) 
 
After screening of many synthetic and natural compound libraries, we concluded that finding non-
carbohydrate inhibitors for LecB is challenge. Thus, we decided to focus on libraries which contain 
glycomimetics or carbohydrate-based compounds. 135 compounds that are mimicking glycans or 
based on non-acetylated carbohydrates was purchased from OTAVA glycomimetic focused library 
(Table S6). The OTAVA library was tested at 50 and 100 µM with LecB and LecA, respectively. Five 
hits (≥ 20 % of inhibition) were identified for LecB, whereas there were 21 hits for LecA (Table S4 & 
S5). All these hits are based on carbohydrates except compound OTAVA-51 (LecA hit). A 
concentration-dependent inhibitory analysis was performed and all LecB hits have IC50 values in a 
range of 6 to 11 µM. Three of them (i.e. OTAVA-91, -122, and -134) are based on L-arabinose, which 
  34 
RESULTS 
 
 
is known to be a LecB inhibitor19, whereas two of them (i.e. OTAVA-112 and -116) are surprisingly 
based on D-xylose, which is usually not recognized by LecB. Therefore, one of two xylose-based hits 
(OTAVA-116) was characterized, using LC-MS and NMR. The LC-MS spectrum showed a major 
peak with m/z = 345.06 that matches the exact mass of the investigated compound, whereas the 
NMR spectrum showed differences in the glycone part of the compound where 4-OH at the pyranose 
ring is axial-oriented instead of being equatorial (Figure S8 and 9). Here, the correct structure of 
OTAVA-116 is based on L-arabinose and we supposed the same for OTAVA-112. 
  
Figure 12. Screening of the glycomimetic-focused library (OTAVA) with LecB (A) and LecA (B) at 100 and 50 
µM, respectively. The dots in the scatter plot represent the averaged data of at least duplicates for each 
screened compound.  
 
Many of LecA hits showed more than 100 % of inhibition which indicates a higher potency compared 
to the used positive control (Methyl ⍺-D-galactose) (Figure 12B, table S5). 15 of the LecA hits are 
based on β-D-galactoside acquiring different substitutes in the aglycon part and they show the IC50 
values in a two-digit micromolar range (Table S5A). In addition to this, some of the LecA hits are 
based on structures with unknown stereochemistry at the pyranose ring, from which we speculated 
that they are D-galactoside-based compounds (Table S5B). This speculation was built on the IC50 
values of the assayed compounds which are similar to IC50 values of β-D-galactoside-based hits and 
to well-characterized carbohydrates binding to LecA.27 OTAVA-51 showed the only non-
carbohydrate hits for LecA in the initial screen, but it failed to show concentration-dependent binding 
to LecA up to 500 µM (Table S5B). Generally, most of LecA hits have IC50 in the range of 20 - 42 µM 
except for three weaker binders (OTAVA-96, -123 and -111) and the best inhibitor in this set of 
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compounds was OTAVA-123 with an IC50 value of 20.3 µM and 5.2 for its relative potency to methyl 
α-D-galactoside. 
   
Summary 
In this study, we developed a high throughput screening assay, using fluorescence polarization 
measurement. A tracer bearing a Cy5 fluorophore was synthezised and evaluated afterwards with 
LecB. Our established screening assay showed good quality where we could avoid the interfering 
signal from the auto-fluorescence compounds by using a tracer containing red-shifted dye. In 
addition to this, it showed a high throughput property with a Z score of 0.8 - 0.9, which is considered 
a good screening assay.  
Various natural, synthetic and semi-synthetic compound libraries were investigated to find potent 
LecB inhibitors or new inhibitor classes that we could use as lead structures in the future. None of 
the tested characterized myxobacteria metabolites could inhibit LecB at 10 µM, and here the 
availability and solubility of these compounds required this low tested concentration. A search of 
myxobacterial extracts was carried out afterwards and thousands of hits were identified, however 
the evaluation if these hits are bacterial secondary metabolite or sugar constituents in the growth 
media, was the bottleneck in this study. 
After validation of the binding of the most potent 7 hits to LecB, our search was narrowed into one 
myxobacterial extract, extract of strain B. We then established a large-scale fractionation, using the 
preparative HPLC in our lab, where we could scale up the fractionation of bacterial extract up to ~ 
50 mg in more than 100 fractions. It was found that the hit signals originated from the cultivating 
medium rather than from the bacterial secondary metabolites. The inordinate length of time involved 
and the complexity of finding a LecB inhibitor among the bacterial extracts as well as false positive 
signals from the media were sufficient reasons to stop working with myxobacterial extracts.  
Thereafter, other natural products and hydrophilic compound libraries, such as NxCL and SPECS, 
were investigated. Among these libraries, only SPECS-836 showed a weak binding affinity at 1 mM 
with incomplete characterization of its chemical structure. More validation and characterization 
should therefore be done with this compound to address its binding to LecB and it may indeed 
become a lead structure for new LecB inhibitors. The glycomimetic library was an interesting library 
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to investigate, since it focuses on carbohydrate-based compounds and compounds mimicking 
carbohydrates. Some hits were identified for LecB and LecA, but all of them were based on known 
inhibitors and better or equivalent inhibitors for both lectins were achieved using a rational structure-
based design strategy.8,9,19,20  
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The  first  example  of the self-assembly  and  lectin  binding  properties  of photoswitchable  glycodendrimer
micelles  is  reported.  Light-addressable  micelles  were  assembled  from  a library  of  12  amphiphilic  Janus
glycodendrimers  composed  of  variable  carbohydrate  head  groups  and  hydrophobic  tail  groups  linked
to an  azobenzene  core.  Spontaneous  association  in water  gave  cylindrical  micelles  with uniform  size
distribution  as determined  by  dynamic  light  scattering  (DLS)  and  small  angle  neutron  scattering  (SANS).
Trans-cis  photoisomerization  of the  azobenzene  dendrimer  core  was  used  to probe  the  self-assembly
behaviour  and  lectin  binding  properties  of  cylindrical  micelles,  revealing  moderate-to-potent  inhibition
of  lectins  LecA  and  LecB  from  Pseudomonas  aeruginosa.
Crown  Copyright  © 2017  Published  by Elsevier  B.V.  All  rights  reserved.
1. Introduction
Non-covalent carbohydrate-protein binding interactions medi-
ate myriad biological processes, yet the binding affinity of
individual interactions are often very weak in highly competi-
tive aqueous environments (disassociation constants ranging from
10−3 to 10−4 M)  [1]. Nature overcomes this intrinsic limitation
through the simultaneous binding of clustered, multivalent gly-
cans expressed on cellular surfaces to their cognate receptors,
or lectins. The so-called ‘multivalent’ or ‘glycoside cluster’ effect
results in several-fold enhancement in binding avidity, with ener-
gies that are greater than the sum of individual interactions [2].
The development of multivalent mimics of natural glycans has
been actively pursued as inhibitors of carbohydrate-protein bind-
ing events, which function as structural probes for understanding
cellular signaling and physiology or as therapeutic agents with
potential anti-microbial, anti-inflammatory and anti-tumour activ-
ity [3]. Conventional approaches toward this goal involve the
elaboration of multivalent scaffolds with carbohydrate epitopes
to yield nanoscale structures including glycodendrimers [4], gly-
copeptides [5], glycopolymers [6], glycodynamers [7], fullerenes
∗ Corresponding author.
E-mail address: brendan.wilkinson@une.edu.au (B.L. Wilkinson).
[8] and calixerenes, etc [9]. In some cases, potent binding affin-
ity and selectivity has been achieved using these structures as a
result of favourable ligand preorganization, however such molec-
ular systems offer limited modes of spatial presentation due to
the underlying rigid scaffold and suffer drawbacks associated with
complex multistep synthesis and purification [10]. An alternative
and promising approach towards multivalent glycan presenta-
tion involves the spontaneous association of glycoamphiphiles in
water to provide self-assembled, soft materials including liposomes
and micelles that are capable of mimicking biological membranes
[10–12]. Self-assembled systems offer several advantages over
rigid molecular assemblies, including ease of molecular synthe-
sis of the monomer and the ability to program ligand density and
valency through appropriate molecular design. With this in mind,
we were interested in exploring multivalent self-assembled struc-
tures possessing light addressable properties in order to tune ligand
topology and therefore lectin-carbohydrate binding. In particular,
we were interested in utilizing these responsive systems for inter-
rogating pathological lectin-carbohydrate interactions in a spatially
and temporally resolved manner, although such systems may  also
find applications as targeted delivery vehicles with phototriggered
release properties.
Reversible trans-cis photoisomerization of the well-
characterised azobenzene chromophore has been widely exploited
for controlling the conformational dynamics of biomolecules [13],
http://dx.doi.org/10.1016/j.colsurfb.2017.08.016
0927-7765/Crown Copyright © 2017 Published by Elsevier B.V. All rights reserved.
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including the three-dimensional arrangement of multivalent
carbohydrates on cluster glycosides [14], cyclodextrin bilayer
vesicles [15], polymers [16] and self-assembled monolayers
[17]. Our group has recently reported the photomodulation of
bacterial biofilm formation using a library of carbohydrate-based
surfactants [18]. Optical control over bacterial growth and biofilm
formation in drug-resistant Gram-positive and Gram-negative
bacteria was shown to be highly sensitive to the carbohydrate
head group and isomeric state of the azobenzene tail group.
Based on these observations, we decided to explore the applica-
tion of amphiphilic, azobenzene functionalized glycodendrimers
that undergo self-assembly to derive responsive, multivalent
soft materials for probing lectin binding. Herein we report the
modular synthesis of a library of 12 amphiphilic ‘Janus’ glycoden-
drimers as photoswitchable inhibitors of soluble lectins LecA and
LecB from Pseudomonas aeruginosa, an opportunistic pathogen
known to cause serious biofilm-related illnesses [19]. Glycoden-
drimers underwent spontaneous association in water to give
light-responsive cylindrical micelles with narrow polydispersity,
as revealed from dynamic light scattering (DLS) and small angle
neutron scattering (SANS), respectively. Micelle structures could
be tuned through UV light irradiation, thus underscoring their
potential application as addressable antimicrobial agents and tools
for studying carbohydrate–protein interactions.
2. Materials and methods
2.1. General methods
Analytical thin layer chromatography (TLC) was performed
on commercially prepared silica plates (Merck Kieselgel 60
0.25 mm F254). Flash column chromatography was  performed
using 230–400 mesh Kieselgel 60 silica eluting with distilled sol-
vents as described. Solvents and reagents were purchased from
Sigma-Aldrich and Merck and used without further purification.
1H NMR  and 13C NMR  spectra were recorded on a Bruker Avance
400 NMR  spectrometer at frequencies of 400 MHz  and 100 MHz
respectively. Chemical shift is reported as parts per million (ppm)
downfield shift to the TMS  internal standard. The data are reported
as chemical shift (!), multiplicity, relative integral, coupling con-
stant (J = Hz) and assignment where possible. IR spectra were
recorded on a Bruker ATR spectrometer. Optical rotation was  mea-
sured on an Optical Activity Polaer 2001 (546 nm)  polarimeter using
a 1 mL  cell volume and a 10 cm path length. LCMS was performed
on an Agilent Infinity 1260 HPLC coupled to an Agilent 6120 B mass
spectrometer. Separations were performed on an Agilent Poroshel
120 high resolution column.
Preparative HPLC was performed on an Agilent Zorbax 300SB
C3 column (20 mm ID × 150 mm)  using a linear gradient of 8:1:1
water/AcN/i-PrOH (Solvent A) and 1:1 AcN/i-PrOH (Solvent B) as
the mobile phase. Separations were performed using a linear gra-
dient of 10% solvent B to 100% solvent B over 30 min, operating at
a flow rate of 10 mL/min.
2.2. UV–vis spectroscopy
The native trans isomers of carbohydrate surfactants were con-
verted into cis states by illumination of their aqueous solutions
under ambient conditions using a UV lamp with "max at 361 nm
in a time-dependant manner (1–30 min). Five minutes of photoex-
citation was found sufficient to convert trans isomers into cis state.
All the studies involving cis isomers were obtained after 10 min  of
illumination with "361nm. Since many biological processes occur at
37 ◦C, the thermal stability of both the native trans isomer as well as
the photoinduced cis isomer was studied at ambient temperature
(20 ◦C) and 37 ◦C using UV–vis spectroscopy. Azobenzene trans-
cis photoisomerisation was  found to be complete within 5 min of
UV irradiation. The native trans isomers remained stable under
ambient lighting conditions at least up to 24 h, as evident from
insignificant changes in their UV–vis absorbance spectra over this
period. The thermal relaxation studies were performed at ambi-
ent temperature and 37 ◦C for 24 h in Milli-Q water. The half-lives
of the cis isomers in Milli-Q water at different temperatures were
estimated from thermal relaxation studies by plotting the ratios of
peak area under 325 nm peak and that under 440 nm peak over a
period of 24 h (Figs. S1 and S2). These peaks were chosen as cis-trans
relaxation results in increase in peak intensity at ∼325 nm, with a
corresponding decrease in peak intensity at 440 nm.
2.3. Determination of CAC
The critical aggregation concentration was determined using
Nile red encapsulation assay [20]. A 1 mg  mL−1 Nile Red stock solu-
tion was prepared in chloroform. A glycodendrimer stock solution
was made up in Milli-Q water at various concentrations depending
on the starting concentration for the assay. Encapsulation samples
were made by adding 10 #L Nile red into 4 mL glycodendrimer
solution. The fluorescence emission was measured on an Agilent
Technology Cary Eclipse fluorescence spectrophotometer using an
excitation wavelength of 550 nm.  Signals were recorded between
570 and 700 nm with 5 nm excitation/emission slit. To investi-
gate the relationship between conformational exchanges and the
concentration of glycodendrimers, the UV–vis spectra of repre-
sentative glycodendrimer 1–4 were measured at concentrations
related to their CAC values (Fig. S8).
2.4. Dynamic light scattering (DLS)
DLS was performed with a Brookhaven NanoBrook Omni instru-
ment. Instrument parameters were determined automatically
along with the measurement times. Experiments were performed
five times independently. The glycodendrimer was dissolved in
Milli-Q water at 0.1 mM concentration and DLS experiments were
measured at 20 ◦C. Samples were irradiated with UV light at 361 nm
for 10 min  before measuring DLS for compounds at cis-dominated
PSS.
2.5. Small angle neutron scattering (SANS)
SANS measurements were made on the Quokka instrument at
the Bragg Institute, ANSTO, Lucas Heights NSW, Australia. For all
samples, raw scattering counts were collected on a 128 × 128 ele-
ment area detector, where the sample–detector distances used
were 2 m and 14 m,  with no detector offset. An incident neutron
wavelength of 5 Å was used with a typical spread of 10%, thus giv-
ing an effective q range of 0.004–0.4 Å−1. Samples were prepared
in circular 12.5 mm Hellma quartz cells with a path length of 2
mm,  and a thermostatically-controlled automatic sample changer
ensured that a temperature of 25 +/– 0.05 ◦C was  maintained. Data
were converted from raw counts at the detector into 1D scatter-
ing spectra by first subtracting the scattering from an empty cell
and then radially averaging the resulting spectrum, normalising for
the measured sample transmission. A D2O background was  then
subtracted from the final 1D sample data to ensure that the scat-
tering signals seen are from the surfactant only. Model fitting was
performed using SasView software, using standard equations for
cylindrical form factors. Cylinders were modelled using the Guinier
equation [21] for the form factor P(q,a):
P (q, a) = 2 (!")Vsin
(
qLcos˛/2
)
/
(
qLcos˛/2
) J1 (qrsin˛)
(qrsin˛)
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where !!  is the scattering length density difference between the
scatter and the D2O solvent, V is the volume of the cylinder, L is
the length of the cylinder, " is the angle between the axis of the
cylinder and the q-vector, J1 is the first order Bessel function, r is
the radius of the cylinder.
Aggregation number (Nagg) was calculated from the volume of
the formed micelle divided by the volume of monomer obtained
by calculating the molecular volume of the structural components
of the monomer from their bulk densities. The volumes (Å3) used
were: triazole 96.2, triethylglycol 221.9, azobenzene 251.5, galac-
tose 173.8, mannose 194.4, fucose 175.2, 2-bromoethanol 117.7,
succinic anhydride 135.1, pae 161.5, 3,5-dihydrobenzoic acid 159.9,
gallic acid 166.2, 1-bromooctane 286.8, 1-bromododecane 398.7,
2-ethylhexyl bromide 295.3.
2.6. Competitive binding assays to LecA or LecB
LecA or LecB were recombinantly produced in E. coli and purified
by affinity chromatography as described.5b,22 Measurements for
competitive binding with LecA and LecB were performed accord-
ing to previously reported protocols.5b,22 A serial dilution of each
tested compounds in TBS/Ca (1000 − 0.013 #M)  was  prepared twice
in two different 96-well plates (Carl Roth GmbH, Germany, Item no.
9292.1). One of these plates was irradiated (with the plate put on
an ice tray to prevent heating) for 30 min  using a UV light source
which was comprised of three 9 W halogen tubes, delivering a total
power of 27 W at $max of 361 nm at the source (Nail gel curing
lamp). After 30 min  of irradiation, 10 #L of a serial dilution of each
tested compounds from each plate were added in triplicates to one
384-well plate (Greiner Bio-One, Germany, cat no 781900). After-
ward, 10 #L of either LecA or LecB and fluorescent galactose-based
compound 9 from reference 5b or fucose-based compound 6 from
reference 22 were added to each well at final concentrations of
20 #M for LecA and 150 nM for LecB and 10 nM for both fluores-
cent ligands. After incubation for 1 h (LecA) or 4 h (LecB) at r.t., blank
corrected fluorescence intensity was recorded using a PheraStar FS
microplate reader (BMG Labtech GmbH, Germany) with excitation
filters at 485 nm and emission filters at 535 nm and fluorescence
polarization was calculated. The data were analyzed using a four
parameter fit of the MARS Data Analysis Software (BMG Labtech
GmbH, Germany). A minimum of two independent measurements
on two separate plates was performed for each compound before
and after irradiation by UV lamp.
2.7. Synthesis
See supplementary information for NMR  spectra and analytical
data for new compounds.
2.7.1. General procedure 1 (Synthesis of 18–21;  27–30)  [10,11a]
Alcohol (1 equiv.), carboxylic acid (1 equiv.), DPTS (1 equiv.) and
DCC (2.6 equiv.) were dissolved in dry DCM and stirred under N2
for 12 h. Then the reaction mixture was diluted with diethyl ether,
filtered off the urea and washed with diethyl ether. The filtrate was
concentrated and purified by flash chromatography.
2.7.2. General procedure 2 (Synthesis of 22–25)
Aldehyde 18–21 (1 equiv.), pentaerythritol (1 equiv.) and p-
toluenesulfonic acid (PTSA, 0.2 equiv.) were dissolved in DMF  and
stirred at 50 ◦C under N2 until TLC showed fully consumption of
the starting materials. The crude mixture was concentrated under
reduced pressure and purified by flash chromatography.
2.7.3. General procedure 3 (Synthesis of 1–12) [10,11a]
Into a solution of 27–30 (1 equiv.) in THF was added 31–33 (2.5
equiv.) in water, CuSO4·5H2O (0.61 equiv.) in water and sodium
ascorbate (0.61 equiv.) in water successively under N2. The reac-
tion mixture was  allowed to stir at room temperature for 36 h.
Then dilute with THF, filtered, concentrated and purified by flash
chromatography (10–20% MeOH in DCM).
2.7.4. General procedure 4 (Synthesis of 13–16)  [23,11a],[23]
A mixture of methyl benzoate (1 equiv.), bromoalkane (2–3
equiv.) and potassium carbonate (1.2 equiv.) in DMF (15 mL) was
heated at reflux with vigorous stirring for 4 h. The reaction mixture
was cooled and poured into ice-water, and the precipitate collected
and dried, and the crude product purified by flash silica chromatog-
raphy or recrystallization. The purified methyl benzoate (1 equiv.),
KOH (5 equiv.) and water-ethanol (1:6 v/v) were heated at 60 ◦C for
2 h. Then the reaction mixture was  cooled to room temperature and
concentrated HCl was added carefully until pH 1. Then the acidic
solution was diluted with water, extracted with DCM  and the com-
bined organic phase was dried over Na2SO4, concentrated under
reduced pressure to afford the final compound.
2.7.5. General procedure 5 (Synthesis of 31–33)  [24–27]
To a cooled solution of acetylated sugar (1 equiv.) and 2-
bromoethanol (1.2 equiv.) in anhydrous DCM was  added dropwise
BF3·Et2O (4 equiv.). The ice-bath was  removed after 1 h and the
reaction was continued at room temperature until the starting
material had been consumed (monitored by TLC). The reaction
mixture was poured onto ice–water and extracted with DCM. The
organic phase was  washed with water, saturated NaHCO3, brine,
dried over Na2SO4 and concentrated under reduced pressure. The
synthesized intermediate compound (1 equiv.) and sodium azide
(10 equiv.) were dissolved in anhydrous DMF  and stirred at 70 ◦C
for 2 h. The reaction mixture was  cooled to room temperature,
extracted with EtOAc, washed with water, dried over Na2SO4 and
filtered. The filtrate was concentrated under reduced pressure and
purified by flash chromatography (2:3 EtOAc/petroleum spirit). The
purified intermediate was  deacetylated under Zemplén conditions
using catalytic sodium methoxide in methanol, followed by neu-
tralization with Amberlite IR120 acidic ion exchange resin.
3. Results and discussion
The synthesis of Janus glycodendrimers 1–12 is presented
in Scheme 1. Glycodendrimers 1–12 were composed of vari-
able monosaccharide head groups as recognition motifs for
LecA and LecB, which show binding specificities to d-galactose
and l-fucose or d-mannose, respectively [28]. To facilitate self-
assembly in water, hydrophobic tail fragments bearing linear and
branched alkyl tail groups (13–16)  were introduced by modified
Steglich esterification of the azobenzene core 17 using catalytic
4-(dimethylamino) p-toluenesulfonate (DPTS) to give hydropho-
bic precursors 18–21 [29]. Divergent elaboration of core fragments
18–21 was then carried out, firstly by acetalization of the aldehyde
with pentaerythritol to give diols 22–25,  followed by esterification
with carboxylic acid 26 to furnish the key alkyne scaffolds 27–30.
Finally, glycoconjugation of 27–30 was performed using the well-
described copper(I)-catalysed azide-alkyne conjugation reaction
(CuAAc) of the corresponding deprotected azidoethyl glycosides
31–33 to furnish glycodendrimers 1–12 (See supplementary infor-
mation for details) [30].
Having obtained glycodendrimers 1–12, we  then investi-
gated their photocontrollable aggregation properties. Azobenzene
trans-cis photoisomerization has been extensively studied by our
group for controlling the self-assembly and interfacial activity of
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Scheme 1. Synthesis of photoswitchable Janus glycodendrimers 1–12. Reaction conditions: i) DPTS, DCC, DCM, 56–61% ii) pentaerythritol, PTSA, DMF, 50 ◦C, 46–61%
iii)  DPTS, DCC, DCM, 46–67% iv) CuSO4, sodium ascorbate, THF/water (2:1 v/v), 40 ◦C, 31–54% DCC = N-N’-dicyclohexylcarbodiimide, DCM = dichloromethane, DMF  = N,N-
dimethylformamide, DPTS = 4-(dimethylamino)pyridinium p-toluenesulfonate, THF = tetrahydrofuran, PTSA = p-toluene sulfonic acid.
Fig. 1. UV–vis spectroscopy of Man(3,5)12 3 at 0.05 mM concentration in ultra-pure water, before and after UV irradiation with an UV LED at 325 nm (left), and a UV lamp
at  361 nm and 36W radiant power (right).
amphiphilic carbohydrates, and was shown to give clean conver-
sion to the cis-dominated photostationary state (PSS) with efficient
conversion to the cis isomer (up to 75%) [18,31]. Preliminary mea-
surements involved the use of Man(3,5)12 (3) as the representative
compound. The UV–vis spectra of 3 were recorded in the (assump-
tively) trans-dominated photostationary state, which indicated an
intense band at around 325 nm corresponding to the azobenzene
! → !* transition, accompanied by a much weaker band at around
425 nm corresponding to the n → !* transition (Fig. 1). In order
to induce trans-cis photoisomerization, compound 3 was  irradi-
ated in water at either 325 nm or 361 nm for 30 min  and the
UV–vis spectrum recorded at 5 min  intervals. After this time, a
small decrease in peak intensity at 325 nm was observed, which
was accompanied by a slight increase in intensity of the peak at
425 nm along with a slight blue shift of approximately 5 nm for
the !max [32]. The thermal half-lives of the cis isomer of glycoden-
drimers 1–4 was  then determined by measuring the relaxation rate
of the dark adapted cis-PSS to the more stable trans isomer at 20 ◦C
and 37 ◦C, respectively (ESI, Figs. S1 and S2). Even at physiolog-
ically relevant temperatures, relatively long lived cis-states were
observed (10–14 h, Fig. S3), which would provide ample oppor-
tunity to elicit a change in the lectin binding response. The ratio
of trans and cis isomers at either PSS could be estimated by inte-
grating selected signals in the 1H NMR  spectrum, before and after
UV irradiation (Fig. S4–S7). In the resting, trans-dominated PSS,
7–9% of molecules existed in cis-form, while after UV irradiation
19–30% of molecules were found in the cis-form. Whilst the cis-
trans ratio in the cis-PSS ratio is low compared to those observed in
previously described azobenzene derivatives [31], these findings
are consistent with derivatives incorporating bulky substituents,
particularly amphiphilic azobenzene analogues leading to densely
packed aggregate geometries that may  impede light penetration
and/or inhibit photoswitching due to steric congestion in the
micelle core [32].
Having examined the photoswitching properties of glycoden-
drimers, our attention focused on the aggregation behaviour of
the assembled micelles in water. Interestingly, amphiphilic gly-
codendrimers did not reduce the surface tension at the air-water
interface, and so it was  not possible to determine the critical micelle
concentration of these compounds by tensiometry. Instead, the
critical aggregation concentration (CAC) was  evaluated using a Nile
Red encapsulation assay [20]. The CAC was  calculated by moni-
toring the wavelength at the maximum intensity for the Nile red
probe as a function of the glycodendrimer concentration, whereby
the inflection point is indicative of the CAC (Fig. 2). Low micro-
molar CAC values were obtained for dendrimers 1–12 in water,
which suggests a strong thermodynamic driving force for aggrega-
tion as a result of the favourable hydrophobic interactions between
azobenzene and alkyl tail groups within the aggregate core [33].
Furthermore, no clear photomodulation of the CAC was evident for
1–12, which was  most likely a result of the low photoisomerization
yields for these molecules. Because of their unusual aggregation
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Fig. 2. Fluorescence spectra of Nile Red in the presence of Man(3,5)8 1 at different concentrations (Left). CAC of Man(3,5)8 1 in ultra pure water before (open symbols) and
after  (closed symbols) UV irradiation at 361 nm for 10 min  (Right). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of  this article.)
behaviour, we then examined the relationship between confor-
mational exchanges and the concentrations of glycodendrimers.
Glycodendrimers 1–4 were dissolved separately in water at 20 ◦C
at several different concentrations: above the CAC (0.05 mM),  at
the CAC, and below the CAC (0.001 mM).  UV–vis spectroscopy was
recorded for all these samples, and the absorbance at 325 nm was
recorded (ESI, Fig. S8). By plotting the absorbance against concen-
tration, linear trends (R2 > 0.999 for all compounds) were observed,
indicating that the glycodendrimers undergo unimolecular confor-
mational exchanges upon self-assembly, which are not affected by
changes in concentration [31,34].
The aggregation properties of the glycodendrimers 1–12 in their
respective trans and cis states was further investigated using DLS
to determine the hydrodynamic diameter and polydispersity of
the assembled structures (ESI, Table S1). Glycodendrimers 1–12
were dissolved in water at a fixed concentration (0.1 mM)  and
DLS measurements were obtained before and after UV irradia-
tion. Aggregates were shown to be of limited polydispersity in
water, with effective diameters of around 100 nm and polydis-
persity indices (PDIs) of approximately 0.2, with the exception
of Fuc(3,5)2Et8 10 which had a larger diameter of 183 nm.  In
most cases, any apparent change in diameter between the trans
and cis states was modest, however the hydrodynamic volume of
these structures generally increased slightly following UV irradia-
tion (361 nm for 10 min), with the largest difference observed for
Man(3,5)8 1.
In order to determine the precise geometry and size of these
aggregates, along with any changes following trans-cis photoi-
somerization of the azobenzene core, SANS measurements were
performed at fixed concentrations above the CAC in D2O (0.1 mM).
Under these conditions, cylindrical geometries of different sizes
were observed in the trans state as shown in the SANS spectra, with
smaller aggregates generally observed for glycodendrimers incor-
porating n-octyl and branched 2-ethylhexyl tail groups (Fig. 3, and
ESI, Table S1). The SANS spectra revealed cylindrical geometries of
various length (104–915 Å) and radii (32–41 Å). Cylindrical geome-
tries are preferred when amphiphiles try to reduce their interfacial
curvature, and the aggregation size can be modulated by adjusting
the relative volume occupied by the head and tail group [35]. The
diameter of these cylinders is approximately equal to the length of
two glycodendrimers that construct the single layered cylindrical
micelle structure, and this is commensurate with a typical surfac-
tant aggregate. The sharp increase in scattered intensity at lowest
q values likely indicated fractal-type critical scattering from attrac-
tive interactions between micelles. This has been seen previously
Table 1
Evaluation of photoswitchable compounds 5–8 with LecA using a competitive bind-
ing  assay based on fluorescence polarization.a,b,c.
bAverages and standard deviations were obtained from two independent experi-
ments.
cRelative potency (rp) = IC50 (monovalent reference)/IC50 (glycodendrimer). The
monovalent reference was methyl !-d-galactoside (!-d-GalOMe) for 5–8.
Compound na IC50 ("M)b IC50 ["M] (UV361nm)b rp (rpUV)c
!GalOMe 92.1 23.2
5 324 22.6 ± 0.9 24.9 ± 5.6 4.1 (4.0)
6  296 20.3 ± 5.2 21.0 ± 5.3 4.5 (4.7)
7  2846 22.9 ± 5.5 23.0 ± 4.4 4.0 (4.3)
8  1072 24.6 ± 2.1 23.1 ± 1.0 3.7 (4.3)
aNumber of sugars per micelle derived from the Nagg values in the SANS spectra.
bAverages and standard deviations were obtained from two independent experi-
ments.
cRelative potency (rp) = IC50 (monovalent reference)/IC50 (glycodendrimer). The
monovalent reference was methyl !-d-galactoside (!-d-GalOMe) for 5–8.
for azobenzene surfactant systems [31,36], and thus we  anticipate
that the same effect occurs here. We  model this contribution using a
mass fractal model for the aggregation of micelles into larger ‘clus-
ters’ [37]. From the fitted SANS spectra, the aggregation number
(Nagg) and area per head group (Ahg) of these micelles could be
determined, thus providing useful insight into the valency and den-
sity of carbohydrates exposed on the micelle surface (ESI, Fig. S9 and
Table S1). In order to evaluate changes in self-assembly properties
following trans-cis photoisomerization, the SANS spectra were also
recorded following UV irradiation of representative compounds
1–4 (Fig. S10). Although no notable change in the geometry and
size of these micelles was  detected in the cis-PSS, this was in good
agreement with the CAC values and can be attributed to the low
photoisomerization yields of the dendrimers and the non-standard
aggregation pathway.
The soluble lectins LecA and LecB were chosen as the targets
in this study owing to their strong potential for therapeutic inter-
vention and the important roles they play as virulence factors
and in biofilm formation [19,38]. Furthermore, both lectins were
shown to be present among a large set of strain isolates from clin-
ical sources [39]. Since these soluble bacterial lectins show good
affinity and specificity for d-galactose and l-fucose/d-mannose
residues, respectively, we measured the binding inhibition of
LecA/B against photoswitchable micelles incorporating these head
groups (Tables 1 and 2). The affinity of glycodendrimer micelles
were measured using a recently described, competitive fluores-
cence polarization-based assay for LecA and LecB, both in the
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Fig. 3. Representative SANS data (symbols) and model fits (lines) for glycodendrimers 1–4 in the trans-dominated PSS at 0.1 mM concentration in D2O (top), and glycoden-
drimer  Man(3,5)8 1 in both the trans- and cis-dominated PSS at 0.1 mM concentration in D2O (bottom). The legend inset shows cross-sectional profiles of corresponding
fitted  micelle geometries. The legend inset shows the cross-sectional profiles of corresponding fitted micelle geometries, where the scale bar defines the length-scale.
trans- and cis-PSS (See ESI for details) [5b,22]. All compounds
were tested over a concentration range from a concentration of
inhibitor above the CAC value at 300 !M,  serially diluted down
to single digit nanomolar concentrations. Methyl "-d-galactoside
("GalOMe), methyl "-l-fucopyranoside ("FucOMe) or methyl "-
d-mannopyranoside ("ManOMe) were used as the monovalent
references in the same assay for LecA and LecB, respectively [5b,22].
In the case of LecA, glycodendrimers 5–8 bearing a #-galactoside
head group showed a modest enhancement (approximately four-
fold) in inhibition potency relative to the monovalent compound.
Whilst this may  suggest a multivalent effect, no clear correlation
between particle size and inhibitory potency could be drawn as
the relatively small micelles bearing two  n-octyl and 2-ethyl hexyl
side chains of 5 and 6, respectively, were shown to be equally
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Table  2
Evaluation of photoswitchable compounds 1–4 and 9–12 with LecB using a compet-
itive binding assay based on fluorescence polarization. a,b,c .
bAverages and standard deviations were obtained from two independent experi-
ments.
cRelative potency (rp) = IC50 (monovalent reference)/IC50 (glycodendrimer). The
monovalent reference was  methyl !-l-fucoside (!-l-FucOMe) for 9–12, and methyl
!-d-mannoside (!-d-ManOMe) for 1–4.
Compound na IC50 ["M]b IC50 ["M] (UV361nm)b rp (rpUV)c
!FucOMe 0.35 ± 0.05
9 182 0.29 ± 0.07 0.32 ± 0.01 1.2 (1.0)
10  1603 0.20 ± 0.00 0.20 ± 0.03 1.7 (1.7)
11  799 0.29 ± 0.04 0.27 ± 0.02 1.2 (1.2)
12  996 0.25 ± 0.06 0.24 ± 0.11 1.4 (1.4)
!ManOMe 87.7 ± 61.2 76.5 ± 38.1
1 138 2.7 ± 0.5 3.5 ± 0.3 32.8 (21.5)
2  128 3.3 ± 0.2 3.8 ± 0.4 26.2 (20.2)
3  918 3.0 ± 0.2 2.6 ± 0.2 29.4 (29.4)
4  795 1.0 ± 0.2 1.2 ± 0.4 85.7 (62.6)
aNumber of sugars per micelle derived from the Nagg values in the SANS spectra.
bAverages and standard deviations were obtained from two independent experi-
ments.
cRelative potency (rp) = IC50 (monovalent reference)/IC50 (glycodendrimer). The
monovalent reference was  methyl !-l-fucoside (!-l-FucOMe) for 9–12, and methyl
!-d-mannoside (!-d-ManOMe) for 1–4.
potent as the larger micelles derived from glycodendrimers 7 and
8 incorporating three alkyl side chains. LecA is a tetrameric protein
that binds preferentially to !-galactosides, although high valency
ligands presenting ˇ-galactosides, as well as monovalent phenyl ˇ-
galactosides have been shown to be potent inhibitors of this lectin.
In our case, the weaker binding affinity for these glycodendrimers
may  be a result of inappropriate ligand spacing due to the flexi-
ble linker, which may  disfavour a chelate binding mode between
adjacent binding sites on the LecA tetramer [3a,40]. Furthermore,
no significant change in binding potency was  observed for the
galacto-configured dendrimers following trans-cis photoisomeriza-
tion, with the exception of 8 which showed a slight enhancement
in inhibition. The negligible photomodulation of binding affinity
is in good agreement with the CAC and SANS data, and is most
likely a result of the low conversion to the cis isomer following UV
irradiation.
In contrast to the inhibition of LecA with d-galactoside
functionalized dendrimers, glycodendrimers 9–12 incorporating
!-fucoside head groups showed good potency against LecB, with
sub micromolar IC50 values obtained in the trans and cis isomeric
states. However, these compounds showed no enhancement in
potency relative to the monovalent reference compound !FucOMe
(IC50 0.35 "M).  Many studies have revealed the importance of mul-
tivalency for generating potent ligands for LecB [41]. However,
similar to the observations of the inhibition of micelles of 5–8
against LecA, the binding potency of 9–12 to LecB was insensitive to
particle size. Furthermore, no clear photomodulation of inhibition
could be detected following UV irradiation, as the trans isomer was
as equally potent inhibitor as the cis-enriched state and is in good
agreement with the self-assembly data.
Mannosides are usually weaker inhibitors of LecB when
compared to fucosides, but through chemical modification,
mannose-derived compounds were also shown to achieve potent
LecB inhibition [42]. Micelles assembled from mannosides 1–4
were also tested for inhibition of LecB and low micromolar IC50
values were obtained. In contrast to all other compounds tested for
LecA and LecB, the relative potencies of mannosides 1–4 (IC50 val-
ues of 1.0–3.4 "M)  with respect to !ManOMe (IC50 87.7 "M)  were
significantly increased up to >80-fold for 4. Due to the identical
aglycons for fucosides 9–12 and mannosides 1–4, this significant
effect observed for mannosides is likely to be a result of an optimal
multivalent presentation of the carbohydrate in the manno-series
that matches the spatial requirements of two  LecB binding sites in
the lectin tetramer.
4. Conclusions
In summary, we  report the modular synthesis of a library of
photoswitchable Janus glycodendrimers bearing variable alkyl tail
groups and carbohydrate head groups. The assembled structures
were characterised using DLS and SANS, and revealed uniform
cylindrical micelles of various size. Glycodendrimer micelles were
assessed as phototuneable inhibitors of LecA and LecB from P.
aeruginosa using a competitive, fluorescence polarization-based
assay and revealed moderate-to-potent inhibition of these bacte-
rial lectins with a significant increase potency for mannose derived
glycodendrimers. Unfortunately, no clear modulation in the self-
assembly and binding potency of these micelles could be observed
following UV light irradiation, owing to the low photoisomeriza-
tion yields for these dendrimers, most likely due to impaired light
penetration and steric congestion within the aggregate core. Lectin
binding potencies also appeared insensitive to the length and radii
of micelles, as smaller structures generally at least as potent binders
as the larger, worm-like micelles. The efficient synthesis of these
constructs facilitates a rapid entry point to responsive structures
with tailored activity against a variety of lectin targets. Future work
will be aimed at developing photocontrollable liposomal systems,
as well as improving linker and ligand design in order to enhance
binding potency and photoswitching efficiency.
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Burkholderia cenocepacia is an opportunistic Gram-negative pathogen and especially hazardous for cystic
fibrosis patients. In analogy to its relative Pseudomonas aeruginosa, B. cenocepacia possess numerous
lectins with roles in adhesion and biofilm formation. The LecB homolog BC2L-A is important for biofilm
structure and morphology. Inhibitors of this D-mannose specific C-type lectin could be useful as tools in B.
cenocepacia biofilm research and potentially as anti-biofilm compounds against chronic infections. Here,
we report the development of a fluorescence polarization-based competitive binding assay and its applica-
tion in an extensive structure–activity relationship study of inhibitors of BC2L-A. In contrast to its homolog
LecB, BC2L-A is highly selective for D-mannose-based ligands with an absolute requirement of its hydroxyl
group at C6. A strict diastereoselectivity was observed for (6S)-mannoheptose-derived ligands. Intriguingly,
bioisosteric substitution or methylation of hydroxyl groups directly involved in the calcium-coordination
resulted in loss of inhibition for the two homologous lectins BC2L-A and LecB.
Introduction
Burkholderia cenocepacia is a Gram-negative bacterium and
belongs to the B. cepacia complex (BCC). BCC currently con-
tains at least 18 genetically different but phenotypically simi-
lar species, which could be isolated from different environ-
ments.1 B. cenocepacia has been recognized as a problematic
opportunistic pathogen, particularly to immunosuppressed
patients and patients suffering from cystic fibrosis (CF).
Compared to its relative Pseudomonas aeruginosa, mortality of
patients infected with B. cenocepacia increased and conditions
like the cepacia syndrome often lead to pulmonary disfunc-
tion.2,3 Treatment of such infections is difficult due to antibi-
otic resistance of B. cenocepacia,4 which is increased by its
ability to form biofilms. In these social colonies the bacteria
are protected by a self-formed extracellular matrix and show
up to fifteen-fold higher resistance against antibiotics than B.
cenocepacia grown in planktonic culture.5 Like for P.
aeruginosa,6 the inhibition of bacterial biofilm formation could
be a promising approach to overcome antibiotic resistance.
Interestingly, B. cenocepacia was shown to form mixed spe-
cies biofilms with CF isolates of P. aeruginosa and both path-
ogens often infect patients simultaneously.7 In P. aeruginosa
the lectins LecA and LecB are necessary for biofilm forma-
tion.8,9 lecB-like genes were also identified in several other
Gram-negative bacteria such as Chromobacterium violaceum,
Ralstonia solanacearum, as well as in B. cenocepacia.10–12 B.
cenocepacia has three lectins homologous to P. aeruginosa
LecB: BclA (BCAM0186), BclB (BCAM0184) or BclC
(BCAM0185), also called BC2L-A, BC2L-B and BC2L-C. BC2L-A
contains only a LecB domain, whereas BC2L-B and BC2L-C
have additional N-terminal domains. This additional domain
is without homology to known domains in BC2L-B, and in
BC2L-C it contains a tumor necrosis factor-fold domain. The
latter has been characterized and reported as super lectin
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where the additional TNF domain binds fucose in addition to
the mannose-binding LecB domain.13,14
The expression of BC2L-A is positively regulated through ac-
tivation of Burkholderia CepR, a protein homologous to LuxR
which is a member of the acyl homoserine lactone quorum
sensing system.15,16 Later, the Burkholderia lectin cluster
bclACB was shown to be mainly regulated by the Burkholderia
diffusable signal factor (BDSF) system with cis-2-dodecenoic
acid as signal molecule and that maximal expression of the
lectins is dependent on both signaling systems.17 Surprisingly,
deletion of the bclACB gene cluster in the CF isolate B.
cenocepacia H111 had no effect on biofilm formation in a static
microtitre plate biofilm assay.18 However, under identical con-
ditions the lectin cluster bclACB showed an effect on biofilm
formation in absence of the major adhesin gene bapA. Expres-
sion of BapA was therefore suggested to compensate the effect
of the lectins BclACB under static biofilm conditions. When an-
alyzed under flow conditions, however, the absence of the
lectins BclACB had a profound effect on the biofilm structure
also in the presence of bapA and large hollow structures were
formed. Based on complementation experiments with individ-
ual lectins and combinations, Eberl and coworkers suggested
that all three lectins cooperate in the structural development of
biofilms. Therefore, inhibitors targeting these lectins could
serve as tools to study Burkholderia biofilm formation.
BC2L-A has been extensively structurally character-
ized.10,19,20 In contrast to the tetramer forming LecB, BC2L-A
forms a dimeric assembly of its 13.8 kDa monomers.10 The
carbohydrate specificity of BC2L-A was determined by glycan
array analysis, which revealed a high specificity of this lectin
for mannose-containing ligands. In contrast to the high affin-
ity of LecB to L-fucose, BC2L-A shows a low affinity to
L-fucose (IC50 = 2.3 mM). Methyl α-D-mannoside is a high af-
finity ligand with a Kd of 2.7 μM and co-operative effects
upon binding were observed in microcalorimetry experi-
ments. The crystal structure was solved and the carbohydrate
specificity was explained on a structural basis: His112 stacks
to lipophilic areas in mannosides but would clash with O-1
of fucose and its conjugates. Marchetti et al. later showed,
that BC2L-A binds also to L-glycero-D-manno-heptose which is
a major constituent of bacterial lipopolysaccharide.20 The
stereochemistry of the glycol side chain was important for
binding and methyl α-L,D-mannoheptoside bound with a Kd
of 54 μM, while its C6 epimer did not bind.
Here, we report the development of a competitive binding
assay for BC2L-A based on fluorescence polarization and its
application in a detailed structure–activity relationship study
with more than 30 potential ligands based on the monosac-
charides fucose and mannose.
Results and discussion
Fluorescence polarization-based competitive binding assays
have been developed for various lectins.21–23 This assay for-
mat allows small scale volumes and convenient in situ quan-
tification of the inhibitory potencies of given inhibitors. Be-
cause BC2L-A binds D-mannosides with high affinity and
L-fucosides with low affinity, we designed the D-mannose-
based fluorescent tracer 3 (Scheme 1) as assay probe. Its syn-
thesis started from D-mannose (1) and an ethyl linker was in-
troduced by borontrifluoride-catalyzed glycosylation of
peracetylated mannose with 2-bromoethanol as published by
Dahmen et al.24 After subsequent nucleophilic displacement
of the bromide with NaN3,
25 Zemplén deacetylation yielded
intermediate azide, which was reduced to the fully unprotected
amine 2.26 The fluorescent tracer 3 was then obtained in 79%
yield after coupling with fluorescein isothiocyanate (FITC).
Then, mannose-based 3 and fucose-based 4 (ref. 22) were ti-
trated with BC2L-A and fluorescence polarization was deter-
mined (Fig. 1A). Mannose derivative 3 showed strong binding
to BC2L-A (Kd 3.1 ± 1.7 μM), whereas fucose derivative 4 only
showed binding at protein concentrations greater than
100 μM. These results are consistent with the known dissocia-
tion constant of methyl α-D-mannoside and BC2L-A of Kd = 2.7
μM and the poor binding of L-fucose.10 The assay was then
evaluated by titration of BC2L-A (1.5 μM) in presence of the re-
porter ligand 3 (10 nM) with a dilution series of D-mannose (1,
Fig. 1B) and an IC50 value of 10.8 ± 0.7 μM was obtained. This
data is in good agreement with published data for D-mannose
(1, Kd 5.15 μM) obtained by isothermal microcalorimetry.
10
After establishing the assay, we tested various derivatives
of L-fucose and D-mannose for inhibition of BC2L-A (Table 1).
The common structural motif contained the 6-membered
tetrahydropyran ring structure and all three calcium-
Scheme 1 Synthesis of fluorescently labeled mannose tracer 3. Reagents and conditions: (a) Ac2O, pyridine, r.t.; (b) BF3·OEt2, 2-bromoethanol; (c)
NaN3, DMF, 70 °C; (d) NaOMe, MeOH, r.t.; (e) H2, Pd/C, EtOH, r.t.; (f) FITC, NaHCO3, DMF, r.t.
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coordinating secondary hydroxy groups were present. In a
first set of compounds (1, 5–12), fucose, mannose and deriva-
tives thereof were tested. This series was previously generated
to explain monosaccharide selectivity of the structurally re-
lated lectin LecB and dissect individual functional group con-
tributions to the binding affinity.27 For BC2L-A, only a weak
affinity of L-fucose (5, IC50 498 μM) was detected and no inhi-
bition by the methyl fucosides α-6 or β-7 was observed up to
666 μM. Removal of the glycosidic linkage of fucose in 8 or
introduction of a C-methyl substituent in 9 also resulted in
inactive compounds. The observation that fucose-containing
conjugates are poor BC2L-A inhibitors was further supported
by the lack of inhibition of BC2L-A by various blood group
antigens, e.g., Lewis-type structures Lex, Ley, Lea, Leb or anti-
gens of the ABO-system blood group A-, B- and H-antigens
(data not shown). In contrast, mannose-derived inhibitors 1,
10–12 were potent inhibitors with IC50 values ranging from
2.9–13 μM. These potent binders all contain the 6-OH group
of D-mannose but possess variations at the anomeric center
of mannose as C-glycoside 10, 1-deoxy mannose 11, free man-
nose 1 or the methyl glycoside 12. A hydroxy group in posi-
tion 6 of mannose was required for efficient binding to
BC2L-A as observed by the comparison of inactive 6-deoxy-9
and potent inhibition of 6-hydroxy-10. This data also rein-
forces the conclusion made by Marchetti et al., that a lack of
an STD effect of D-rhamnose (i.e., 6-deoxy D-mannose) with
BC2L-A by NMR spectroscopy resulted from the loss in affin-
ity of such 6-deoxygenated mannose-derivatives.20 Variation
of the aglycon in mannosides 12–15 had only a minor effect
(7.0–14.5 μM), and methyl glycoside α-12 was as potent as
the bulky β-15 (IC50 = 7.0 μM for 12 and 7.4 μM for 15).
Deoxygenation in position-6 of mannosides resulted in
complete loss in binding. Therefore, we isosterically replaced
this hydroxy group with other small substituents which could
establish attractive interactions with amino acids of the pro-
tein, i.e. halogens28,29 in 16–18 or an amino group in 19.
Halogenated mannosides 16–18 were synthesized by selective
activation of the 6-hydroxy group in methyl mannoside 12 as
tosylate22 and its nucleophilic substitution with the corre-
sponding halogenide salts in DMF at elevated temperatures
(Scheme 2). Remarkably, none of the halogenated
mannosides nor the amine substituted derivative were able
to inhibit the lectin (Table 1), confirming that the presence
of a free 6-OH group is essential for binding.
Marchetti et al. previously reported the binding of BC2L-A
to L,D-mannoheptose with a Kd of 54 μM for its α-methyl gly-
coside.20 This heptose is a constituent of bacterial surface li-
popolysaccharide (LPS) and may play a role in BC2L-A medi-
ated bacterial adhesion. In a previous study, we synthesized a
set of mannoheptose derivatives as inhibitors for the homolo-
gous lectin P. aeruginosa LecB.30 These compounds differ in
their stereochemical configuration at position 6 and bear
amido- and sulfonamido-substituents in position 7. All com-
pounds were tested for their inhibition of BC2L-A (Table 2).
In agreement with the selectivity reported by Marchetti et al.,
we observed a preferential binding of BC2L-A to the (6S)-dia-
stereomers 20–22 in the amide series with IC50 values of
116, 104 and 64.0 μM, respectively, whereas the correspond-
ing (6R)-diastereomers D,D-mannosides 23 and 24 did not
show any inhibition. The (6S)-configurated sulfonamides 25
and 26 both inhibited BC2L-A function and were the most
potent inhibitors in the mannoheptose series with IC50s of
14–19 μM. This inhibitory potency is superior to the
unsubstituted heptoside previously reported by Marchetti
et al. The mannohexose analogs bearing these amide and sul-
fonamide substituents in position 6 were previously reported
as potent inhibitors of LecB.22,31 However, since these com-
pounds lack a free hydroxy group in position 6, the observed
Fig. 1 (A) Titration of mannose-based reporter ligand 3 and fucose-based reporter ligand 4 with BC2L-A and determination of the fluorescence
polarization. Binding of 3 (Kd = 3.1 ± 1.7 μM) compared to the low affinity fucose-based ligand 4 indicate the carbohydrate specificity of BC2L-A.
(B) Competitive inhibition of the binding of 3 to BC2L-A with D-mannose (1, IC50 = 10.8 ± 0.7 μM). One representative titration of independent trip-
licates (three plates) is shown here and error bars represent standard deviation of triplicates on one plate, standard deviations given for Kd and IC50
represent data from three independent experiments (three plates of triplicates each).
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lack of inhibition of BC2L-A (data not shown) was consistent
with the observations for the relative behavior of e.g., com-
pound 9 and 10 (Table 1).
The crystal structure of methyl α-L,D-mannoheptoside in
complex with BC2L-A was solved by Marchetti et al.20 In this
structure, the 6-OH of the glycol side chain establishes a hy-
drogen bonding network with the side chain of Asp110 and
the main chain nitrogen of Glu31, an interaction pattern sim-
ilar to 6-OH of mannose10 in complex with BC2L-A. Both,
(6S)-22 and (6R)-24 were docked into the ligand-free form of
the mannoheptose-BC2L-A crystal structure previously pub-
lished by Marchetti et al. (Fig. 2). The docking pose of
mannoheptose amide (6S)-22 corresponds to the crystal struc-
ture of methyl α-L,D-mannoheptoside and the 6-OH group
forms the previously mentioned hydrogen bonding interac-
tions since both heptoses have the same stereochemistry at
position 6. The diastereomeric analog (6R)-24 could also be
docked with its pyranose ring in the same position as the
one observed for methyl α-L,D-mannoheptoside, but the OH
group at C6 cannot take the same position since it would
generate steric hindrance between the rest of the side chain
and the protein surface. Thus, the side chain is rotated in its
docking pose and the 6-OH group in this (6R)-diastereomer
Scheme 2 Synthesis of 6-deoxy-6-halo mannosides 16, 17 and 18.
Reagents and conditions: (a) TsCl, pyridine, DMF, 0 °C – r.t.; (b)
(CH3)4NCl for 16, KBr for 17 or KI for 18, DMF, 65 °C.
Table 2 Biochemical evaluation of mannoheptose derivatives for BC2L-A binding. IC50 values were determined using competitive binding assay and are
averages of at least three independent experiments, standard deviations are given. n.i.: no inhibition observed up to 666 μM
Compound BC2L-A IC50 [μM] Compound BC2L-A IC50 [μM]
20
116 ± 22
23
n.i.
21
104 ± 18
24
n.i.
22
64.0 ± 3.5
25
19.1 ± 1.2
26
13.8 ± 0.9
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cannot be optimally accommodated in the binding site. In
(6S)-22, the cinnamide substituent extends along the cleft
and interacts with BC2L-A, whereas in (6R)-24, the same sub-
stituent is oriented towards the solvent as a result of the al-
tered stereochemistry at C6. Both properties, the hydrogen-
bonding network of 6-OH as well as the van der Waals inter-
action of the amide substituents as in (6S)-22 could explain
the strong selectivity of BC2L-A for (6S)-heptose derivatives
over their (6R)-diastereomers.
We were further interested in the importance of the ring
hydroxy groups for binding, which are directly coordinating
to the two Ca2+ ions in BC2L-A or in the related P. aeruginosa
LecB. Is it possible to replace or to modify one or more of
these hydroxy groups and retain or improve affinity to LecB-
like proteins? In 2004, Plenio described attractive Ca2+–F
interaction in organofluorine compounds.32 In addition, due
to similar size, fluorine became an established bioisoster for
hydrogens and hydroxyl groups in medicinal chemistry.33
The introduction of fluorine can have profound effects on a
diverse set of properties of drugs, e.g., changes in acidity, li-
pophilicity or metabolic stability. On the other hand, some
lectins are known to preferentially bind to O-methylated car-
bohydrates, for example Laccaria bicolor tectonin34 or Bos
taurus galectin-1.35 Both lectins, however, do not belong to
the C-type lectin family. Galectin-1 was also probed with
fluorine-substituted galactose derivatives and binding was
completely lost for the 4- and the 6-fluorine analog, whereas
a 3-fluoro substitution was well tolerated by galectin-1.35
Fluorinated saccharides as ligands for other carbohydrate
binding proteins have been described, e.g. glycogen phos-
phorylase,36 Toxoplasma adhesin TgMIC1,37 calnexin and
calreticulin,38,39 as well as NMR-active probes for cyano-
virin.40 However, none of these carbohydrate-binding pro-
teins are C-type lectins. One example of C-type lectins bind-
ing fluorinated glycan ligands has been reported by Hoechst
AG for fluorinated sialyl Lewisx and E-selectin.41 It is impor-
tant to note, that in this study fluorine was introduced at the
galactose moiety of the tetrasaccharide, which is not involved
in direct coordination to the protein-bound calcium ion.
Two commercially available fluorinated mannose deriva-
tives (34 and 35, Table 3) were used to study the effect of the
substitution of 2-OH and 3-OH with a fluorine atom. A fluo-
rine derivative corresponding to the substitution of mannose
4-OH was not commercially accessible. Therefore, we synthe-
sized 1,2-dideoxy-2-fluoro-L-fucose (30) bearing the fluorine at
position C-2 of fucose which corresponds to position C-4 in
mannose (Scheme 3). An inversion of the free hydroxy group,
its activation as leaving group and fluorination via SN2-type
substitution are the key steps in the synthesis of such fluori-
nated carbohydrates. However, all attempts to invert the
equatorial hydroxyl group at position 2 in selectively
protected 27 into its axial epimer 28 failed (Scheme 3), al-
though various conditions were tested. After activation of the
hydroxyl group as mesylate, tosylate or triflate leaving groups,
the subsequent inversion using various nucleophiles (NaOH,
KOH, BzOH or cesium benzoate) was unsuccessful. An at-
tempt to invert the stereochemistry under Mitsunobu condi-
tions was also unsuccessful. Finally, Lattrel–Dax conditions
using nitrite ions as nucleophile reagent was tested on the
triflate due to previous success in epimerisation of carbohy-
drate triflates.42 Also under these conditions access to 28
remained unsuccessful. In contrast, a direct fluorination of
the free hydroxy group in 27 using the reagent Deoxo-Fluor
yielded the fluorinated compound 29 with the desired stereo-
chemistry, however, this was only successful in a small scale
Table 3 Biochemical evaluation of derivatives substituted in one of the
three Ca2+-chelating hydroxyl groups for binding to BC2L-A and its
homolog from P. aeruginosa LecB. n.i.: no inhibition observed up to 666
μM
Compound BC2L-A IC50 [μM] LecB IC50 [μM]
30
n.i. n.i.
34
n.i. n.i.
35
n.i. n.i.
36
56% inhib.
(666 μM)
n.i.
33
n.i. n.i.
Fig. 2 Molecular docking of cinnamide modified mannoheptose C-6
(S) isomer 22 (A) and C-6 (R) isomer 24 (B) with BC2L-A. The two C-6
diastereomers show same orientation of the carbohydrate ring but dif-
fer in orientation of 6-OH and the cinnamide moiety. Carbohydrate
recognition domain of BC2L-A is presented as cartoon with transpar-
ent surface. Ligands and amino acids forming interaction with 6-OH
are depicted as sticks colored by elements (N: blue, O: red, C: grey).
Two Ca2+-ions in the binding site are shown as green spheres.
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test reaction. Finally, 29 could be smoothly obtained in good
yields using N,N-diethylamino-S,S-difluorosulfinium tetra-
fluoroborate (XtalFluor-E), a new generation fluorination re-
agent43 with enhanced stability and selectivity. The stereo-
chemistry of 29 and hydrogenolytically deprotected 30 was
confirmed using 1H-NMR (for 29, 30) and 1H,1H-NOESY NMR
(for 29) spectroscopy. The proton NMR spectrum and ob-
served NOE cross peaks (see ESI‡ for spectra) between the
benzylidene aliphatic proton and H2 in 29 unambiguously
confirmed the presence of only one diastereomer, i.e., exo-29.
The question whether exclusively the exo-isomer of 27 reacted
to exo-29 or the endo/exo-mixture of 27 anomerized during
the acidic reaction conditions was not further analyzed.
For the selective methylation of calcium-coordinating hy-
droxy groups, we used the previously reported34 3-O-methyl
mannoside 36 (Table 3) and designed the synthesis of its
4-methoxy analogon 33. Fischer glycosylation of D-mannose
(1) in allylic alcohol, isopropylidene masking of the cis-diol
OH-2/3 and subsequent tritylation of the primary hydroxyl
group yielded the selectively protected mannoside 31 in 23%
over 3 steps (Scheme 3). Methylation of 31 using methyl io-
dide and subsequent simultaneous deprotection of the trityl
and isopropylidene protecting groups yielded 4-O-methyl
mannoside 33 in good yield.
All fluorinated (30, 34, 35) and methylated (33, 36) poten-
tial ligands were evaluated in the corresponding competitive
binding assays for both C-type lectins, B. cenocepacia BC2L-A
and its homolog LecB from P. aeruginosa. Surprisingly, no
competitive binding was observed for any of these derivatives
up to concentrations of more than 650 μM, a concentration
more than 10–100-fold above the affinities of the correspond-
ing derivatives with unmodified hydroxy groups. Only com-
pound 36 showed a weak inhibition of BC2L-A. Based on our
previous observations, 2-fluoro fucose 30 was not expected to
bind to BC2L-A due to the lack of the primary hydroxy group
(see Table 1 for the parent compound 8). However, 8 is a po-
tent inhibitor of LecB27 and no inhibition of LecB function
with its fluoro-analog 30 was observed even at concentrations
of more than 400-fold higher than the reported IC50 of 8.
These observations indicate the crucial importance of free
hydroxy groups in all calcium-coordinating positions for
binding to LecB and its homolog BC2L-A.
The fluorinated mannose analogs 34 and 35 are hemiace-
tals and their conformation is not fixed as glycoside in a py-
ranose ring. Introduction of a strongly electronegative fluo-
rine substituent in positions 2 or 3 could therefore influence
the reactivity of the adjacent aldehyde and hydroxyl groups.
The influence of these substitutions on the equilibrium of
the various cyclic forms in aqueous solution was therefore
analyzed by NMR spectroscopy and J-coupling analysis
(Table 4). When comparing the proton NMR spectra of
D-mannose (1) and its fluorinated analogs 34 and 35 under
identical conditions, in all three cases both pyranose forms
were observed with comparable α/β-ratios. In addition, com-
parable 3J-coupling constants between H2 and H3 (2.2–3.5
Hz) and between H3 and H4 (9.4–9.8 Hz) indicate compara-
ble conformations for D-mannose (1) and its fluorinated ana-
logs 34 and 35 in aqueous solution. Thus, an influence of the
fluorine substituents on the conformational equilibrium of
mannose could not account for the loss in lectin binding
activity.
Summary
In summary, we have developed a fluorescence polarization-
based competitive binding assay to quantify inhibitory
Scheme 3 Synthesis of 1,2-dideoxy-2-fluoro L-fucose (30) and allyl 4-O-methyl α-mannopyranoside (33). Reagents and conditions: (a) benzalde-
hyde dimethyl acetal, camphorsulfonic acid, DMF, r.t.; (b) XtalFluor-E, Et3N·3HF, CH2Cl2, r.t., 2 h; (c) Pd/C, H2, EtOH, r.t.; (d) all OH, Amberlite/H+,
70 °C; (e) acetone/H2O = 40 : 1, pTsOH, 40 °C; (f) triphenylmethyl chloride, pyridine, 50 °C; (g) NaH, MeI, DMF, 0 °C-r.t.; (h) acetone, conc. HCl,
50 °C.
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potencies of different inhibitors of BC2L-A, a potential target
for anti-infectives against infections with B. cenocepacia. With
the help of this assay, we extensively studied the structure–ac-
tivity relationship of its glycan ligands based on thirty natural
carbohydrates and synthetically derived inhibitors. The previ-
ously proposed role of the 6-OH group of D-mannosides for
the binding to BC2L-A was found to be fundamental for activ-
ity, based on a set of approximately 10 compounds including
this hydroxyl group, potential bioisosters thereof or with
compounds lacking this hydroxyl group. In addition, we
tested a set of diastereomeric mannoheptose derivatives,
quantified the diastereoselectivity of BC2L-A and proposed
the binding mode of the potent derivative which could assist
the design of novel heptose-based inhibitors. The
diastereoselectivity of BC2L-A is very tight compared to the
previously reported data for its homolog LecB.30 This strin-
gent selectivity is likely to originate from its high require-
ment for optimal coordination of the hydroxyl group at man-
nose C6, whereas for LecB27 this hydroxyl group does not
contribute to the overall binding affinity. Surprisingly, bio-
isosteric substitution or methylation of hydroxyl groups di-
rectly involved in the calcium-coordination resulted in com-
plete loss of inhibition for the two homologous lectins BC2L-
A and LecB. Thus, the assay developed here and the detailed
information gained from this study will guide future develop-
ment of lectin-directed inhibitors and anti-virulence drugs
against B. cenocepacia and P. aeruginosa.
Experimental
Chemical synthesis
Thin layer chromatography (TLC) was performed using silica
gel 60 coated aluminum sheets containing fluorescence indi-
cator (Merck KGaA, Darmstadt, Germany) using UV light (254
nm) and by charring either in anisaldehyde solution (1% v/v
4-methoxybenzaldehyde, 2% v/v concentrated H2SO4 in EtOH),
in aqueous KMnO4 solution or in a molybdate solution (a
0.02 M solution of ammonium cerium sulfate dihydrate and
ammonium molybdate tetrahydrate in aqueous 10% H2SO4)
with heating. Medium pressure liquid chromatography
(MPLC) was performed on a Teledyne Isco Combiflash Rf200
system using pre-packed silica gel 60 columns from Teledyne
Isco, SiliCycle or Macherey-Nagel. Commercial chemicals and
solvents were used without further purification. Deuterated
solvents were purchased from Eurisotop (Saarbrücken, Ger-
many). Nuclear magnetic resonance (NMR) spectroscopy was
performed on a Bruker Avance III 400 or 500 UltraShield
spectrometer at 400/500 MHz (1H) or 101/126 MHz (13C), re-
spectively. Chemical shifts are given in ppm and were cali-
brated on residual solvent peaks as internal standard.44 Mul-
tiplicities were specified as s (singlet), d (doublet), t (triplet)
or m (multiplet). The signals were assigned with the help of
1H,1H-COSY, DEPT-135-edited 1H,13C-HSQC, 1H,13C-HMBC
and 1H,1H-NOESY experiments. Mass spectra were obtained
on a Bruker amaZon SL spectrometer, high resolution mass
Table 4 Conformational analysis of D-mannose (1), 2-deoxy-2-fluoro-D-mannose (35) and 3-deoxy-3-fluoro-D-mannose (34) by 1H-NMR in D2O. The
depicted 1H-NMR spectra show the anomeric protons and quantification of anomeric ratios. Anomeric ratios (α : β) of the pyranose ring forms were
comparable in 1, 34, 35. 3J-coupling analysis of between H2/H3 and H3/H4 indicate comparable coupling constants, and thus comparable conforma-
tions in all three compounds analyzed
1H-NMR α/β J H3–H2 J H3–H4
1
2 : 1 α 3.2 α 9.7
β 2.2 β 9.7
34
2.6 : 1 α 3.5 α 9.4
β 3.5 β 9.4
35
2 : 1 α 2.7 α 9.8
β 2.7 β 9.7
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spectra on a Bruker micrOTOF II ESI spectrometer and the
data were analyzed using DataAnalysis from Bruker.
L-Fucose (5), D-mannose (1), umbelliferyl α-D-mannoside
(14) and umbelliferyl β-D-mannoside (15) were from Dextra Lab-
oratories (Reading, UK), methyl α-L-fucoside (6), methyl β-L-
fucoside (7) and fluoromannoses 34 and 35 from Carbosynth
Ltd. (UK). Methyl α-D-mannoside (12) was purchased from
Sigma Aldrich (Germany). Fluorescein isothiocyanate isomer I
was from Serva Biochemicals (Heidelberg, Germany).
N-(Fluorescein-5-yl)-N′-(α-D-mannopyranosyloxyethyl)-thio-
carbamide (3). 2-Aminoethyl α-D-mannopyranoside (2) (53 mg,
0.24 mmol) was dissolved in DMF (3 mL) and FITC (93 mg,
0.24 mmol, 1.0 equiv.) was added. The reaction mixture was
stirred at r.t. for 17 h, concentrated in vacuo and the residue
was purified by MPLC (SiO2; solvent A: CH2Cl2 with 1%
HOAc, solvent B: EtOH with 2% HOAc; gradient of 0–57% B)
to give the title compound as orange solid (115 mg, 0.19
mmol, 79%). 1H NMR (500 MHz, MeOH-d4) δ 8.17 (d, J = 1.8
Hz, 1H, ArH), 7.79 (dd, J = 8.3, 2.0 Hz, 1H, ArH), 7.17 (d, J =
8.3 Hz, 1H, ArH), 6.75–6.65 (m, 4H, ArH), 6.55 (dd, J = 8.7,
2.4 Hz, 2H, ArH), 4.83 (d, J = 1.7 Hz, 1H, H-1), 3.99–3.80 (m,
5H), 3.77–3.68 (m, 3H), 3.65–3.55 (m, 2H); 13C NMR (126
MHz, MeOH-d4) δ 183.1 (CS), 171.3 (CO), 154.4 (ArC),
142.4 (ArC), 131.6 (ArCH), 130.4 (ArCH), 129.5 (ArC), 125.9
(ArCH), 120.1 (ArCH), 114.0 (ArC), 111.7 (ArCH), 103.5
(ArCH), 101.8 (C-1), 74.8, 72.6, 72.1, 68.6 (C-2, -3, -4, -5), 67.0
(CH2), 62.9 (CH2), 45.4 (CH2); HR-MS calcd. for
C29H27N2O11S
−: calcd: 611.1341 found: 611.1320.
Methyl 6-chloro-6-deoxy-α-D-mannopyranoside (16). Methyl
mannoside 12 was tosylated according to Wang et al.,45 crude
methyl 6-O-tosyl-α-D-mannopyranoside (200 mg, 0.57 mmol, 1
equiv.) was then stirred in DMF (5.7 mL) in presence of
(CH3)4NCl (314 mg, 2.87 mmol, 5 equiv.) at 65 °C for 2 d. The
solvent was removed in vacuo and the residue was purified by
MPLC (SiO2; gradient of CH2Cl2 to CH2Cl2/MeOH = 10 : 1) to
give 16 as colorless solid (32 mg, 26%, 2 steps). 1H NMR (500
MHz, MeOH-d4) δ 4.64 (d, J = 1.7 Hz, 1H, H-1), 3.92–3.88 (m,
1H, H-6a), 3.79 (dd, J = 3.3, 1.7 Hz, 1H, H-2), 3.69–3.61 (m,
3H, H-3, -4, -6b), 3.60–3.54 (m, 1H, H-5), 3.39 (s, 3H, OCH3);
13C NMR (126 MHz, MeOH-d4) δ 102.8 (C-1), 74.2 (C-3 or -4),
72.5 (C-3 or -4), 71.9 (C-2), 69.8 (C-5), 55.2 (OCH3), 45.7 (C-6);
ESI-MS calcd. C7H13ClNaO5
+: 235.0; found: 234.8. 16 was first
reported by Jennings and Jones46 and the proton NMR data
corresponded to the data disclosed in the literature.47
Methyl 6-bromo-6-deoxy-α-D-mannopyranoside (17).
Methyl mannoside 12 was tosylated according to Wang
et al.,45 crude methyl 6-O-tosyl-α-D-mannopyranoside (300 mg,
0.86 mmol, 1 equiv.) was stirred in DMF (8.6 mL) in presence
of KBr (512 mg, 4.31 mmol, 5 equiv.) at 65 °C for 3 d. The
solvent was removed in vacuo and the residue was purified by
MPLC (SiO2; gradient of CH2Cl2 to CH2Cl2/MeOH = 10 : 1) to
give 17 as colorless solid (60.7 mg, 31%, 2 steps). 1H NMR
(500 MHz, MeOH-d4) δ 4.64 (d, J = 1.6 Hz, 1H, H-1), 3.81–3.77
(m, 2H, H-2, -6a), 3.66–3.60 (m, 2H, H-3, -4), 3.56–3.48 (m,
2H, H-5, -6b), 3.41 (s, 3H, OCH3).
13C NMR (126 MHz, MeOH-
d4) δ 102.8 (C-1), 74.0 (C-3 or -4), 72.5 (C-3 or -4), 71.9 (C-2),
70.9 (C-5), 55.3 (OCH3), 33.9 (C-6); ESI-MS calcd.
C7H13BrNaO5
+: 279.0; found: 278.8. 17 was first reported by
Valentin48 and the carbon NMR data corresponded to
disclosed data in the literature.49
Methyl 6-deoxy-6-iodo-α-D-mannopyranoside (18). Methyl
mannoside 12 was tosylated according to Wang et al.,45 crude
methyl 6-O-tosyl-α-D-mannopyranoside (300 mg, 0.86 mmol, 1
equiv.) was stirred in DMF (8.6 mL) in presence of KI (715
mg, 4.31 mmol, 5 equiv.) at 65 °C for 3 d. The solvent was re-
moved in vacuo and the residue was purified by MPLC (SiO2;
gradient of CH2Cl2 to CH2Cl2/MeOH = 10 : 1) to give 18 as col-
orless solid (88.1 mg, 34%, 2 steps). 1H NMR (500 MHz,
MeOH-d4) δ 4.62 (d, J = 1.7 Hz, 1H, H-1), 3.78 (dd, J = 3.4, 1.7
Hz, 1H, H-2), 3.68–3.60 (m, 2H, H-3, -6a), 3.47–3.41 (m, 5H,
H-4, -5, OCH3), 3.27–3.19 (m, 1H, H-6b).
13C NMR (126 MHz,
MeOH-d4) δ 102.9 (C-1), 74.2 (C-5), 72.5 (C-4), 72.3 (C-3), 72.1
(C-2), 55.5 (OCH3), 6.4 (C-6); ESI-MS calcd. C7H13INaO5
+:
327.0; found: 326.8. 18 was first reported by Lehmann and
Benson50 and the NMR data corresponded to disclosed data
in DMSO-d6 in the literature.51
3,4-O-Benzylidene-1-deoxy-L-fucose (27). 1-Deoxy-L-fucose27
(8) (315 mg, 2.13 mmol) was dissolved in DMF (14 mL) and
to the solution were added camphorsulfonic acid (50 mg,
0.21 mmol, 0.1 equiv.) and benzaldehyde dimethyl acetal (1
mL, 6.38 mmol, 3 equiv.). The mixture was stirred at r.t. for
19 h. Then, triethylamine (30 μL) was added, the volatiles
were removed in vacuo and the residue was purified by MPLC
(gradient petrol ether to petrol ether/EtOAc = 2 : 1) to give 27
as diastereomeric mixture (442 mg, 1.87 mmol, 88%) as col-
orless solids (ratio S/R = 1/1.5). 1H NMR (400 MHz, MeOH-d4)
S-isomer: δ 7.59–7.29 (m, 5H, ArCH), 5.91 (s, 1H, PhCH_(OR)2),
4.15 (dd, J = 6.1, 2.3 Hz, 1H, H-4), 4.08 (t, J = 6.5 Hz, 1H, H-
3), 3.94–3.68 (m, 3H, H-2, -5, -1eq), 3.23–3.10 (m, 1H, H-1ax),
1.36 (d, J = 6.6 Hz, 3H, H-6); R-isomer: δ 7.59–7.29 (m, 5H,
ArCH), 6.10 (s, 1H, PhCH_(OR)2), 4.24 (dd, J = 6.9, 5.2 Hz, 1H,
H-3), 4.05 (dd, J = 5.4, 2.0 Hz, 1H, H-4), 3.94–3.68 (m, 3H, H-
2, H-5, H-1eq), 3.23–3.10 (m, 1H, H-1ax), 1.32 (d, J = 6.6 Hz,
3H, H-6). 13C NMR (101 MHz, MeOH-d4) δ 140.9 (ArC), 139.4
(ArC), 130.2 (ArCH), 129.9 (ArCH), 129.3 (2C, ArCH), 129.2
(2C, ArCH), 127.8 (2C, ArCH), 127.3 (2C, ArCH), 105.3
(PhC_HĲOR)2, S-isomer), 104.2 (PhC_HĲOR)2, R-isomer), 81.8 (C-
3, R-isomer), 80.0 (C-4, S-isomer), 80.0, 77.6 (C-4, R-isomer),
73.9, 73.2, 70.4, 69.6 (C-1, R-isomer), 69.5 (C-1, S-isomer),
67.2, 17.3 (C-6, R-isomer), 17.1 (C-6, S-isomer). HR-MS calcd.
for C13H16NaO4
+: 259.0941; found: 259.0933.
(R)-3,4-O-Benzylidene-1,2-dideoxy-2-fluoro-L-fucose (29). To
a solution of selectively protected (R/S)-27 (100 mg, 423 μmol)
in CH2Cl2 (1.3 mL) was added XtalFluor-E (145 mg, 635 μmol,
1.5 equiv.) and Et3N·3HF (173 μL, 0.85 mmol, 2 equiv.) at r.t.
and the mixture was stirred for 4 h. The mixture was poured
into saturated NaHCO3 solution (0.5 mL), the organic layer
was separated and the aqueous layer was extracted with
CH2Cl2 (2 × 2 mL). The combined organic layers were dried
over Na2SO4 and filtered. The solvent was removed in vacuo
and the residue was purified by MPLC (petrol ether to petrol
ether/EtOAc = 6 : 1) to give only the (R)-3,4-O-benzylidene-1,2-
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dideoxy-2-fluoro-L-fucose (29) (65 mg, 272 μmol, 65%) as col-
orless solid. 1H NMR (400 MHz, MeOH-d4) δ 7.52–7.30 (m,
5H, ArCH), 6.15 (s, 1H, PhCH_(OR)2), 4.75 (dddd, J = 49.7, 9.6,
9.6, 6.2 Hz, 1H, H-2), 4.52 (dt, J = 18.9, 6.1 Hz, 1H, H-3), 4.14
(dt, J = 5.8, 1.7 Hz, 1H, H-4), 4.08 (ddd, J = 11.5, 7.2, 5.8 Hz,
1H, H-1eq), 3.82 (qd, J = 6.6, 1.8 Hz, 1H, H-5), 3.42 (ddd, J =
11.6, 9.4, 6.6 Hz, 1H, H-1ax), 1.32 (d, J = 6.6 Hz, 3H, H-6). 13C
NMR (101 MHz, MeOH-d4) δ 140.5 (ArC), 130.1 (ArCH), 129.3
(2C, ArCH), 127.3 (2C, ArCH), 104.8 (PhC_HĲOR)2), 88.2 (d, JCF
= 177.3 Hz, C-2), 78.5 (d, JCF = 23.8 Hz, C-3), 78.0 (d, JCF = 7.0
Hz, C-4), 73.5 (C-5), 66.6 (d, JCF = 26.8 Hz, C-1), 17.0 (C-6).
19F
NMR (376 MHz, MeOH-d4) δ −197.0. HR-MS calcd. for
C13H15FNaO3
+: 261.0897; found: 261.0778.
1,2-Dideoxy-2-fluoro-L-fucose (30). Protected 2-fluoro-fucose
29 (35 mg, 0.147 mmol) was stirred in MeOH (10 mL) under
hydrogen atmosphere (1 atm) with 10% Pd–C (10 mol%) at r.t.
over night. The mixture was filtered through celite and the sol-
vent was removed in vacuo. The residue was purified by MPLC
(CH2Cl2 to CH2Cl2/MeOH = 8 : 1) to give 1,2-dideoxy-2-fluoro-L-
fucose (30) (21 mg, 0.142 mmol, 97%) as colorless solid. 1H
NMR (400 MHz, MeOH-d4) δ 4.60 (dddd, J = 51.3, 10.4, 9.0, 5.8
Hz, 1H, H-2), 4.01 (dd, J = 10.9, 5.7 Hz, 1H, H-1eq), 3.72–3.60
(m, 2H, H-3, H-4), 3.55 (qd, J = 6.5, 1.2 Hz, 1H, H-5), 3.27 (td, J
= 10.7, 4.2 Hz, H-1ax), 1.22 (d, J = 6.4 Hz, 3H, H-6). 13C NMR
(101 MHz, MeOH-d4) δ 89.7 (d, JCF = 176.1 Hz, C-2), 76.5 (C-5),
74.7 (d, JCF = 16.6 Hz, C-3), 73.9 (d, JCF = 9.4 Hz, C-4), 68.1 (d,
JCF = 28.2 Hz, C-1), 16.8 (C-6).
19F NMR (376 MHz, MeOH-d4) δ
-208.4; ESI-MS calcd. C6H11FNaO3
+: 173.1; found: 172.8.
Allyl 2,3-O-isopropylidene-6-O-trityl-α-D-mannopyranoside
(31). Allyl α-D-mannopyranoside34 (13) was converted to allyl
2,3-O-isopropylidene-α-D-mannopyranoside as described by
Kochetkov et al.52 1H NMR (500 MHz, DMSO-d6) δ 5.88 (dddd,
J = 17.2, 10.4, 6.0, 5.2 Hz, 1H, CH_CH2-allyl), 5.24 (dq, J = 17.2,
1.7 Hz, 1H, CHCH_2-allyl), 5.16–5.08 (m, 2H, CHCH_2-allyl, OH-
5), 4.92 (br s, 1H, H-1), 4.54 (t, J = 6.0 Hz, 1H, OH-6), 4.12
(ddt, J = 13.1, 5.2, 1.6 Hz, 1H, OCH_2-allyl), 4.02 (dd, J = 5.8,
0.9 Hz, 1H, H-2), 3.93 (ddt, J = 13.1, 6.0, 1.4 Hz, 1H, OCH_2-al-
lyl), 3.88 (t, J = 6.2 Hz, 1H, H-3), 3.62 (ddd, J = 11.9, 6.0, 1.8
Hz, 1H, H-6a), 3.41 (dt, J = 11.8, 5.8 Hz, 1H, H-6b), 3.30–3.25
(m, 2H, H-4, H-5), 1.35 (s, 3H, OCH_3), 1.23 (s, 3H, OC(CH_3)2);
13C NMR (126 MHz, DMSO-d6) δ 134.4 (C_HCH2-allyl), 117.1
(CHC_H2-allyl), 108.2 (OC_(CH3)2), 95.5 (C-1), 78.5 (C-3), 75.2
(C-2), 71.3 (C-4/C-5), 68.2 (C-4/C-5), 66.8 (OC_H2-allyl), 60.6
(C-6), 28.0 (OC(C_H3)2), 26.2 (OC(C_H3)2). ESI-MS calcd.
C12H20NaO6
+: 283.1; found: 283.1. Allyl 2,3-O-isopropylidene-
α-D-mannopyranoside was transformed to allyl 2,3-O-
isopropylidene-6-O-trityl α-D-mannopyranoside (31) following
the protocol from Gigg et al.53 1H NMR (500 MHz, DMSO-d6)
δ 7.45–7.36 (m, 6H, ArCH), 7.37–7.29 (m, 6H, ArCH), 7.29–
7.21 (m, 3H, ArCH), 6.03 (dddd, J = 17.3, 10.4, 5.9, 5.2 Hz,
1H, CH_CH2-allyl), 5.33 (dq, J = 17.3, 1.7 Hz, 1H, CHCH_2-allyl),
5.27–5.21 (m, 1H, CHCH_2-allyl), 5.13 (d, J = 6.9 Hz, 1H, OH-
4), 5.08 (s, 1H, H-1), 4.41 (ddt, J = 13.0, 5.3, 1.6 Hz, 1H,
OCH_2-allyl), 4.15 (ddt, J = 12.9, 6.0, 1.4 Hz, 1H, OCH_2-allyl),
4.10 (dd, J = 5.7, 0.8 Hz, 1H, H-2), 3.93 (dd, J = 7.3, 5.8 Hz,
1H, H-3), 3.67 (ddd, J = 9.7, 7.6, 1.7 Hz, 1H, H-5), 3.35–3.28
(m, 1H, H-6a), 3.21 (dt, J = 10.5, 7.1 Hz, 1H, H-4), 3.03 (dd, J
= 9.9, 7.6 Hz, 1H, H-6b), 1.38 (s, 3H, OC(CH_3)2), 1.27 (s, 3H,
OC(CH_3)2);
13C NMR (126 MHz, DMSO-d6) δ 143.9 (3C, ArC),
134.4 (C_HCH2-allyl), 128.3 (6C, ArCH), 127.9 (6C, ArCH),
127.0 (3C, ArCH), 117.1 (CHC_H2-allyl), 108.3 (OC_(CH3)2), 95.5
(C-1), 85.8 (C-Tr), 78.5 (C-3), 75.2 (C-2), 69.8 (C-5), 68.5 (C-4),
66.9 (OC_H2-allyl), 63.5 (C-6), 27.9 (OC(C_H3)2), 26.2 (OC(C_H3)2);
ESI-MS calcd. C31H34NaO6
+: 525.2; found: 525.2.
Allyl 2,3-O-isopropylidene-4-O-methyl-6-O-trityl-α-D-manno-
pyranoside (32). Allyl 2,3-O-isopropylidene-6-O-trityl-α-D-
mannopyranoside (31) (310 mg, 0.62 mmol, 1 equiv.) was
dissolved in dry DMF (1.5 mL) and NaH (60%, 74 mg, 1.85
mmol, 5 equiv.) was added at 0 °C under nitrogen atmo-
sphere. After 10 min, MeI (116 μL, 1.85 mmol, 5 equiv.) was
added dropwise and the reaction was stirred for 1 h at 0 °C.
The reaction mixture was quenched with EtOH (1 mL), sat.
NaHCO3 solution (2 mL) was added and the reaction mixture
was extracted with EtOAc (3 × 10 mL). The combined organic
layers were dried over Na2SO4 and the solvent was removed in
vacuo. The title compound 32 (262 mg, 0.51 mmol, 83%) was
obtained after purification by MPLC (petrol ether/EtOAc = 9 :
1). 1H NMR (500 MHz, DMSO-d6) δ 7.45–7.38 (m, 6H, ArCH),
7.38–7.30 (m, 6H, ArCH), 7.29–7.23 (m, 3H, ArCH), 5.97
(dddd, J = 17.3, 10.4, 5.9, 5.2 Hz, 1H, CH_CH2-allyl), 5.30 (dq, J
= 17.3, 1.7 Hz, 1H, CHCH_2-allyl), 5.24–5.17 (m, 1H, CHCH_2-al-
lyl), 5.11 (s, 1H, H-1), 4.29 (ddt, J = 13.0, 5.2, 1.5 Hz, 1H,
OCH_2-allyl), 4.13 (dd, J = 5.7, 0.8 Hz, 1H, H-2), 4.12–4.04 (m,
2H, OCH_2-allyl, H-3), 3.60 (ddd, J = 10.2, 5.7, 1.9 Hz, 1H, H-
5), 3.29 (dd, J = 10.2, 6.9 Hz, 1H, H-4), 3.25 (dd, J = 9.9, 1.9
Hz, 1H, H-6a), 3.21 (s, 3H, OCH3), 3.08 (dd, J = 9.9, 5.7 Hz,
1H, H-6b), 1.48 (s, 3H, OC(CH_3)2), 1.30 (s, 3H, OC(CH_3)2);
13C
NMR (126 MHz, DMSO-d6) δ 143.7 (3C, ArC), 134.2 (C_HCH2-
allyl), 128.2 (6C, ArCH), 127.8 (6C, ArCH), 127.0 (3C, ArCH),
117.2 (CHC_H2-allyl), 108.6 (OC_(CH3)2), 95.5 (C-1), 85.7 (Ph3-
C_O-), 77.8 (C-3), 77.4 (C-4), 75.1 (C-2), 68.0 (C-5), 67.1 (OC_H2-
allyl), 62.5 (C-6), 58.3 (OC_H3), 27.7 (OC(C_H3)2), 26.1
(OC(C_H3)2); ESI-MS calcd. C32H36NaO6
+: 539.2; found: 539.2.
Allyl 4-O-methyl-α-D-mannopyranoside (33). Allyl 2,3-O-
isopropylidene-4-O-methyl-6-O-trityl-α-D-mannopyranoside (32)
(131 mg, 0.254 mmol) was stirred in acetone (1.6 mL) in pres-
ence of aqueous acetic acid (80%, 0.8 mL) for 21 h at r.t. The
reaction mixture was neutralized with NaOH, the volatiles
were removed in vacuo and the residue was purified by MPLC
(CH2Cl2/EtOH = 95 : 5) to give 33 as solid (16.2 mg, 0.07
mmol, 27%). 1H NMR (500 MHz, MeOH-d4) δ 5.92 (dddd, J =
17.2, 10.5, 5.9, 5.1 Hz, 1H, CH_CH2-allyl), 5.28 (dq, J = 17.3,
1.7 Hz, 1H, CHCH_2-allyl), 5.21–5.13 (m, 1H, CHCH_2-allyl),
4.77 (d, J = 1.3 Hz, 1H, H-1), 4.18 (ddt, J = 13.1, 5.1, 1.6 Hz,
1H, OCH_2-allyl), 3.99 (ddt, J = 13.1, 5.9, 1.4 Hz, 1H, OCH_2-al-
lyl), 3.81–3.74 (m, 3H, H-2, -3, -6a), 3.69 (dd, J = 11.8, 5.1 Hz,
1H, H-6b), 3.54 (s, 3H, OCH_3), 3.48 (dddd, J = 9.9, 5.2, 2.3, 0.6
Hz, 1H, H-5), 3.41–3.32 (m, 1H, H-4); 13C NMR (126 MHz,
MeOH-d4) δ 135.4 (C_HCH2-allyl), 117.3 (CHC_H2-allyl), 100.6
(C-1), 78.4 (C-4), 73.8 (C-5), 72.7 (C-2/3), 72.5 (C-2/3), 68.8
(OC_H2-allyl), 62.5 (C-6), 60.9 (OC_H3); ESI-MS calcd.
C10H18NaO6
+: 257.1; found: 256.9.
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Expression of recombinant BC2L-A and LecB and Competitive
binding assays
BC2L-A10 and LecB22 were produced according to the previ-
ously published protocols. The competitive binding assay for
BC2L-A based on fluorescence polarization was performed in
analogy to the published protocol22 for LecB. For titration of
3 and 4 with BC2L-A, 10 μL of fluorescent reporter ligand
N-(fluorescein-5-yl)-N′-(α-D-mannopyranosyloxyethyl)-thiocarbamide
3 (30 nM) or N-(fluorescein-5-yl)-N′-(α-L-fucopyranosyl-O-ethyl)-
thiocarbamide 4 (30 nM) in TBS/Ca (20 mM Tris, 137 mM
NaCl, 2.6 mM KCl at pH 7.4 supplemented with 100 μM
CaCl2) were mixed with 20 μL serial dilutions (507 μM to
0.247 μM, i.e., a final concentration of 338 μM to 0.165 μM)
of BC2L-A in TBS/Ca in triplicates. For compound inhibition
assay, 20 μL of a stock solution of BC2L-A (2.25 μM) and fluo-
rescent reporter ligand 3 (15 nM) in TBS/Ca were mixed with
10 μL serial dilutions (2 mM to 25.6 nM) of testing com-
pounds in TBS/Ca in triplicates in black 384-well microtiter
plates (Greiner Bio-One, Germany, cat no. 781900). In all ex-
periments, the microtiter plates were centrifuged at 800 rpm
for 1 min at 23 °C and incubated for 3–4 h at r.t. Fluorescence
emission parallel and perpendicular to the excitation plane
was measured on a PheraStar FS (BMG Labtech, Germany)
plate reader with excitation filters at 485 nm and emission
filters at 535 nm. The measured intensities were reduced by
buffer values and fluorescence polarization was calculated.
The data were analyzed using BMG Labtech MARS software
and/or with Graphpad Prism and fitted according to the
four parameter variable slope model. A minimum of three
independent measurements of triplicates each was performed
for every ligand. To assure reliability of the read signal and
exclude any influence of the test compounds on the total
intensity of the fluorescence of the tracer molecule 3, total
fluorescence intensities of each well were monitored. Concen-
trations of test compounds yielding deviations in fluores-
cence intensity of >20% of tracer 3 in absence of test com-
pound are generally not taken for determination of IC50
values. Here, none of the tested compounds showed any in-
fluence on the total fluorescence intensity of tracer 3, yield-
ing reliable fluorescence polarization data.
Measurements with LecB were performed according to
previously reported protocol using the fucose based fluores-
cent reporter ligand 4.22
Molecular Docking
The docking study was performed using PLANTS v1.1.54 The
calculation of charge and energy minimization of the protein
and tested compounds was done using Molecular Operating
Environment (MOE), 2014.09 (Chemical Computing Group
Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Can-
ada, H3A 2R7, 2015). Thereafter, the standard docking proce-
dure (PLANTS Manual, available at http://www.tcd.uni-
konstanz.de/plants_download/download/manual1.1.pdf) was
validated by removing the mannoheptose ligand and
redocking it inside the active site of BC2L-A (PDB code:
4AOC). The docking site was limited inside a 13.3 Å radius
sphere centered in the mass center (coordination: X = −27.73,
Y = 53.64 and Z = −12.64) of the crystallized ligand. Glu31,
Asp110, Gly111 and His112 were set as flexible residues in
the input file. After docking the original mannoheptose li-
gand for validation of the process, a good agreement was ob-
served between the localization of the docked ligand and in
the crystal structure (rmsd = 2.0 Å). This validated docking
protocol was then used for docking the derivatives 22 and 24
into the crystal structure of the protein.
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Photorhabdus luminescens lectin A (PllA): A new probe for
detecting !-galactoside–terminating glycoconjugates
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Lectins play important roles in infections by pathogenic bac-
teria, for example, in host colonization, persistence, and biofilm
formation. The Gram-negative entomopathogenic bacterium
Photorhabdus luminescens symbiotically lives in insect-infect-
ing Heterorhabditis nematodes and kills the insect host upon
invasion by the nematode. The P. luminescens genome harbors
the gene plu2096, coding for a novel lectin that we named PllA.
We analyzed the binding properties of purified PllA with a gly-
can array and a binding assay in solution. Both assays revealed a
strict specificity of PllA for !-galactoside–terminating glyco-
conjugates. The crystal structures of apo PllA and complexes
with three different ligands revealed the molecular basis for the
strict specificity of this lectin. Furthermore, we found that a 90°
twist in subunit orientation leads to a peculiar quaternary struc-
ture comparedwith that of its ortholog LecA fromPseudomonas
aeruginosa.We also investigated the utility of PllA as a probe for
detecting !-galactosides. The !-Gal epitope is present on wild-
type pig cells and is themain reason for hyperacute organ rejec-
tion in pig to primate xenotransplantation. We noted that PllA
specifically recognizes this epitope on the glycan array anddem-
onstrated that PllA can be used as a fluorescent probe to detect
this epitope on primary porcine cells in vitro. In summary, our
biochemical and structural analyses of the P. luminescens lectin
PllA have disclosed the structural basis for PllA’s high specific-
ity for !-galactoside–containing ligands, and we show that PllA
can be used to visualize the !-Gal epitope on porcine tissues.
Photorhabdus luminescens is a Gram-negative !-proteobac-
terium belonging to the Enterobacteriaceae family. In its com-
plex life cycle it lives symbiotically in the intestine of Heterorh-
abditidae entomopathogenic nematodes and pathogenically in
insect larvae upon nematode invasion. P. luminescens was first
isolated in 1977 as a symbiont bacterium of Heterorhabditidae
nematodes and classified initially as Xenorhabdus luminescens
(1, 2) and later renamed P. luminescens (3). The genus Photorh-
abdus consists of the four species P. luminescens, P. temperata,
P. heterorhabditis, and P. asymbiotica (4–6), with the latter
species being pathogenic to humans (7). BothXenorhabdus and
Photorhabdus species enter a wide range of insect larvae via
Steinernematidae and Heterorhabditidae nematodes, respec-
tively (4, 8). Once the nematodes enter into the insect at their
infective juvenile developmental stage, their bacterial symbi-
onts are released into the insect’s blood, and both bacteria and
nematode are able to kill the larvae within 48 h (9).
The complete genome of P. luminescens subsp. laumondii
TTO1was published in 2003 by Duchaud et al. (10). Compared
with other bacteria, it shows a high number of genes predicted
as toxins, and some of them, such as Tca and Tcd, have been
extensively studied (10–12). Often, bacterial carbohydrate-
binding proteins, i.e. lectins, also act as toxins in addition to
their function as adhesins to enable host colonization. A num-
ber of predicted lectins are present in the genome of P. lumine-
scens, but only one example, the fucose-binding protein PLL
(13), has been experimentally characterized. In Pseudomonas
aeruginosa, a ubiquitous opportunistic pathogen with a high
current medical need for new therapeutics (14), the two lectins
LecA and LecB are both toxins and adhesins with roles in bio-
film formation and persistent infection (15–17). LecB (18, 19)-
type proteins are relatively common, and several LecB homo-
logs have also been previously characterized in other bacterial
species such as Ralstonia solanaceum (20), Burkholderia ceno-
cepacia (21–23), and Chromobacterium violaceum (24). The
P. luminescens genome harbors several genes of predicted lec-
tins that are homologs of LecB (25). In contrast, homologs of
LecA are comparably rare and are not present in the genomes of
the former species. InP. luminescens, a single gene encoding for
a LecA homolog (plu2096) was predicted by Duchaud et al.
(10).
Here, we report the biochemical and structural character-
ization of the P. luminescens lectin PllA. We demonstrate
that PllA is highly specific for "-galactoside–containing
ligands. By determining several crystal structures of PllA in
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complex with ligands, we were able to rationalize PllA’s
strong preference for !-galactosides. We further demon-
strate that PllA can serve as a detection tool for the specific
visualization of the !-Gal epitope present on porcine tissue.
This epitope is responsible for hyperacute rejection of pig to
primate organ xenotransplants.
Results and discussion
Identification and production of PllA
Although P. aeruginosa LecB orthologs have been widely
studied, orthologs of LecA have not been characterized in
detail. We searched the publicly accessible NCBI database
using protein blast and the protein sequence of LecA from
strain PAO1 as a template. A moderate number of orthologs
was retrieved from only a few different genera of Gram-nega-
tive bacteria. These were mainly entomopathogenic Photorh-
abdus and Xenorhabdus species, as well as human opportunis-
tic pathogens from the Enterobacter spp. and a few other
pathogenic bacterial species (see supplemental Fig. S1).
In P. luminescens, the gene plu2096was previously proposed
as the coding gene for a LecA-like protein (10) and later con-
firmed (26) to be a galactose-binding lectin. An alignment of the
retrieved orthologs of LecA in each Photorhabdus and Xenorh-
abdus species shows a high degree of similarity within these
entomopathogenic species (Fig. 1). Although the residues
involved in metal and ligand binding in LecA are relatively
conserved, distinct differences to P. aeruginosa LecA were
observed; LecA contains an insert flanked by two cysteines that
are absent in PllA, and the Photorhabdus and Xenorhabdus ho-
mologs contain an additional C-terminal tail of 5–13 amino
acids, which is partially conserved (Fig. 1).
PllA has 37% sequence identity to LecA, and all amino acids
whose side chains are involved in calcium ion binding are con-
served except for one Asn (LecA) to Asp (PllA) variation.
Amino acids involved in carbohydrate recognition are only par-
tially conserved.
Recombinant production and purification of PllA
The plu2096 gene was amplified from genomic DNA of
P. luminescens subsp. laumondii TTO1 and cloned into the
pET22b(!) vector. Recombinant expression in Escherichia
coli BL21(DE3) yielded a protein product at a 13-kDa appar-
ent molecular mass by SDS-PAGE (Fig. 2A), which corre-
sponds to its predicted size of 12.95 kDa. Because of the
sequence homology to galactose-binding LecA, we subjected
the cell lysate to galactosylated Sepharose (27), and PllA was
retained on this affinity resin. Subsequent elution was
achieved using galactose in the elution buffer. Purification
yielded "6 mg of PllA/liter of bacterial culture, which was
later improved to 19 mg/liter by purification on melibiose-
coupled Sepharose (see below).
Because lectins often oligomerize and LecA forms a
tetramer (28), we analyzed PllA’s multimeric state using
Figure 1. Sequence alignment of LecA from P. aeruginosa with hypothetical LecA-like proteins from Photorhabdus and Xenorhabdus species (one
single orthologper organism selected based onhighest identity to LecA). Strictly conserved amino acids are shaded black, and similarly conserved amino
acids are shaded gray. Black dot, amino acid of LecA involved in Ca2! binding; black triangles, amino acids of LecA involved in sugar binding; asterisks, amino
acids of LecA involved in both Ca2! and sugar binding. Amino acid numbering follows the LecA crystal structure where the N-terminal methionine is lacking.
The depicted protein sequence of P. luminescens (PllA) is encoded by the plu2096 gene.
Photorhabdus lectin A—PllA
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size-exclusion chromatography (SEC).3 The protein’s
observed apparent molecular mass was 27 kDa, which sug-
gested a PllA dimer (Figs. 2B and supplemental Fig. S2). When
we used the more robust technique of dynamic light scattering
(DLS), we observed a homogeneous sample with an apparent
molecular mass of 52.1 kDa (Fig. 2C). The tetramer LecA was
also studied byDLSunder identical conditions, and its apparent
molecularmass of 52.4 kDa (supplemental Fig. S3)matched the
value for PllA and thus suggests the tetramerization of PllA in
solution. The observed differences for PllA in SEC and DLS
could result from weak interactions between PllA and the gly-
can-based Sepharose resin, altering the observed molecular
mass to a smaller size.
Carbohydrate-binding specificity of PllA using the CFG glycan
array
To assess the carbohydrate-binding specificity of PllA, the
protein was fluorescently labeled using fluorescein isothiocya-
nate (FITC), and binding to a glycan array containing over 600
carbohydrate epitopes was performed at the Consortium for
Functional Genomics (Fig. 3A). The LecA homolog PllA
showed a strict specificity toward glycans with terminal !-gal-
actosides, whereas"-galactosides and other carbohydrates only
showed very weak or no binding. The highest apparent binding
affinity was detected for the bivalent !-Gal-terminating N-
glycan (Gal-!-1,3-Gal-"-1,4-GlcNAc)2Man3GlcNAc2 (glycan
nos. 360 and 550) or its difucosylated derivative glycan no. 368
bearing blood group B antigens at the non-reducing end and
the two monovalent disaccharides Gal-!-1,3-GalNAc (glycan
no. 112) and Gal-!-1,4-GlcNAc (glycan no. 123).
The highest apparent binding was observed for bivalent
Gal-!-1,3-Gal-"-1,4-GlcNAc terminating glycans (glycans no.
360, 368, and 550). This glycan structure, called the !-Gal
epitope (29), is a ubiquitous constituent of glycans in non-
primate mammals and new world monkeys. The nematode
Parelaphostrongylus tenuis also contains N-glycans deco-
rated with this epitope (30). This epitope is mainly respon-
sible for hyperacute rejection of porcine organ transplants in
humans during xenotransplantation (29, 31). Interestingly,
the corresponding monovalent glycans (no. 105 and 115)
showed a 4–5-fold lower binding signal (Table 1), indicating
that PllA binds carbohydrates multivalently as known for its
ortholog LecA. Interestingly, when the same monovalent
epitopes were presented on a shorter spacer (Sp0) with one
mannose between spacer and epitope (no. 516 and 517),
binding was reduced further.
Apart from the divalent ligands, only the two disaccharides,
Gal-!-1,3-GalNAc and Gal-!-1,4-GlcNAc, showed a high
binding signal among the monovalent series (Fig. 3A). These
two ligands are monovalently displayed and may reveal the
intrinsic specificity of PllA, because other monovalent ligands
showed only weak or no binding to PllA on this glycan array.
Interestingly, these two ligands displayed much stronger bind-
ing than analogous Gal-!-1,3-Gal and Gal-!-1,2-Gal, suggest-
ing an important role of the acetamide moiety in the penulti-
mate residue for binding to PllA (Table 1). Among the
monovalent ligands on the array, the observed linkage specific-
ity of PllA was broad for glycans containing terminal Gal-!-1,3
and Gal-!-1,4 linkages. The single present Gal-!-1,6-linked
ligand (Gal-!-1,6-Glc) wasmoderately bound, whereas the sin-
gle Gal-!-1,2-linked ligand (Gal-!-1,2-Gal) was not recognized
by PllA (Table 1).
To compare the carbohydrate specificity of PllA with its pre-
viously characterized ortholog LecA (32), glycan array binding
data of monovalent glycan ligands for both lectins was normal-
ized and plotted (Fig. 3B). Notably, LecA showed the best bind-
ing to Gal-!-1,4-Gal-"-1,4-GlcNAc, which is only weakly rec-
ognized by PllA. This glycan is part of the glycosphingolipid
Gb3,whichwhen bound by LecA triggersmembrane bending, a
process that was proposed as an entry pathway for P. aerugi-
nosa invasion into the host cell (33). In contrast, PllA showed
high apparent binding to the epitopes Gal-!-1,3-GalNAc and
Gal-!-1,4-GlcNAc, whereas LecA only showsmoderate appar-
ent binding as observed for a number of other!-galactosides on
the glycan array (Fig. 3B). In summary, LecA is a rather promis-
cuous receptor for a variety of monovalent galactosides. In
addition to PllA’s binding to the bivalent N-glycan structures
described above, PllAwas rather specific forGal-!-1,3-GalNAc
and Gal-!-1,4-GlcNAc, one or both of which may be the natu-
ral ligand of PllA.
Development of a competitive binding assay for PllA
To rapidly assess and quantify the binding specificity of PllA,
we developed a competitive binding assay for PllA by utilizing
fluorescence polarization, which is based on our previous work
(19, 21, 27, 34) for four different lectins. Four different FITC-
labeled D-galactosides (27) were titrated with increasing
amounts of PllA (Fig. 4, A–C). All three "-linked galactosides
3 The abbreviations used are: SEC, size-exclusion chromatography; PDB, Pro-
tein Data Bank; r.m.s.d., root mean square deviation; BisTris, 2-[bis(2--
hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; DLS, dynamic
light scattering; GTKO, !-1,3-galactosyltransferase knock-out; SCNT,
somatic cell nuclear transfer; IPTG, isopropyl 1-thio-"-D-galactopyrano-
side; BAC, bacterial artificial chromosome.
Figure 2. A, recombinant expression and affinity purification of PllA analyzed
by SDS-PAGE (15%). E. coliwhole-cell extracts of uninduced (lane 1) and IPTG-
induced cultures (lane 3), and purified PllA (lane 4), molecular mass marker in
kDa (lane 2) are shown. B, Sepharose size-exclusion chromatogram of PllA; C,
DLS analysis of PllA.
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(2–4) did not show binding up to 300 !M PllA. In contrast,
titration of "-galactoside 1 resulted in binding with aKd of 62.7
!M as observed by the increase in fluorescence polarization.
These data confirmed the strict"-galactoside specificity of PllA
in solution that was observed on the glycan array.
The latter system was then used for a competitive binding
assay, where fluorescent "-galactoside 1was competitively dis-
placed fromPllA usingmethyl"-D-galactoside (12), and a set of
available D-galactose derivatives (Fig. 4D and Table 2). Interest-
ingly, the obtained IC50 for 12 was 0.52 mM, which is!10-fold
weaker than the determined affinity of the fluorescent analog 1.
Among the monosaccharides tested, free D-galactose (9),
showed inhibition of PllA with a reduced affinity (IC50 " 1.57
mM) compared with glycoside 12, probably due to the partial
presence of the non-binding #-anomer. Methyl "-glycosides of
D-glucose (5), L-fucose (6), D-mannose (7), or methyl #-D-ara-
binoside (8) did not show detectable binding to PllA. Replace-
ment of the 2-hydroxy group of galactose with a free amine in
D-galactosamine (10) led to a 2-fold increase in the binding
affinity (IC50 " 0.86 mM). Acetamide substitution in the same
position, i.e. N-acetylgalactosamine (11), resulted in a complete
loss of binding. Next, we tested "-galactosides with different
aglycons of varying size, e.g. methyl, allyl, 4-nitrophenyl,
4-methylumbelliferyl, and X-Gal (12–14, 16–18). These mod-
ifications only showed a small effect on the binding affinity.
O-Alkylation of ring hydroxyl groups is a requirement for
ligand binding of some lectins like the tectonins (35, 36). For
PllA,O-methylation of the 3-hydroxyl group resulted in a com-
plete loss of affinity (14 3 15). A similar loss of affinity was
observed for O-methylation of the P. aeruginosa LecB or
B. cenocepacia BC2L-A ligands fucose and mannose (21).
Figure 3. Carbohydrate specificity of PllA on a glycan array.A,profiling of
the glycan-binding specificity of PllA on a glycan array. Glycans containing
terminal "-galactoside are colored black; those with terminal #-galactoside
are red, and oligosaccharides with neither of these terminal moieties are col-
ored blue. Selected structures showing highest apparent binding are illus-
trated in CFG notation. B, comparison of glycan-binding specificity between
PllA (this work) and LecA (PA-IL (32)) from P. aeruginosa based on normalized
CFG glycan array data. Normalization was done by dividing RFU averages of
theglycanof interestby theRFUaverageof the ligandwith thehighest appar-
ent affinity on the respective array (i.e. glycan 550 for PllA and glycan 31 for
LecA). Glycan structures are indicated anddepictedwith thedifferent spacers
of the array for LecA. For the PllA array, identical glycans generally contain
#-Sp8 spacers except 105 (Sp0) and 116 (#-Sp0). Numbers on top of columns
indicate glycan number of the respective arrays. A and B, error bars corre-
spond to six replicates.
Table 1
Comparison between high binding glycans and structurally related
glycans on the array, i.e. comparison of linkagetypes andmultivalent-
monovalent effect
Note: Spacers vary on the glycan array.
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We also tested a set of oligosaccharides containing !-galac-
tosyl residues for competitive binding to PllA. Gal-!-1,3-Gal
(20, IC50 ! 0.90 mM) and Gal-!-1,4-Gal (21, IC50 ! 1.08 mM)
showed a 2-fold lower binding affinity to PllA than melibiose
(Gal-!-1,6-Glc, 22, IC50 ! 0.39 mM), whereas Gal-!-1,2-Gal
(19) was only weakly active and resulted in"50% inhibition at
10 mM. A comparable binding specificity for Gal-!-1,6-Glc has
been reported for LecA from P. aeruginosa (37). The plant tri-
saccharide raffinose (25) contains a terminal melibiose motif
and showed the highest binding to PllA among all tested com-
pounds with an IC50 of 0.11 mM. This ubiquitous plant galacto-
side has also shown an inhibitory effect on P. aeruginosa bio-
films and inhibits LecA in a similar affinity range (Kd! 32 "M)
(37, 38). The tetrasaccharide stachyose (26) is another plant
derivative of raffinose with an additional 1,6-linked !-galacto-
side moiety. For PllA an IC50 of 0.34 mMwas observed, indicat-
ing that longer oligosaccharides do not improve the binding
affinity to PllA, which is different for LecA. Bivalent oligosac-
charides containing the !-Gal antigen Gal-!-1,3-Gal-#-1,4-
GlcNAc were identified as the apparent best ligands of the
glycan array (Fig. 3A). The corresponding monovalent trisac-
charide 27 was tested in our competitive binding assay and
showed only"70% inhibition of PllA at 10mM.Thisweak bind-
ing is in good agreement with the glycan array data where the
monovalent !-Gal epitope had reduced binding to PllA com-
pared with its bivalent structure (see Table 1).
Because Gal-!-1,3-GalNAc and Gal-!-1,4-GlcNAc were
identified as the monovalent ligands with the highest apparent
affinity on the glycan array, we tested the corresponding bioti-
nylated disaccharides 23 and 24, respectively. Both soluble gly-
cans differ only in spacer identity and for 23 also in the ano-
meric configuration from those glycans used for the production
of the glycan array. Surprisingly, they were as active as the com-
parably biotinylated !-galactosyl monosaccharide 13, display-
ing IC50 values from 0.59 to 0.66 mM.
The human blood group antigen P1 (28) (39) was also mod-
erately recognized by PllA on the glycan array (ligand 121, sup-
plemental Table S1) and in the competitive binding assay solu-
ble monovalent 28 showed a moderate binding affinity (IC50!
1.80mM) to this lectin. Because PllAwas shown to bind to!-Gal
residues but not to GalNAc residues (see above) and it recog-
nized the blood group B-terminating ligand 368 on the glycan
array (Fig. 3A), we also tested soluble blood group B antigens
29 and 30. These oligosaccharides were inhibitors of PllA
with moderate potency (IC50 of 1.18 and 1.35 mM, respec-
tively). This specificity of PllA is in contrast to LecA, which
binds to B and A antigens (27). Thus, PllA could be used as a
new reagent for rapid identification of blood group B sero-
Figure 4. Establishing a carbohydrate-binding assay for PllA in solution. A, structure of fluorescent ligands 1–4 based on D-galactose. B, titration of
fluorescent ligands 1–4 with PllA. C, dissociation constant for 1 was obtained from a four-parameter fitting procedure to the dose-dependent increase in
fluorescence polarization (Kd, 62.7# 3.8"M).D, competitive inhibition of the binding of 1 to PllA withmethyl !-D-galactoside (12, IC50! 0.52# 0.07mM) and
raffinose (25, IC50 ! 0.11 # 0.01 mM). One representative titration experiment of triplicates on one plate is shown. Dissociation constant and standard
deviations given were obtained from at least three independent replicates of triplicates on three plates each.
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types such as the currently used GS-IB4 isolectin from Grif-
fonia simplicifolia (40).
PllA, a lectin with a unique tetrameric structure
Apo-PllA crystallizes in space group P3221 and crystals dif-
fracted to 1.7 Å. Data collection and refinement statistics for all
presented PllA structures can be found in Table 3. The core of
PllA consists of two four-stranded anti-parallel !-sheets (Fig.
5). We did not observe the canonical Ca2! ion found in other
C-type lectins at the sugar-binding site, whichmay be a result of
the crystallization buffer that contained a high concentration of
citrate known to chelate calcium ions.
The asymmetric unit contained two PllA dimers, which form
tetramers with symmetry mates in accordance with DLS data.
The C-terminal five-residue extension (Fig. 1) of the four
protomers are engaged in well-defined interactions leading to a
90° twist in the tetramer (Fig. 6A). Of the tail residues (YSPLK),
Tyr-118 packs hydrophobically against Pro-120, and Ser-119
forms two hydrogen bonds with the tetramer partner (Ser-119
side-chain hydroxyl with side-chain amino group of Lys-82,
Ser-119 carbonyl with the main chain of Thr-83). Residue Leu-
121 is inserted into a tailored hydrophobic pocket of the
tetramer partner, which is composed of residues Leu-22, Ile-28,
Ala-60, Ile-68, Phe-73, Ile-75, Val-79, Val-84, and Leu-90 (Fig.
6B). When we compared the structure of PllA with the struc-
ture of the well-studied protein LecA, we found the structures
to be very similar (C" r.m.s.d. of 0.67 over 78 atoms, supple-
mental Fig. S11). The main differences are found in the region
between !3 and !7 (Fig. 5C), which has a profound impact on
carbohydrate binding (see below).
The sequence alignment of PllA with LecA from P. aerugi-
nosa and the LecA homologs from Photorhabdus and Xenorh-
abdus species showed that PllA and LecA homologs from the
latter two species possess an extension at their C termini. This
extension led to the surprising result that the dimerization of
dimers is twisted by 90° in PllA. In contrast, LecA does not
possess the five C-terminal residues. As a result, the LecA
tetramer is planar and formed by the tail-to-tail arrangement of
two dimers (Fig. 6, C and D). We have no indication as to the
biological significance of this arrangement, but we believe that
the interactions between the tails of the tetramer partners will
lead to a significant stabilization of the tetrameric assembly.
Structural basis of!-galactoside specificity of PllA
Tounderstand the"-galactoside specificity of PllA,we deter-
mined the crystal structures of several PllA–carbohydrate
complexes in the presence of 3 mM calcium chloride in the
crystallization buffer (Fig. 7): PllA in complex with the mono-
saccharide methyl "-D-galactoside (12), the trisaccharide raffi-
nose (25), and an "-D-galactoside linked to fluorescein (1).
Table 2
Evaluation of natural and synthetic inhibitors of PllA using the competitive binding assay
Averages and standard deviations were obtained from three independent experiments. n.i.: no inhibition observed up to 10 mM. SP: spacer –(CH2)3NH–CO(CH2)5NH–.
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Complex crystals of PllA with 12 were obtained by co-crystal-
lization. The resulting crystals belonged to space group P21 and
were diffracted to 1.56 Å. The overall structure of PllA does not
change upon complex formation (C! r.m.s.d. of 0.12 Å), andwe
observed unambiguous electron density for Ca2! and the
ligand in each of the eight protomers in the asymmetric unit.
The canonical Ca2! ion at the sugar-binding site is coordinated
by the side chains of Asp-96, Thr-100, Asp-103, andAsn-104 as
well as the main-chain carbonyl oxygen atoms of Tyr-38 and
Thr-100. The ligand is not involved in crystal contacts and ori-
ented in the same way in each protomer. It sits in a shallow
binding pocket and is engaged in a total of 10 hydrogen bonds
(protein and the Ca2! ion): the anomeric oxygen (O1) and gal-
actoside C2 hydroxyl with the side chain of Glu-44; sugar C3
hydroxyl with the Ca2! ion, the side chain of Asp-103, and the
main chain of Tyr-38; sugar C4 hydroxyl with the Ca2! ion, the
side chain of Asp-96, and the main chain of Tyr-38; sugar ring
O5 with the side chain of Gln-57; and sugar C6 hydroxyl with
the side chain of Gln-57. From this complex structure, it is clear
that PllA is only able to bind to!-galactosides; the side chains of
the two amino acids Val-43 and Asn-55 that are absent in LecA
form a barrier and any"-linkagewould result in a clashwith the
PllA surface (Fig. 8). The structure also allowed us to rationalize
why D-galactosamine (10) is a better binder than D-galactose
(9), and why N-acetylgalactosamine (11) shows no detectable
binding. By swapping the C2 hydroxyl group for an amino
group, the sugar can now engage in an additional hydrogen
bond with the side chain of Asp-103 (see supplemental Fig. S8).
Acetylation of the amino group leads to a clash with the protein
and thus abolishes binding.
Complex crystals of PllAwith raffinose were also obtained by
co-crystallization. The resulting crystals belonged to space
group P1 and diffracted to 1.75 Å. As expected, the overall
structure of PllA does not change upon complex formation (C!
r.m.s.d. of 0.12Å). There are eight protomers in the asymmetric
unit, and we observed unambiguous electron density for raffi-
nose in all of them. Although some of the raffinose molecules
are involved in crystal contacts, the orientation and shape of the
trisaccharide is virtually identical in each protomer. The orien-
tation of the galactosemoiety does not differ between themon-
osaccharide and raffinose structures, and the same hydrogen
bonds are formed. The !-1,6-linkage leads glucose away from
the PllA surface, but the C4 hydroxyl forms one hydrogen bond
with the side chain of Gln-57. Interestingly, the final fructose
moiety is pointing back toward the PllA surface, giving the raf-
finose an overall horseshoe shape. The fructose C3 and C4
hydroxyls are engaged in a hydrogen bondwith the side chain of
Glu-44. Glu-44 is also involved in hydrogen bond formation
with the galactose C2 hydroxyl, thus linking the two ends of
the raffinose horseshoe resulting in an additional intraligand
hydrogen bond between fructose C6 hydroxyl with galactose
C2 hydroxyl.
Table 3
Data collection and refinement statistics
Statistics for the highest-resolution shell are shown in parentheses. r.m.s. is root mean square.
PllA, apo,
PDB 5OFZ
PllA, Me-!-Gal (12),
PDB 5ODU
PllA, raffinose (25),
PDB 5OFX
PllA, fluorescent ligand 1,
PDB 5OFI
Resolution range 46.05–1.75 (1.81–1.75) 47.2–1.56 (1.62–1.56) 44.09–1.75 (1.81–1.75) 43.76–2.0 (2.07–2.0)
Space group P 32 2 1 P 1 21 1 P 1 P 21 21 21
Unit cell 92.1 92.1 164.2
90 90 120
62.9 103.3 76.1
90 93.0 90
59.0 63.0 75.9
101.1 112.8 94.4
48.6 134.3 153.0
90 90 90
Total reflections 725,065 (34,414) 597,157 (60,933) 539,432 (54,563) 126,530 (12,830)
Unique reflections 81,583 (7832) 133,175 (13,311) 89,118 (9042) 65,944 (6644)
Multiplicity 8.9 (4.4) 4.5 (4.6) 6.1 (6.0) 1.9 (1.9)
Completeness (%) 99.59 (96.57) 96.18 (95.63) 90.73 (92.05) 95.91 (97.62)
Mean I/#(I) 26.62 (3.32) 11.19 (1.22) 9.08 (2.02) 8.23 (2.54)
Wilson B-factor 23.67 14.93 13.78 23.65
R-merge 0.04649 (0.3966) 0.09883 (1.261) 0.1569 (0.7841) 0.05735 (0.2516)
R-meas 0.04921 (0.451) 0.1121 (1.427) 0.1719 (0.8578) 0.08111 (0.3558)
R-pim 0.01592 (0.2106) 0.05232 (0.6619) 0.06949 (0.345) 0.05735 (0.2516)
CC1/2 0.999 (0.886) 0.998 (0.358) 0.994 (0.78) 0.996 (0.907)
CC* 1 (0.969) 1 (0.726) 0.999 (0.936) 0.999 (0.975)
Reflections used in refinement 81,572 (7830) 132,517 (13,152) 89,095 (9038) 65,903 (6639)
Reflections used for R-free 4183 (452) 6491 (608) 4458 (428) 3335 (326)
R-work 0.2006 (0.2858) 0.2050 (0.3530) 0.1849 (0.2669) 0.1864 (0.2446)
R-free 0.2202 (0.3105) 0.2334 (0.3668) 0.2133 (0.2986) 0.2216 (0.3016)
CC(work) 0.943 (0.876) 0.960 (0.626) 0.954 (0.867) 0.957 (0.905)
CC(free) 0.937 (0.823) 0.958 (0.620) 0.940 (0.834) 0.939 (0.820)
No. of non-hydrogen atoms 4138 8639 8749 8306
Macromolecules 3608 7264 7264 7264
Ligands 112 246 180
Solvent 530 1263 1239 862
Protein residues 480 968 968 968
r.m.s. (bonds) 0.009 0.003 0.004 0.004
r.m.s. (angles) 1.00 0.58 0.69 0.61
Ramachandran favored (%) 97.46 98.00 97.69 97.37
Ramachandran allowed (%) 2.54 2.00 2.31 2.63
Ramachandran outliers (%) 0.00 0.00 0.00 0
Rotamer outliers (%) 0.26 0.76 0.51 0.25
Clashscore 3.35 3.92 2.18 1.85
Average B-factor 30.15 22.83 19.00 29.55
Macromolecules 28.81 20.95 17.24 28.84
Ligands 27.65 21.05 29.75
Solvent 39.27 33.22 28.88 35.49
No. of TLS groups 28 50 76 46
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Because we used fluorescent probe 1 in our competitive
binding assays, we wanted to understand how the probe binds
to PllA. Complex crystals of PllA with 1 were also obtained by
co-crystallization. The resulting crystals belonged to space
group P212121 and diffracted to 2.0 Å. The overall structure of
the eight protomers in the asymmetric unit did not differ sig-
nificantly from the apo structure (C! r.m.s.d. of 0.15 Å), andwe
observed unambiguous density for 1 in four of the protomers
(Fig. 7, E and F, and supplemental Fig. S10). The interactions of
the galactose include all of those observed in the other two
structures. Through fortuitous crystal packing, we were able to
obtain good electron density for the fluorophore and were able
to fit it. The ordered nature of the fluorophore is the result of
"-stacking between the tricyclic ring systems of two molecules
of 1 bound to symmetry mates.
The strict specificity toward !-galactosides is unique for
PllA when compared with LecA. From the crystal structure
of PllA with 12, it becomes clear that #-galactosides cannot
be recognized without a steric clash with the protein surface
of PllA (Fig. 8A). In contrast, LecA opens a shallow cleft close
to its anomeric center that allows the accommodation of
large #-linked aglycons, such as in 4-nitrophenyl #-D-galac-
toside. From a superposition of the binding site amino acid
residues of PllA with LecA, it can be deduced that the addi-
tional amino acids Val-43 and Asn-55 present in PllA are
responsible for preventing PllA from binding #-galactosides
(Fig. 8B).
Application of PllA for the detection of the!-Gal epitope
PllA showed the highest apparent binding on the glycan array
to a biantennaryN-glycan structure carrying the !-Gal epitope
on its antenna. This antigen (Gal-!-1,3-Gal-#-1,4-GlcNAc) is a
ubiquitous epitope in non-primate mammals and new world
monkeys. This carbohydrate structure is the major factor of
hyperacute rejection of xenotransplanted organs in humans
(29, 41, 42). In pigs, genetic engineering resulted in animals
lacking the corresponding galactosyltransferase thus reducing
the risk of severe immune responses (31, 43, 44). By usingmod-
ern techniques such as CRISPR/Cas to engineer animals or
animal tissue lacking the !-Gal epitope, quality controls for
the complete suppression of the biosynthetic machineries
are of crucial importance. Currently, the isolectin GS-IB4
Figure5.A, sequenceofPllA. Secondarystructureelementsareshownabovethesequence (bluearrows,#-strands; redbarrel,!-helix).Residues responsible for sugar
bindingarehighlightedwithmagenta stars, Ca2!-binding residueswith cyancircles,andaminoacidscoordinatingbothasyellow triangles. Tail residuesunique toPllA
and its close homologs are highlightedwith a blue box. B, schematic representation of a PllA apomonomer. C, fold diagram for the structure shown in B.
Figure 6. Overall structure of PllA and comparison to LecA. A, schematic representation of the PllA tetramer. Two parallel dimers (yellow/magenta and
green/cyan) form tail-to-tail dimers with a 90° twist. B, detailed view of the PllA tail-to-tail interface. We observe two hydrogen bonds between the side chains
of tail Ser-119 (cyan) and Lys-82 (yellow) and the C terminus of the tail and the backbone nitrogen of Ala-74 (yellow). In addition, tail residue Leu-121 is inserted
into a hydrophobic pocket of its binding partner. C, LecA tetramer is planar, formed by tail-to-tail dimerization of two parallel dimers (yellow/magenta and
green/cyan).D,much shorter tail of LecAprovides several stabilizinghydrogenbonds (dashed lines), but the interactions are not sufficient to cause a twist of the
two dimers relative to each other.
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purified from the plant G. simplicifolia is used as a tool to
identify a wide range of !-galactoside epitopes, among which
is the !-Gal epitope (45). Because of the high selectivity of
PllA, this bacterial lectin could be an alternative to the cur-
rently used GS-IB4.
The crystal structure of GS-IB4 in complex with the terminal
disaccharide Gal-!-1,3-Gal (20) as a methyl glycoside shows
extensive interactions between the terminal galactose residue
and the protein but no contacts with the reducing-end galac-
tose moiety (46). To compare the recognition features of both
proteins to this epitope, we have docked themethyl glycoside of
20 into the carbohydrate-binding site of PllA (supplemental
Fig. S9). In this computed structure, the terminal saccharide
moiety forms extensive contacts with the lectin receptor. In
contrast to GS-IB4, the reducing-end galactose established two
more hydrogen bonds with Glu-44 and Asn-55 of PllA, which
may serve as an explanation for the high specificity of PllA for
the Gal-!-1,3-Gal epitope.
Figure 7. PllA–carbohydrate complex structures. A and B, PllA bound to methyl !-D-galactoside (12). This interaction is stabilized through 10 hydrogen
bonds (dashed lines). Eight of them are between the ligand and the protein, and two are provided by the Ca2! ion. C and D, PllA bound to raffinose (25). In
addition to the hydrogen bonds observed in A, the glucose moiety forms a hydrogen bond with the side chain of Gln-57, whereas terminal fructofuranoside
forms two hydrogen bonds with the side chain of Glu-44, which results in the ligand adopting a horseshoe shape. E and F, PllA bound to fluorescent tracer 1.
No interactionswith theprotein areobservedbeyond the carbohydratemoiety. The fluorescein canonlybeobservedas the result of fortuitous crystal contacts
in half of the monomers in the asymmetric unit. PllA is shown as a yellow schematic/surface representation, ligand as gray sticks, oxygen atoms in red, nitrogen
atoms in blue, sulfur atoms in yellow, and Ca2! ions as green spheres. Difference electron density (Fo" Fc) contoured to 3"with phases calculated fromamodel
that was refined in the absence of metal ions is shown as gray isomesh (B, D, and F).
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We thus tested the suitability of PllA to detect the !-Gal
epitope in wild-type primary pig kidney cells and cells derived
from the corresponding !-1,3-galactosyltransferase knock-out
(GTKO) animals (Fig. 9). Both PllA and the current standard
lectin GS-IB4 visualized the !-Gal antigen in wild-type porcine
cells similarly. Because the !-Gal antigen is also present on
glycolipids in red blood cells (41), we performed hemagglutina-
tion experimentswith red blood cells (RBC) fromwild-type and
GTKOpigs. PllA agglutinated wild-type porcine red blood cells
butwas unable to agglutinate RBCs from theGTKOpig (Fig. 10,
A and B). In addition, we could further show that this aggluti-
nation was galactose-dependent and could be inhibited by the
presence of raffinose (Fig. 10C).
Conclusion
The opportunistic pathogen P. aeruginosa utilizes the two
soluble lectins LecA and LecB for infection of the host and
biofilm formation. Althoughnumerous LecB-like proteins have
been characterized, LecA orthologs are scarce. Here, we show
that various orthologs of LecA are present in the insect patho-
genic bacteria from thePhotorhabdus andXenorhabdus species
as well as in the human gut bacterium and pathogen Enterobac-
ter spp. A high degree of similarity was observed among those
orthologs with LecA having a sequence insert and lacking an
otherwise conserved C-terminal tail.
The gene plu2096 from the entomopathogenic bacterium
P. luminescenswas cloned and recombinantly produced in high
production yields. It encodes the galactose-binding lectin PllA
with 37% identity to LecA. The carbohydrate-binding specific-
ity of PllA was assessed on a glycan array containing over 600
different carbohydrate epitopes. Interestingly, PllA showed
very strict specificity toward !-galactosides with high apparent
binding to the !-Gal epitope as well as to Gal-!-1,4-GlcNAc
and Gal-!-1,3-GalNAc.
To date, the biological role of the Gal-!-1,4-GlcNAc epitope
remains unclear, and natural sources have not been identified
despite the fact that anti-Gal-!-1,4-GlcNAc antibodies are
present in human serum (47). In contrast, Gal-!-1,3-GalNAc
epitopes are present in nematodes and have, for example, been
described in glycolipids from the worms Ascaris suum and
Caenorhabditis elegans (48). Furthermore, Gal-!-1,3-GalNAc
is a ubiquitous epitope present on glycoproteins of the nema-
tode Hemonchus contortus, and vaccination of lambs with gly-
coproteins of the sheep parasite H. contortus specifically elic-
ited anti-Gal-!-1,3-GalNAc IgG antibodies (49). In addition,
!-linked galactosyl residues have been identified in C. elegans
N-glycans attached to mannose residues (50, 51) or attached
to core fucose residues (52). Importantly, the nematodes
C. elegans and H. contortus are both phylogenetically closely
related to Heterorhabditis, whereas A. suum is more distantly
related (53). It is thus reasonable to speculate that the Gal-!-
1,3-GalNAc epitope recognized by the bacterial lectin PllA is
also present in the nematodeHeterorhabditis and plays a role in
bacterial attachment or symbiosis ofPhotorhabdus specieswith
their native nematode hosts. Moreover, this epitope has been
described as one terminal constituent of glycosphingolipids of
the insect Calliphora vicina pupae (54) and members of the
order of diptera, i.e. flies, are generally susceptible to infection
withHeterorhabditis and P. luminescens. Therefore, it is possi-
ble that Gal-!-1,3-GalNAc is one natural ligand bound by PllA
both in the nematode symbiont and in infected insects.
Based on the carbohydrate specificity of PllA as determined
by the glycan array, PllA was tested in a porcine cell culture
staining experiment for the detection of the !-Gal epitope, the
prime reason for hyperacute organ rejection in xenobiotic
transplants. PllA proved to be a suitable detection tool and spe-
cifically detected the !-Gal epitope in porcine tissue and on red
blood cells. This fact qualifies recombinantly produced PllA for
the efficacy assessment of methods to genetically manipulate
cells, such as CRISPR/Cas, for the production of alternative
animal cells, tissue, or organisms lacking the !-Gal epitope as
donors for xenotransplantation.
We are currently analyzing the biological role of PllA in
P. luminescens for its life cycle in nematodes and insects. Fur-
thermore, it will be of interest to analyze the role of PllA
orthologs in the human pathogens P. asymbiotica and the
Enterobacter spp., a groupof bacteria that are part of the normal
human gut flora with pathogenic potential.
Materials andmethods
Chemicals
Methyl !-L-fucoside (6), methyl !-D-mannoside (7), and
D-galactose (9) were purchased from Dextra Laboratories
(Reading, UK); D-galactosamine (10), methyl !-D-galactoside
Figure 8. Rationalizing PllA!-galactoside specificity. A, representation of
the PllA (yellow)-binding pocket withmethyl!-D-galactoside (12, gray sticks).
4-Nitrophenyl "-D-galactoside (salmon sticks and isomesh, taken from PDB
3ZYF)was superposedonto!-D-galactoside. Becauseof the restricted ligand-
binding site of PllA only !-substituted ligands, leading away from the surface,
can be accommodated,whereas"-substituted ligands clash. B, superposition of
the binding site amino acid residues of PllA (blue) with LecA (magenta), oxygen
atoms, red; nitrogen atoms, blue. Residue numbers correspond to PllA.
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(12), p-nitrophenyl !-D-galactoside (16), 4-methylumbelliferyl
!-D-galactoside (17), 5-bromo-4-chloro-3-indolyl!-D-galacto-
side (18), isopropyl "-D-1-thiogalactoside (IPTG) were from
Carbosynth Ltd. (UK); methyl "-D-arabinoside (8) was from
Tokyo Chemical Industry (Japan); methyl !-D-glucoside (5),
N-acetyl-D-galactosamine (11), and stachyose (26) were from
Sigma (Germany); melibiose (22) was from MP Biomedicals
Llc. (France); raffinose (25) was from Th. Geyer Laboratories
(Germany); Gal-!-1,3-Gal (20), Gal-!-1,4-Gal (21), Xeno anti-
gen (27), P1 antigen (28), and blood group B antigens (29, 30)
were from Elicityl OligoTech (France); Gal-!-SP-biotin (13),
Gal-!-1,3-GalNAc-!-SP-biotin (23), and Gal-!-1,4-GlcNAc-
"-SP-biotin (24)were fromLectinity (Russia); andGal-!-1,2-Gal-
"-1-OMe (19) was from Carbohydrate Synthesis (Oxford, UK).
Fluorescent ligands 1–4were synthesized as described (27).
Allyl !-D-galactopyranoside (14) was synthesized from
galactose in a Fischer-type glycosylation with allyl alcohol in
presence of Amberlite IR120/H! (supplemental Scheme 1).
The title compoundwas obtained by recrystallization. 1HNMR
(400 MHz, MeOH-d4) # 5.98 (dddd, J" 17.2, 10.4, 6.1, 5.2 Hz,
1H, CH2CHCH2O-), 5.33 (dq, J " 17.2, 1.7 Hz, 1H,
CH2CHCH2O-), 5.17 (dq, J" 10.4, 1.4Hz, 1H, CH2CHCH2O-),
4.87 (d, J" 3.0 Hz, 1H, H1), 4.23 (ddt, J" 13.0, 5.3, 1.5 Hz, 1H,
CH2CHCH2O-), 4.04 (ddt, J " 13.0, 6.1, 1.4 Hz, 1H,
CH2CHCH2O-), 3.93–3.89 (m, 1H, H4), 3.85–3.78 (m, 1H, H5),
3.78–3.76 (m, 2H, H2, H3), 3.73–3.69 (m, 2H, H6). 13C NMR
(101 MHz, MeOH-d4) # 135.65 (CH2CHCH2O-), 117.48
(CH2CHCH2O-), 99.46 (C1), 72.37 (C5), 71.51 (C2/3), 71.16
(C4), 70.21 (C2/3), 69.39 (CH2CHCH2O-), 62.78 (C6). Tran-
scripts of NMR spectra are shown in supplemental Figs. 4
and 5).
For allyl 3-O-methyl-!-D-galactopyranoside (15), a micro-
wave vial was filled with allyl galactoside 14 (57mg, 0.26mmol)
and dibutyltinoxide (71 mg, 0.29 mmol), and the reagents were
dried in vacuo. Dry PhMe/MeCN (5:1, 660 $l) was added, and
the suspension in the sealed tube was exposed to microwave
irradiation for 20 min at 150 °C. The clear solution was allowed
to cool to 50 °C, and to the resulting suspension was addedMeI
(405$l, 6.5mmol) dropwise. The reactionwas stirred for 48 h at
Figure 9. Staining of primary porcine kidney cells from wild-type pigs (WT) and GGTA1 KO (GTKO) animals unable to produce the !-Gal antigen.
Fluorescein-tagged PllA or GS-IB4 were used as probes and detected the !-Gal antigen in WT cells. Lectin concentration: PllA, 50 $g/ml; GS-IB4, 500 $g/ml,
400#magnification.
Figure 10. Hemagglutination of porcine red blood cells by PllA. A, wild-
type pig RBCs. B,GTKO pig RBCs. C, inhibition of PllA-mediated agglutination
of wild-type pig RBCs with raffinose.
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50 °C, after removal of the volatiles in vacuo and purification of
the crude product by MPLC, the title compound was obtained
as a pure product (40mg, 65%). 1HNMR (400MHz,MeOH-d4)
! 6.08–5.89 (m, 1H, CH2CHCH2O-), 5.34 (dd, J! 17.2, 1.8 Hz,
1H, CH2CHCH2O-), 5.17 (dd, J ! 10.4, 1.6 Hz, 1H,
CH2CHCH2O-), 4.85 (d, J! 4.0Hz, 1H,H1), 4.23 (ddt, J! 13.0,
5.3, 1.6 Hz, 1H, 1H, CH2CHCH2O-), 4.13 (dd, J ! 3.3, 1.2 Hz,
1H, H4), 4.04 (ddt, J ! 13.0, 6.1, 1.4 Hz, 1H, CH2CHCH2O-),
3.85 (dd, J ! 10.1, 3.9 Hz, 1H, H2), 3.82–3.77 (m, 1H, H5),
3.76–3.63 (m, 2H, H6), 3.46 (s, 3H, CH3), 3.42 (dd, J! 10.1, 3.2
Hz, 1H, H3). 13C NMR (101 MHz, MeOH-d4) ! 135.65
(CH2CHCH2O-), 117.50 (CH2CHCH2O-), 99.37 (C1), 81.15
(C3), 72.35 (C5), 69.38 (CH2CHCH2O-), 69.22 (C2), 66.91 (C4),
62.74 (C6), 57.24 (CH3). Transcripts of NMR spectra are shown
in supplemental Figs. 6 and 7).
Bioinformatics
A BLAST search (blastp) was done using the amino acid
sequences of LecA fromP. aeruginosa as query (accessionnumber
Q05097). The search was carried out choosing non-redundant
protein sequence database with exclusion of P. aeruginosa (taxid:
287).Thebest100matcheswerechosen foranalignmentusing the
COBALT tool (55). The aligned sequences were clustered using
the SECATORalgorithm (56), which relies onBIONJ (57) to build
the phylogenetic tree. The best LecA-like sequences (with lowest
E-value) from each Xenorhabdus and Photorhabdus species were
aligned with LecA using COBALT, and the conserved sequence
was colored using Color Align Conservation (58). The amino acid
sequence of hypothetical LecA homologs (with lowest E-value in
Xenorhabdus and Photorhabdus species) were WP_011146351.1
(P. luminescens),WP_046975865.1 (P. temperata),WP_065824676.1
(P. asymbiotica), WP_054480913.1 (P. heterorhabditis), WP_
038256436.1 (Xenorhabdus bovienii), WP_013184196.1 (Xenorh-
abdus nematophila), WP_047963870.1 (Xenorhabdus khoi-
sanae), WP_074019816.1 (Xenorhabdus thuongxuanensis),
WP_038237499.1 (Xenorhabdus szentirmaii), and GenBankTM
number SFO04414.1 (Xenorhabdus japonica), and SFJ01328.1
(Xenorhabdus mauleonii).
Cloning, expression, and purification of recombinant PllA
Genomic DNA was isolated from P. luminescens subsp. lau-
mondii TTO1 using GenElute Bacterial Genomic DNA Kit
(Sigma). The plu2096 gene sequence was amplified by PCR
with Phusion polymerase (New England Biolabs, UK) and
primers introducing NdeI (5"-GGAATTCCATATGTCT-
GATTGGTCAGGAAG-3") and BamHI (5"-CGGGATCCT-
TATTTTAAAGGGGAGTATCGAG-3") restriction sites. After
digestion of the expression vector pET22b(#) (Novagen, Ger-
many) and the PCR product with NdeI and BamHI (New
England Biolabs, UK), ligation of the insert was performed with
T4 DNA ligase (New England Biolabs, UK) resulting in plasmid
pET22b-pllA. The sequence was confirmed by sequencing
(GATC Biotech, Germany) with primers T7 promotor (5"-
TAATACGACTCACTATATAGG-3") and T7 terminator
(5"-GCTAGTTATTGCTCAGCGG-3").
For expression, pET22b-pllA was transformed into chemi-
cally competent E. coli BL21(DE3), and the expression strain
was selected on LB agar supplemented with ampicillin (100 "g
ml$1). 2 liters of LB supplemented with ampicillin (100 "g
ml$1) were inoculatedwith a preculture and grown at 37 °C and
180 rpm to an A600 of 0.5–0.6. Expression was induced with
addition of IPTG (0.5 mM final concentration), and bacteria
were then further cultured for 6 h at 30 °C and 180 rpm. The
cells were harvested by centrifugation (3000 % g, 10 min), and
the pellet was washed with TBS/Ca (20 mM Tris, 137 mMNaCl,
2.6 mM KCl, pH 7.4, supplemented with 100 "M CaCl2). The
cells were resuspended in 25 ml of TBS/Ca with PMSF (1 mM)
and lysozyme (0.4mgml$1) and subsequently disrupted by five
cycles in a microfluidics homogenizer (Microfluidics Corp.).
Cell debris was removed by centrifugation (10,000% g, 60min),
and the supernatant was loaded onto a column containing
galactosylated (59) or later melibiose-coupled Sepharose CL-
6B. The column was washed with TBS/Ca, and PllA was eluted
by addition of 100 mM galactose or 100 mM raffinose to the
buffer. The eluted fractions were extensively dialyzed against
distilled water and then TBS/Ca buffer. The concentration was
determined by UV absorbance at 280 nm using a calculated
molar extinction coefficient of 19,480 M$1 cm$1. The yield of
purified PllAwas 6mg (galactose-column) or 19mg (melibiose-
column) per liter of culture volume.
Gel filtration
A HiLoad 16/600 Superdex 200 pg (GE Healthcare) was
equilibratedwith TBS/Ca buffer (20mMTris, 137mMNaCl, 2.6
mM KCl, pH 7.4, supplemented with 1 mM CaCl2) with a flow
rate of 1 ml/min. A calibration curve for molecular size estima-
tion was generated by loading 10 "M of mixture of standard
proteins (lysozyme, DNase I, ovalbumin, and BSA). Thereafter,
10 "M PllA was loaded on the column and analyzed with the
same flow rate.
Dynamic light scattering (DLS)measurements
DLSmeasurements were performed on a Zetasizer Nano-ZS
(Malvern Instruments, UK). Stock solutionswere filteredwith a
syringe filter before measurements. 50 "l of PllA or LecA (100
mM) in TBS/Ca (20mMTris, 137mMNaCl, 2.6mMKCl, pH 7.4,
supplemented with 1 mM CaCl2) was measured at 25 °C.
Fluorescent labeling of PllA and glycan array analysis
PllA (700"l, 58"M in Na2CO3 buffer, pH 9.3) was incubated
at room temperature under shaking (500 rpm) with fluorescein
isothiocyanate (FITC, 33 "l, 3 mg ml$1, in sodium carbonate
buffer, pH 9.3) for 1 h. Purification of the labeled protein was
performed as described above for unlabeled PllA; the protein
concentration was determined as described previously for
LecB-PA14 (19) using an extinction coefficient of 19,480 M$1
cm$1 for PllA.
FITC-labeled PllA was tested on the Consortium for Func-
tional Glycomics (CFG) mammalian glycan array (Core H)
version 5.3 containing 600 printed glycans in replicates of 6.
Standard procedures of Core H (details see http://www.
functionalglycomics.org/glycomics/publicdata/selectedScreens.
jsp)4were run at 5 and 50"gml$1 protein based on the protocol
4 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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by Blixt et al.(60). Raw data of the PllA binding experiments
are available as supplemental Tables S1 and S2 as an XLS
spreadsheet.
Direct binding of fluorescent ligands 1–4 to PllA
10 !l of a serial dilution of PllA in TBS/Ca (618–0.30 !M)
was added in triplicate to a 384-well plate (Greiner Bio-One,
Germany, catalog no. 781900). Then, 10!l of fluorescent ligand
1–4 dissolved in TBS/Ca were added to PllA to a final concen-
tration of 10 nM. After incubation for 1 h at room temperature,
blank corrected fluorescence intensity was recorded using a
PheraStar FS microplate reader (BMG Labtech GmbH, Ger-
many) with excitation filters at 485 nm and emission filters at
535 nm, and fluorescence polarization was calculated. The data
were analyzed using a four-parameter fit of the MARS Data
Analysis Software (BMG Labtech GmbH, Germany). A mini-
mum of three independent experiments on three plates was
performed for each fluorescent ligand.
Competitive binding assay for PllA
10!l of a serial dilution of each tested compounds in TBS/Ca
(20 to 0.01 mM) were added in triplicate to a 384-well plate
(Greiner Bio-One, Germany, catalog no. 781900). Afterward,
10 !l of PllA and 1 were added to each well at final concentra-
tions of 55 !M and 10 nM, respectively. After incubation for 1 h
at room temperature, fluorescence polarization was deter-
mined using a microplate reader as described above. The data
were analyzed using a four-parameter fit of the MARS Data
Analysis Software (BMG Labtech GmbH, Germany). A mini-
mum of three independent experiments on three plates was
performed for each compound.
X-ray crystallography
Crystals of apo-PIIA were obtained in 1.6 M sodium citrate
tribasic dihydrate, pH 6.5. To solve the PIIA–ligand complex
structures, PIIA was co-crystallized in the presence of 10 mM
ligand and 3 mM calcium chloride. Optimized crystals of PIIA-
12, PIIA-25, and PIIA-1 were grown under conditions of 0.2 M
ammonium acetate, 0.1 M BisTris buffer, pH 5.5, and 25% PEG
3350; 0.2 M magnesium acetate and 20% PEG 3350; and 0.15 M
DL-malic acid and 20% PEG 3350, respectively. Diffraction data
for all proteins was collected from single crystals at 100 K. Data
for apo-PIIA and PllA-12 were obtained at beamline ID23-2
(ESRF) at a wavelength of 0.873 Å, whereas data for the PIIA-25
and PIIA-1 were collected at beamline ID30-B (ESRF) at a
wavelength of 0.967 Å. Data were processed using Xia2 (61) or
XDS (62), and the structures were solved using PHASER (63)
molecular replacement with LecA (PDB code 1L7L) as a search
model. Themodels weremanually rebuilt with COOT (64) and
refined using PHENIX (65) and Refmac5 (66). The structures
were validated using MolProbity, and all images were created
using PyMOL (67).
Molecularmodeling
Docking was performed using PLANTS version 1.1 (68). The
calculation of charge and energy minimization of the protein
and ligand was performed with Molecular Operating Environ-
ment (MOE) version 2014.09 (Chemical Computing Group
Inc., Montreal, Quebec, Canada). Then, the standard docking
procedure was used to dock D-galactosamine (10) and the
methyl glycoside of 20 into the binding pocket of the apo-PllA
crystal structure. The docking site was limited to a 13 Å radius
sphere centered in the mass center (coordination: X!"8.624,
Y ! 15.131, and Z ! 45.115) of the crystallized protein. Asp-
103, Asp-96, Gln-57, and Glu-44 were set as flexible residues in
the input file.
Generation of primary GTKO cells
Pigs lacking the GTKO were generated by disrupting the
causative galactosyltransferase gene GGTA1, according to the
procedure described in Klymiuk et al. (69). First, a bacterial
artificial chromosome (BAC) containing the target region of
the porcine genome, CH242-21F3, was modified by bacterial
recombineering in a way that it contained a STOP box right
after the START codon ofGGTA1, resulting in the termination
of protein translation as well as RNA transcription of the gene,
and a floxed resistance cassette for neomycin selection. Then,
this modified BAC was nucleofected into pig primary cells
according to Richter et al. (70), and single-cell clones were gen-
erated under antibiotic selection and propagated to yield cells
for DNA isolation and somatic cell nuclear transfer (SCNT).
Single-cell clones were screened for homologous recom-
bination by a quantitative PCR-based loss-of-wild-type allele
approach, and cell clones that indicated a heterozygous modi-
fication of the GGTA1 allele were used for SCNT to generate
heterozygous knock-out pigs. After birth, one of the animals
was sacrificed, and primary cells were cultivated and nucleo-
fectedwith a plasmid encodingCre recombinase. Again, single-
cell clones were generated and now screened for the removal of
the neomycin selection cassette. Another round of SCNT was
performed to generate heterozygous KO animals lacking the
neomycin selection cassette. Pigs were then maintained and
bred to achieve homozygous GTKO pigs after two generations.
Primary cells from suchGTKOanimalswere isolated according
to the procedure described by Richter et al. (70), and these cells
were used for evaluating the specificity and sensitivity of the
PllA lectin.
Lectin staining of porcine cells
For lectin staining, 1 # 104 cells were seeded in 6-channel
slides (IBIDI,Martinsried, Germany), coatedwith collagen type
1 (Serva Electrophoresis, Heidelberg, Germany), and cultivated
under conventional conditions (70). When reaching a conflu-
ence of 80–100%, cells were stained for 15 min with 5 !g/ml
Hoechst 33342 and subsequently with FITC-labeled isolectin
B4 (GS-IB4, Sigma, 500 !g/ml) or FITC-labeled PllA (50
!g/ml) for 1 h at room temperature. After washing with PBS,
cells were visualized in a fluorescence microscope (Axiovert
200, Zeiss).
Hemagglutination of porcine red blood cells
Hemagglutination was done in analogy to a previously pub-
lished protocol (34). Lithium-heparinized pig blood was centri-
fuged at 1000 # g for 5 min. Plasma was removed, and the
pRBCswerewashedwith 45ml of PBS three times. A 10%pRBC
solution was prepared by diluting 1 ml of pRBCs with 9 ml of
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PBS (A600! 7). Then, 50 !l of PBS was added to each well of a
96-well plate. Thereafter, 50!l of PIIA (2.5 mg/ml) were added
to the first well and mixed, and 50 !l of this mixture was trans-
ferred to the second well. Serial dilution of PIIA was continued
until 23 dilutions were obtained. 50 !l of 10% pRBCs fromWT
or GTKO pig were added to each well, and the plate was incu-
bated for 2 h at room temperature. Inhibition of PllA-mediated
WTpRBC agglutination was then tested with raffinose. A serial
dilution of raffinose (20 mM) was mixed with the lowest lectin
concentration showing agglutination (2.4!g/ml). After incuba-
tion for 30 min at room temperature, pRBCs were added. The
plate was incubated for 2 h at room temperature.
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Introduction 
The role of lectins in glycomics and the need to characterize more lectins were previously 
mentioned in subchapter 1.3. An alternative approach to improve lectin-based glycome 
profiling is engineering of the exciting lectins, thereby gaining more lectins with different 
specificities.1 Structure-based site-directed mutagenesis is the most widely used method to 
alter lectin specificity, enhance the binding affinity of lectins to their ligand, or understand the 
basis of the interactions between lectins and their binding partners.2–8 In subchapter 3.4, we 
characterized  a new lectin (called PllA) in entomopathogenic Photorhabdus luminescens 
bacterium, which has a sharp specificity toward α-galactoside epitopes.  
In this study, we have aimed to extend the scope of the application of PllA through structure-
based, site-directed mutagenesis. Here, we tried to modify PllA’s binding specificity through a 
structural comparison with its ortholog LecA from P. aeruginosa, which binds D-galactosides 
(Gal), and N-acetylgalactosamine (GalNAc) without anomeric specificity. Based on our 
detailed knowledge of the PllA structure, we modified the CRD of PllA with the aim to get two 
novel recombinant PllA mutants: one with a relaxed ⍺-/β-Gal specificity and another with ⍺-Gal 
and ⍺-GalNAc specificity. This would extend the available lectin repertoire and provide useful 
insights, also for comparable approaches to other lectins in the future. 
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Experimental details 
Homology model 
The homology models of the PllA-V43G/N55G were generated via the Phyre2 web portal using 
PllA-wild type crystal structure (PDB code 5OUD) as the template.9  
 
Site-directed mutagenesis  
 
All mutants were generated by a QuickChange site-directed mutagenesis10 using plasmid 
pET22b-pllA as the template and phusion polymerase (New England Biolabs, UK). The PCR 
primers (MWG-Biotech AG, Ebersberg, Germany) were designed to introduce point mutation 
at the desired positions (Table 1A). The reaction for either a forward or a reverse primer was 
separately performed in a 25 µL volume using a PCR thermocycler (TProfessional 
thermocycler, analytic jena, Germany) (Table 1B). Thereafter, the separately amplified DNA 
strands were combined and reannealed, as in Table 1C. The parent template was afterwards 
digested by DnpI restriction enzymes (New England Biolabs, UK) (> 1 h at 37 ℃) and then 10 
µL of reaction was transformed (electroporation, 1800 V, 25 μF, 200 Ω, 5.2 ms) into E. coli XL-
blue cells and plated onto LB agar supplemented with 0.1 mg/mL ampicillin. After overnight 
incubation at 37 °C, 3 colonies for each mutant were randomly selected and isolated their 
plasmids (GenEluteTM Plasmid miniprep Kit, SIGMA, Germany). Finally, the isolated plasmids 
were sequenced at GATC (Konstanz, Germany) to confirm the correct generation of the 
desired mutations.  
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Table 1. Designing and generating of PllA mutants. A) DNA Oligonucleotides used in PCR to generate 
PllA mutants. For: forward primer; Rev: reverse primer. B) PCR conditions for Quickchange site-
directed mutagenesis. C) Reannealing conditions of separately amplified DNA stands. 
 
 
Expression and purification of PllA mutants  
 
PllA mutants were expressed and purified according to the previously published protocol.11 In 
short, pET22b-pllA with the desired mutation was transformed into a chemically competent E. 
coli BL21(DE3) and the expression strain was selected on LB agar, supplemented with 
ampicillin (100 µg mL−1). 1 L of LB supplemented with ampicillin (100 µg mL−1) was inoculated 
Temperature
[℃] Time[min]
98 1:00
30 X
98 0:30
60 0:50
72 2:48
72 10:00
4 Holding
Temperature
[℃] Time[min]
95 5:00
90 1:00
80 1:00
70 0:30
60 0:30
50 0:30
40 0:30
37 Holding
B C
Primer name oligonucleotides
V43G-For 5´-GTGATAATGGTGAATGGGCAGCACCTG-3´
V43G-Rev 5´-CCATTCACCATTATCACGGCCATATTTCAC-3´
N55G-For 5´-CCAATGGTCCACAACCGTCATCAATAGC-3´
N55G-Rev 5´-GTTGTGGACCATTGGGTACAGGACCATC-3´
R40G-For 5´-GAAATATGGCGGTGATAATGTTGAATGGGC-3´
R40G-Rev 5´-CATTATCACCGCCATATTTCACCCATCC-3´
R40P-For 5´-GAAATATGGCCCGGATAATGTTGAATGGGC-3´
R40P-Rev 5´-CATTATCCGGGCCATATTTCACCCATCC-3´
D103N-For 5´-CTTTTGGTAATAATTCAGGTGAATTTCAAGTCG-3´
D103N-Rev 5´-CTGAATTATTACCAAAAGTACCCGGTACG-3´
A
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with a preculture and grown at 37 °C and 180 rpm to an OD600 of 0.5-0.6. Expression was 
induced with the addition of IPTG (0.5 mM final concentration) and the bacteria were then 
further cultured for 6h at 30 °C and 180 rpm. The cells were harvested by centrifugation (9000 
x g, 10 min) and the pellet was washed with TBS/Ca (20 mM Tris, 137 mM NaCl, 2.6 mM KCl 
at pH 7.4, supplemented with 100 µM CaCl2). The cells were resuspended in 25 mL TBS/Ca 
with PMSF (1 mM) and lysozyme (0.4 mg mL−1) and subsequently disrupted by 5 cycles in a 
microfluidics homogenizer (Microfluidics Corp., USA). Cell debris was removed by 
centrifugation (19’000 x g, 60 min) and the supernatant was loaded onto a column containing 
galactosylated or melibiose-coupled sepharose CL-6B.2 The column was washed with TBS/Ca 
and PllA mutants were eluted by the addition of 100 mM galactose to the buffer. The eluted 
fractions were extensively dialyzed against distilled water and then a TBS/Ca buffer. The 
concentration was determined by UV absorbance at 280 nm using the calculated molar 
extinction coefficient (19480 M-1 cm-1). 
 
Competitive binding assay for PllA  
 
10 µL of a serial dilution of each of the tested compounds in TBS/Ca (20 - 0.01 mM) were 
added in triplicates to a 384-well plate (Greiner Bio-One, Germany, cat no 781900). 
Afterwards, 10 µL of PllA and fluorescent ligand 1 (subchapter 3.4) were added to each well 
at final concentrations of 55 µM and 10 nM, respectively. After incubation for 1 h at r.t., the 
blank corrected fluorescence intensity was recorded, using a PheraStar FS microplate reader 
(BMG Labtech GmbH, Germany) with excitation filters at 485 nm and emission filters at 535 
nm, and the fluorescence polarization was calculated. The data were analyzed using a four-
parameter fit of the MARS Data Analysis Software (BMG Labtech GmbH, Germany).  
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Results and discussion 
 
The two CRDs of PllA and LecA were superposed and, as previously reported in subchapter 
3.4, the side-chains of the amino-acids V43 and N55 build a close cleft, which narrows the 
binding pocket for any β-Gal (Figure 1A). In order to widen the binding pocket, we first 
generated a homology model of a PllA mutant, where V43 and N55 are mutated into glycine 
(PllA-V43G/N55G). As depicted in figure 1B, an open cleft was created, which might allow β-
substituents at D-galactosides to be accommodated. Thus, the in-vitro mutations of V43 and 
N55 were carried out in a stepwise manner, using site-directed mutagenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Assignment of the mutated PllA residues to gain PllA with ⍺-/β-Gal specificity. A) Overlay of 
crystal structures of P. aeruginosa LecA (Red, PDB code 1OKO) and P. luminescens PllA (marine, PDB 
code 5OUD). B) Overlay of crystal structures of P. aeruginosa LecA (Red, PDB code 1OKO) and the 
homology model of PllA-V43G/N55G. The homology model was generated based on the PllA crystal 
structure (PDB code 5OUD) using a Phyre2 web portal.9 Methyl ⍺-D-galactose is depicted as sticks 
coloured by elements (O: red, C: grey) and PllA residues (O: red, C: grey, N: blue). Ca2+ ion in the 
binding site is shown as a green sphere. Residue numbers correspond to PllA. 
 
 
Both PllA-V43G and PllA-V43G/N55G were separately generated, expressed, purified and 
evaluated, using the established fluorescence polarization assay, which was used for the PllA 
wild-type (PllA-wt) (subchapter 3.4). 
 
 
A B
V43 N55
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Table 2. Biochemical evaluation of β-D-galactosides for PllA-V43G and PllA-wt. The IC50 values were 
determined using a competitive binding assay, based on fluorescence polarization, and the standard 
deviations represent at least two independent experiments. n.i.: no inhibition up to 10 mM. 
 
 
The single point mutation (PllA-V43G) showed a slight improvement in the binding towards β-
Gal, especially with phenyl substituents, compared to the PllA-wt (Table 2). In contrast to this,  
PllA-V43G/N55G could not be purified on D-galactose column, which indicates that the 
insertion of additional N55G mutation led to a complete loss of binding to the D-galactose 
(Figure 2A). N55 builds two hydrogen bonds with Y36 and Q57 and upon the N55G mutation, 
these bonds were disrupted and might lead to a misfolding of the binding pocket (Figure 2B). 
PllA-V43G/N55S could be next investigated, since the hydroxyl group of serine could retain 
bridges to Y36 and Q57. Moreover, serine has shorter side chain than asparagine which might 
reduce the blocking at the binding pocket. 
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Compound
IC50 [mM]
PllA-V43G
IC50 [mM]
PllA-wt
0.11 ±  0.06 35 ± 5 % inhib. @10 mM
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Figure 2. A) 15% SDS page of PllA-V43G/N55G expression and attempted purification on the D-
galactose column. The lanes are as follows: molecular mass marker in kDa (M); Un-induced E. coli 
whole-cell extracts (U); IPTG- induced cultures (I); Supernatant (S); Pellet (P); Flow-through from the D-
galactose column (F); Wash (W); Elution with 100 mM of D-galactose (E). The PllA mutant (13 kDa) did 
not bind to the column. B) CRD of PllA (PDB code 5ODU) showing the interaction between N55 and 
Y36 and Q57. Methyl ⍺-D-galactose is depicted as sticks coloured by elements (O: red, C: grey) and 
PllA residues (O: red, C: grey, N: blue). Ca2+ ion in the binding site is shown as green sphere.  
 
The same approach was followed to design PllA mutants with extending specificity towards ⍺-
GalNAc. The inability of PllA to bind	⍺-GalNAc is likely to have been caused by a restriction of 
the binding pocket around the C2 position, where the acetamide group of ⍺-GalNAc is pointed. 
Structural analysis indicates that the R40 side-chain or the corresponding backbone loop might 
make a barrier for C2 substituents at ⍺-GalNAc (Figure 3). Reducing blocking at this loop might 
lead to ⍺-GalNAc binding PllA, which might potentially function as a tumour probe for Tn 
antigen (GalNAcα1-O-Ser/Thr). Tn antigen is expressed in the majority of carcinoma cells and 
does not appear in normal tissues.12  
Two point mutations were attempted: the substitution of R40 through glycine, which might 
eliminate the steric hindrance of the R40 side-chain, and D103 by a neutral residue 
asparagine, which mimics the charge of the LecA binding pocket close to the acetamide group 
of GalNAc.  
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Expression and purification of PllA mutant (V43G and N55G) 
 
 
 
 
 
 
 
 
 
 
Figura 1. PllA mutant (V45G,N55G) expression and attempted purification on D-Galactose column (15 % SDS-
page). Un-induced E. coli whole-cell extracts of un-induced (U) and IPTG- induced cultures (I), supernatant 
(S), pellet (P), Flow-through from D-Galactose column (F), wash (W), elution with 100 mM of D-Galactose (E).  
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Figure 3. Assignment of the mutated PllA residues to gain PllA with an ⍺-Gal and ⍺-GalNAc specificity. 
A) Overlay of the crystal structures of P. aeruginosa LecA (Red, PDB code 1OKO) and P. luminescens 
PllA (marine, PDB code 5ODU). Methyl ⍺-D-galactose is depicted as sticks coloured by elements (O: 
red, C: grey) and PllA residues (O: red, C: marine, N: blue). Ca2+ ion in the binding site is shown as 
green sphere. Residue numbers correspond to PllA and the label starts with PllA residue and then LecA. 
The arrow points to the C2 of the carbohydrate ligand where the acetamide group in the GalNAc is 
extended. 
 
PllA-R40G/D103N was successfully performed, expressed, purified, and biochemically 
evaluated. Unfortunately, these mutations did not extend the binding to GalNAc and it is 
therefore not a successful PllA mutant (Table 3). D-galactosamine is a compound that binds to 
the PllA-wt, and upon changing the charge at the CRD of the PllA mutant through inserting a 
neutral residue (N103), it led to complete loss of binding to D-galactosamine. This can be 
explained by a missing hydrogen bond, which should be  formed by D103 in the PllA-wt (see 
subchapter 3.4)  
Thereafter, an R40 was mutated to proline in addition to D103N to ensure that the proline might 
bend the loop in a favourable way, thus creating more space to accommodate the substituents 
at C2 of the D-galactosides. The successfully purified PllA-R40P/D103N was evaluated with 
some sugars and, like PllA-wt, it could not recognize GalNAc (Table 3).  
 
 
 
 
 
 
R40
D103N
C2
D41
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Table 3. IC50 values of GalNAc, D-galactosamine and other sugars for PllA-R40G/D103N and PllA-
P40G/D103N are compared to IC50 values of PllA-wt from subchapter 3.4. The IC50 values were 
determined once in duplicates, using a competitive binding assay based on fluorescence polarization. 
n.i.: no inhibition up to 10 mM. 
 
 
In conclusion, the knowledge that we gained from this study highlighted the importance of N55 
in PllA’s CRD and the possibility to alter the binding specificity of PllA towards D-galactosamine 
by D103 mutation.  
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Bacterial biofilm is a survival strategy which protects bacteria from their outer environments, 
particularly from antibiotics. Nowadays, many bacteria have developed resistance to most 
existing antibiotics, and consequently finding a new target or a new class of anti-infective agents 
is the focus of many research groups. Several strategies, such as the inhibition of quorum 
sensing, adhesive organelle, cell division, and bacterial lectins as well as the cleavage of 
peptidoglycan, have been pursued to prevent biofilm formation. The targeting of Gram-negative 
bacterial lectins is a recent approach to hinder biofilm formation, which eventually led to improve 
the efficacy of existing antibiotics.36,53  Our research group has successfully developed 
glycomimetic inhibitors for P. aeruginosa LecB, using a rational structure-based design approach, 
and valuable progress has also been made in terms of the potency and the pharmacokinetic 
properties of inhibitors.43 This work aimed to find new classes of anti-biofilm agents for 
opportunistic human pathogens, such as P. aeruginosa and B. cenocepacia, by screening 
libraries, studying self-assembled  photo-switchable  multivalent inhibitors, and exploring the 
recognition of inhibitors of the investigated lectins. 
 
The search for new classes of lectin inhibitors from non-carbohydrate-based compound libraries 
was a challenge and with a very low hit rate (0.05 %). Lectins are highly specific to their 
carbohydrate ligands. As reported in subchapters 3.3 and 3.4, masking or changing any of 
hydroxyl groups at the carbohydrate ligand, which coordinate the calcium ions in the CRD, leads 
to a complete loss of binding affinity. In this context, the simplest strategy to develop a potent 
lectin inhibitor is structure-based drug design. Whereas by the screening approach, there is a 
high cost associated with this process and it has been estimated that approximately 20,000 
compounds need to be tested in order to find one that become a marketable drug.54 However, for 
any future screening work for lectin inhibitors, there are several points that should be taken into 
consideration.  
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First, the search should be focused on libraries that contain carbohydrate-based compounds, 
where the sugar recognizes the lectin’s CRD and the aglycon part additionally interacts with the 
protein surface to enhance the binding affinity. Second, the finding of non-carbohydrate LecB or 
LecA inhibitors remains a challenge. Third, for any future investigation of bacterial extracts 
against lectins we should be aware of the false positive signals that might come from sugars in 
the cell-cultivating media.  
 
Glycans generally have a weak binding affinity to their lectins; in nature, they overcome this 
problem by multivalency.36 Thus, several multivalent inhibitors have been designed and 
synthesized for bacterial lectins, such as P. aeruginosa LecA and LecB, which display a higher 
potency compared to their monovalent ligands. Most of the multivalent inhibitors are based on 
calixarene, pentaerythritol, glyconanoparticle or peptide dendrimer scaffolds and their 
presentation is sometime limited due to scaffold rigidity and furthermore their synthesis and 
purification are complicated.38,55 In contrast to the conventional multivalent LecA and LecB 
inhibitors, it was demonstrated in this work the simple preparation of self-assembled photo-
switchable multivalent inhibitors using glycoamphiphiles, which can be easily synthesized and 
the ligand valency of which can be controlled through the appropriate molecular design. 
Moreover, the glycoamphiphiles were seen to have moderate-to-potent inhibition of both P. 
aeruginosa lectins. This system is new and still needs further optimization but may be applied in 
the future as a targeted delivery vehicle with photo-triggered release properties.  
 
Exploring P. aeruginosa lectin homologs from other pathogenic bacteria and characterizing them 
was the second objective of this work. Here, a SAR study to understand the recognition of 
carbohydrates in newly discovered B. cenocepacia BC2L-A was carried out. Using our knowledge 
of its homolog from P. aeruginosa (LecB), we could develop the first set of glycomimetic BC2L-A 
inhibitors.48 In addition to this, this SAR study on B. cenocepacia BC2L-A lectin highlighted the 
possibility of developing a broad-spectrum anti-biofilm agent that could inhibit the biofilm 
formation in both human pathogens (i.e. P. aeruginosa and B. cenocepacia) by targeting their 
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mannose-binding lectins (i.e. LecB and BC2L-A), as they infect patients simultaneously and a 
mixed biofilm from both bacteria has been identified in CF isolates.56 Therefore, mannoheptose 
with a (6S)-configuration is a potential candidate and requires further optimization, since it 
showed moderate binding to LecB and BC2L-A in the IC50 range of 82 - 217 µM and 13 - 116 µM, 
respectively.48,57 
 
LecA homologs were identified for the first time in this work in several Photorhabdus, 
Xenorhabdus, and Enterobacter species; this is a new area of exploration in the search for more 
pathogenic bacterial lectins (see subchapter 3.4). The characterization of the P. luminescens PllA 
lectin was a successful contribution to glycomics, particularly for lectin microarray technology and 
biomedical research. In addition to using PllA as a probe in xenotransplantation, PllA could be 
also utilized to detect ⍺-Gal terminals in other biomedical research, such as in malaria and 
tuberculosis control, the agglutination of blood group B, the differentiation of endothelial cells, and 
the tracing of central and peripheral neuronal pathways.58–61 We therefore have to continue 
characterizing more new lectins and exploring their carbohydrate specificity to improve glycome 
profiling as well as to understand their biological roles.  
 
In subchapter 3.4, we identified several LecA homologs in Enterobacter spp. These bacteria are 
Gram-negative bacilli and belong to the Enterobacteriaceae family. They are taken on a clinical 
significance over the last decade and the National Healthcare Safety Network (2008) reported 
that approximately 5 % of nosocomial bacteremia cases originated from Enterobacter spp.62–64 
The characterization of LecA homologs in Enterobacter spp is therefore a project of high 
importance, which I am currently supervising a master thesis on this work to reveal the role of 
LecA homologs in Enterobacter pathogenicity and might become a new target for new anti-
infectives. 
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5. SUPPORTING INFORMATION 
5.1. SUPPORTING INFORMATION FOR SUBCHAPTER 3.1  
 
Table S1. Testing of LecB stability at different concentration of DMSO by determine the IC50 value of compound 
2 at different DMSO concentration. This experiment was performed once,  
 
 
Table S2. List of compounds of test plate with their DMSO stocks. n.p. : the concentration of compound 
was not provided. 
 
 
 
 
 
 
 
 
IC50 [µM]
LecB
0 % DMSO 1 % DMSO 2 % DMSO 5 % DMSO
O
HOOH
OH
OMe
2
0.79 0.92 0.51 0.57
 Compound Concentration in DMSO stock  Compound 
Concentration 
in DMSO stock 
1 Actinomycin D 1 mM 25 Quercetin 3 mg/ml 
2 Acyclovir 0.5 mg/ml 26 Rapamycin 11 µM 
3 Amphotericin B 0.2 mg/mL 27 Resveratrol 0.1 mg/ml 
4 Ampicillin 1 mg/ml 28 Rifampicin 1 mg/ml 
5 Anisomycin 45 µM 29 Staurosporine 0.05 mg/ml 
6 Antimycin A 0.1 mg/ml 30 Sulfamethazin 0.1 mg/ml 
7 Bay 11-7085 1 mg/mL 31 Sulfamethoxazol 2 mg/ml 
8 Brefeldin A 1100 µM 32 Tetrazyklin 0.1 mg/ml 
9 Cisplatin 0.5 mg/ml 33 Trichostatin 1 mM 
10 Colchicine 10 mM 34 Zanamivir 0.5 mg/ml 
11 Cycloheximide n.p. 35 WTE (A-A-D-H-A-A-C) 2mM 
12 Cytochalasin D 500 µM 36 WTE (A-A-D-E-A-A-C) 2 mM 
13 Dexamethasone 1 mM 37 WTE (A-A-H-F-A-A-C) 2 mM 
14 Doxorubicin 1100 µM 38 WTE (A-A-I-T-A-A-C) 2 mM 
15 Erythromycin 0.1 mg/ml 39 WTE (A-A-K-W-A-A-C) 2 mM 
16 Etoposide 1 mM 40 WTE (A-A-R-Q-A-A-C) 2 mM 
17 Fluconazol 0.2 mg/ml 41 WTE (A-A-W-E-A-A-C) 2 mM 
18 Fludioxonil 1 mg/ml 42 WTE (A-A-W-R-A-A-C) 2 mM 
19 Hydroxyurea 5 mg/ml 43 WTE (A-A-N-K-A-A-C) 2 mM 
20 Mevastatin 1200 µM 44 PD98059 10 mM 
21 Okadaic acid 80 µM 45 SB203580 1 mg/ml 
22 Oligomycin 5 mM 46 Simvastatin 0.8 mM 
23 PDTC 0.1 mg/ml 47 Chloramphenicol 2 mg/ml 
24 Purvalanol A n.p. 48 Luciferase inhibitor 5 mg/ml 
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Figure S1. Screening of pure myxobacteria secondary metabolites at 500 µM using a competitive binding 
assay based on fluorescence polarization. Black columns represent the calculated percentage of inhibition; 
red squares represent the normalized fluorescence intensity signals to the signal of positive control. The 
acceptable fluorescence intensity data should have 0.8 < fluorescence intensity < 1.2. Each column and square 
represent the average of results from three different wells. +ve control is L-fucose; -ve control is LecB with 
tracer 1 and without inhibitors.  
 
Figure S2. Validation of inhibitory effect of active fractions in myxobacterial extracts to LecB from initial screen 
by generating their concentration-dependent inhibition curves. Standard deviations were obtained from 
triplicates on one plate. Fr: fraction. 
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Figure S3. LC-MS spectrum at fraction 73 in fractionation of strain B extract.  
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Table S3.  Media and their ingredients which were used in strain B cultivation.  
 Media  
CLF  CYH P POL TS  
Ingredients  
0.4 % Fructose 
0.6 % Glucose 
1 % Skim milk 
 0.2 % Yeast 
extract  
0.1 % CaCl2 
0.1 % MgSO4 
50 mM HEPES  
8 mg/L EDTA-
iron  
 
pH = 7 
CY: 
 
0.3 % Casiton 
0.1 % Yeast extract  
0.1 % CaCl2  
50 mM HEPES 
 
 
H : 
 
0.2 % Soy flour 
0.2 % Glucose 
0.8 % Starch 
0.2 % Yeast extract  
0.1 % CaCl2 
0.1 % MgSO4 
50 mM HEPES  
8 mg/L EDTA-iron  
 
pH = 7 
 
0.2 % Peptone 
0.8 % Starch 
0.4 % Probion  
0.2 % Yeast extract 
0.1 % CaCl2 
0.1 % MgSO4 
100 mM HEPES  
8 mg/L EDTA-iron  
 
 
pH = 7.5 
0.3 % Starch 
0.3 % Probion 
0.05 % CaCl2 
0.2 % MgSO4 
50 mM HEPES  
 
pH = 7.2 
0.4 % Starch 
1 % Trypton 
0.2 % MgSO4 
100 mM 
HEPES  
 
pH = 7.2 
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Figure S4. LecB hits from SPECS library, which were identified by screening at 500 µM. 
 
 
 
 
Figure S5. Competitive inhibition of the binding of 1 to LecB with SPECS hits. Left: concentration-dependent 
inhibition curves of SPECS-367 and -308 (max conc. is 500 µM). Right: concentration-dependent inhibition 
curves of SPECS-605 and -836 (max conc. is 1000 µM. Standard deviations were obtained from triplicates on 
one plate.  
N
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Figure S6. 1H NMR of SPECS836   
O
O O
O
O NH
S
HO
O
O
SPECS-836
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Figure S7. Molecular dynamics study of SPECS-836 in DMSO. The dihedral angles at the tetrahydrothiophene 
ring of SPECS-836 were recorded each 0.5 sec for 50 sec .    
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Figure S8. LC-MS spectrum of compound OTAVA-116. 
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Figure S9. 1H NMR measurements of compound OTAVA-116 in different solvents (1:1 DMSO:D2O, DMSO 
+ 10 % D2O, DMSO). The analysis was done by Dr. Calvert. 
 
H1 H1
H1
H2 H2H2
H3H3H3
H4+5
H4+5
H4+5
5.03 -> 3.64 coupling constant = 6.9, axial-axial (anomeric)
3.64 -> 5.31 = 5.1, thus 3.64 -> 3.49 = 8.8, axial-axial
3.49 -> 4.91 = 5.7, thus 3.49 -> 3.72 = 3.2, axial-equatorial
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Table S4. Competitive binding assay of identified OTAVA hits with LecB in the initial screen. The red 
coloured compounds are based on D-xylose which their structures were characterized and showed 
compounds based on L-arabinose. 
 
 
 
 
 
 
 
 
 
 
 
 
O
HOOH
OH
O O O
O
HOOH
OH
O O O
O
HOOH
OH
O O O
O
OH
OHHO O
O
O
O
OH
OHHO O
O
O
 9.4 6.7  11.3
91 122  134
IC50 [µM]
LecB
 7.7
 116
7.4
112
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LecB
O
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O
O
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O
OH
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O
O
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Table S5. Competitive binding assay of OTAVA hits with LecA. A) Hits with known stereochemistry at pyranose 
ring B) Hits with unknown stereochemistry at pyranose ring and the non-carbohydrates one. The relative 
potency was calculated for methyl α-D-galactoside. n.d: not determined due to solubility issue. 
 
A 
 
 
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
O
O
O
O
132
126O
O
96O
O
131O
O
90
O
O
Cl
102
O
O
125
O
O
100
O
O
98
O
O
O
123
O
O
O
O
O
105
114
O
O
120
108
IC
50  [µM
]
LecA
20.3
R
el. potency to 
M
e a-D
-gal
45.8
149.5
20.9
27.7
37.1
IC
50  [µM
]
LecA
R
el. potency to 
M
e a-D
-gal
25.7
42.6
n.d
190.5
O
O
O
IC
50  [µM
]
LecA
R
el. potency to 
M
e a-D
-gal
28.6
34.5
15.7
22.5
5.2
2.2
0.7
5.0
3.8
2.8
4.1
2.5
n.d
0.6
3.7
3.0
6.7
4.7
O
OH
O
HO
HO
H
O
R
O
OH
O
HO
HO
H
O
R
O
OH
O
HO
HO
H
O
R
O
O
F
423.9
0.2
111
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B 
 
 
 
  
O
O
N
O
O
5
15
O
O
N
S
64
OH
O
O
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OH
O
OOHO
HO
HO
OH
R
N
O
O
O
O
O
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IC50 [µM]
LecA
30.6
IC50 [µM]
LecARel. potency to 
Me a-D-gal
21.7
37.6
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IC50 [µM]
LecA
Compound
n.b
Rel. potency to 
Me a-D-gal
3.4
4.8
2.8
3.5
3.6
OOHO
HO
HO
OH
R
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Table S6. List of tested compounds in glycomimetic-focused library (OTAVA) and their chemical 
names. 
cpd# Chemical name 
1 3,7-bis(methoxycarbonyl)-2,6-dioxobicyclo[3.3.1]nonane-1,5-dicarboxylic acid 
2 1-[(3aR,5R,6S,6aR)-6-[(4-ethoxyphenyl)methoxy]-2,2-dimethyl-tetrahydro-2H-furo[2,3-
d][1,3]dioxol-5-yl]ethane-1,2-diol 
3 (2R)-7-{[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2S,3R,4R,5R,6S)-
3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-5-hydroxy-2-(4-
hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one 
4 3-{[2-(dimethylamino)ethyl]amino}-4-hydroxy-1lambda-thiolane-1,1-dione 
hydrochloride 
5 3-(pyridin-2-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-
one 
6 N-{3,4,5,14-tetramethoxy-13-oxotricyclo[9.5.0.0?,?]hexadeca-1(16),2,4,6,11,14-hexaen-
10-yl}acetamide 
7 3,6-dimethyl 4-[(3-{[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}phenyl)amino]quinoline-3,6-dicarboxylate 
8 3-(4-chlorophenyl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-
chromen-4-one 
9 3-(7,8-dimethoxy-2-methyl-4-oxo-3,4-dihydro-2H-1-benzopyran-2-yl)propanoic acid 
10 1-(3-{4-[3-(4-carbamoylpiperidin-1-yl)-2-hydroxypropoxy]phenoxy}-2-
hydroxypropyl)piperidine-4-carboxamide 
11 (2S)-2-[(4-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}piperazine-1-carbonyl)amino]-3-
phenylpropanoic acid 
12 3-hydroxy-4-[(2-methoxyethyl)amino]-1lambda-thiolane-1,1-dione 
13 3-{[2-(furan-2-yl)ethyl]amino}-4-hydroxy-1lambda-thiolane-1,1-dione 
14 2-(4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetic acid 
15 3-phenyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one 
16 2-[(5Z)-5-[(4-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-
N-[2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide 
17 3-{[3-(dimethylamino)propyl]amino}-4-hydroxy-1lambda-thiolane-1,1-dione 
18 3,6-dimethyl 4-[(4-{[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}phenyl)amino]quinoline-3,6-dicarboxylate 
19 2-methyl-3-(pyridin-2-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-
chromen-4-one 
20 1-(3,5-dimethoxybenzoyl)piperidine-3-carboxylic acid 
21 2-(4-carbamoylpiperidin-1-yl)-2-oxoacetic acid 
22 tert-butyl 4-[(3-methoxy-3-oxopropyl)carbamoyl]piperazine-1-carboxylate 
23 1-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
24 3-hydroxy-4-[4-(2-hydroxyethyl)piperazin-1-yl]-1lambda-thiolane-1,1-dione 
25 2-(hydroxymethyl)-6-(naphthalen-2-yloxy)oxane-3,4,5-triol 
26 3-(1,1-dioxo-1??-thiolan-3-yl)-1-methyl-1-(3-methyl-1,1-dioxo-1lambda-thiolan-3-
yl)urea 
27 2-(3,4,5-trihydroxyoxan-2-yl)-2,3,4,5-tetrahydro-1,2,4-triazine-3,5-dione 
28 3-{[2-(dimethylamino)ethyl]amino}-4-hydroxy-1lambda-thiolane-1,1-dione 
29 N-[2-(4-{[2-(4-chlorophenyl)quinazolin-4-yl]amino}phenoxy)-4,5-dihydroxy-6-
(hydroxymethyl)oxan-3-yl]acetamide 
30 5-hydroxy-7-(octyloxy)-3-(4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}phenyl)-4H-chromen-4-one 
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31 4-amino-7-methoxy-2,3,4,5-tetrahydro-1-benzoxepin-5-ol hydrochloride 
32 ethyl 2-(4-carbamoylpiperidin-1-yl)acetate 
33 4-(3-Methoxy-propylamino)-1,1-dioxo-tetrahydro-1lambda*6*-thiophen-3-ol 
34 2-{1-[(tert-butoxy)carbonyl]-4-hydroxypiperidin-4-yl}acetic acid 
35 3-hydroxy-4-{[3-(morpholin-4-yl)propyl]amino}-1lambda-thiolane-1,1-dione 
hydrochloride 
36 5,7-dihydroxy-3-(4-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}phenyl)-4H-chromen-4-one 
37 3-hydroxy-4-[(3-methoxypropyl)amino]-1lambda-thiolane-1,1-dione hydrochloride 
38 9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-(methylamino)-6,9-dihydro-1H-
purin-6-one 
39 3-(2-fluorophenyl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-
chromen-4-one 
40 methyl 7,8-dichloro-4-[(4-{[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}phenyl)amino]quinoline-3-carboxylate 
41 3-(4-fluorophenyl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-
chromen-4-one 
42 1-(2-hydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-2-(1,3-
thiazol-4-yl)ethan-1-one 
43 (4R,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol hydrochloride 
44 3-[5-amino-4-(4-methyl-1,3-thiazol-2-yl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-4-hydroxy-
1lambda-thiolane-1,1-dione 
45 5,5-dimethyl 2,2-dimethyl-1,3-dioxane-5,5-dicarboxylate 
46 (1S,2R)-2-({4-[(1R,2S)-2-carboxycyclohexaneamido]phenyl}carbamoyl)cyclohexane-1-
carboxylic acid 
47 3-hydroxy-4-{[2-(morpholin-4-yl)ethyl]amino}-1lambda-thiolane-1,1-dione 
48 4-[N-(4-methoxyphenyl)acetamido]-1,1-dioxo-1lambda-thiolan-3-yl acetate 
49 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-{[2,3,4-trihydroxy-5-
(hydroxymethyl)cyclohexyl]oxy}-4H-chromen-4-one 
50 3-(4-ethylbenzenesulfonyl)-4-[(2-methoxyethyl)amino]-1lambda-thiolane-1,1-dione 
51 5,7-diethyl 1,2,3-trimethyl-6-oxo-2H,6H-cyclohepta[c]pyrrole-5,7-dicarboxylate 
52 1-(2-hydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-2-(4-
methoxyphenyl)ethan-1-one 
53 3-(2-methyl-1,3-thiazol-4-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
4H-chromen-4-one 
54 6,7-dimethoxy-5-oxo-2H,3H,5H,9bH-[1,3]thiazolo[2,3-a]isoindole-3-carboxylic acid 
55 1,3-diethyl 2-(1,1-dioxo-1lambda-thiolan-3-yl)propanedioate 
56 1-tert-butyl 3-methyl 4-oxopyrrolidine-1,3-dicarboxylate 
57 1-[(6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)sulfonyl]piperidine-3-
carboxylic acid 
58 3-hydroxy-4-[(3-hydroxypropyl)amino]-1lambda-thiolane-1,1-dione 
59 4-[N-(4-chlorophenyl)acetamido]-1,1-dioxo-1lambda-thiolan-3-yl acetate 
60 2-amino-8-bromo-9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-
purin-6-one 
61 4-(2-{[(3S,4R)-4-(4-ethylbenzenesulfonyl)-1,1-dioxo-1lambda-thiolan-3-
yl]amino}ethyl)benzene-1-sulfonamide 
62 3-[(6-tert-butyl-3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-
yl)carbamoyl]propanoic acid 
63 3-(4-bromophenyl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-
chromen-4-one 
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64 3-(4-methyl-1,3-thiazol-2-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
4H-chromen-4-one 
65 methyl (2R,3S)-2-[(4-{[(2S,3R)-1-methoxy-3-methyl-1-oxopentan-2-
yl]carbamoyl}piperazine-1-carbonyl)amino]-3-methylpentanoate 
66 2-(1,1-dioxo-1lambda-thiolan-3-yl)-N,N'-bis(2-hydroxyethyl)propanediamide 
67 1-tert-butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate 
68 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-
methyloxan-2-yl]oxy}-4H-chromen-4-one 
69 N-[6-(2-chlorophenoxy)-2-(furan-2-yl)-8-hydroxy-hexahydro-2H-pyrano[3,2-
d][1,3]dioxin-7-yl]acetamide 
70 3-[(3-acetylphenyl)amino]-4-hydroxy-1lambda-thiolane-1,1-dione 
71 8-bromo-9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one 
72 methyl 7,8-dichloro-4-[(3-{[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}phenyl)amino]quinoline-3-carboxylate 
73 2-methyl-4-(3,4,5-trimethoxybenzoyl)morpholine 
74 5-hydroxy-7-methoxy-3-(4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}phenyl)-4H-chromen-4-one 
75 3-(4-methoxyphenoxy)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-
chromen-4-one 
76 (2S)-2-[(4-{[(1S)-1-carboxy-2-methylpropyl]carbamoyl}piperazine-1-carbonyl)amino]-
3-methylbutanoic acid 
77 3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-4-hydroxy-1lambda-thiolane-1,1-dione 
78 2-{1-[(3,5-dimethoxyphenyl)methyl]-3-oxopiperazin-2-yl}acetic acid 
79 (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(3,4,5-trihydroxy-6-{[(3,4,5-
trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-2-yl)oxy]-3,4-dihydro-2H-1-
benzopyran-4-one 
80 3-hydroxy-4-[(2-methoxyethyl)amino]-1lambda-thiolane-1,1-dione hydrochloride 
81 3,4-dimethyl 2-(2-methoxyacetamido)-4H,5H,6H-cyclopenta[b]thiophene-3,4-
dicarboxylate 
82 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-4H-chromen-4-one 
83 N-[4,5-dihydroxy-6-(hydroxymethyl)-2-(3-{[2-(4-methylphenyl)quinazolin-4-
yl]amino}phenoxy)oxan-3-yl]acetamide 
84 N-[2-(4-acetylphenoxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide 
85 1-(2-hydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-2-
phenylethan-1-one 
86 1-{4-[(3,4,5-trihydroxyoxan-2-yl)amino]phenyl}ethan-1-one 
87 (2S)-2-[(4-{[(1S)-1-carboxy-2-methylbutyl]carbamoyl}piperazine-1-carbonyl)amino]-3-
methylpentanoic acid 
88 3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6H-
benzo[c]chromen-6-one 
89 4-methyl-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H,11H-cyclohepta[c]chromen-6-one 
90 4-methyl-3-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
91 3-{[(2S,3S,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-6H,7H,8H,9H,10H-
cyclohexa[c]chromen-6-one 
92 4-(4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
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93 4-ethyl-7-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
94 7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
1H,2H,3H,4H-cyclopenta[c]chromen-4-one 
95 3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
96 3-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6H-
benzo[c]chromen-6-one 
97 3,4,7-trimethyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
98 7-methyl-9-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
1H,2H,3H,4H-cyclopenta[c]chromen-4-one 
99 6-chloro-4-ethyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
100 6-methyl-7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
1H,2H,3H,4H-cyclopenta[c]chromen-4-one 
101 4-methyl-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
102 2-chloro-3-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
103 3,4,8-trimethyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
104 6-methyl-7-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-1H,2H,3H,4H-
cyclopenta[c]chromen-4-one 
105 4-phenyl-7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2H-
chromen-2-one 
106 3-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-6H,7H,8H,9H,10H-
cyclohexa[c]chromen-6-one 
107 2-chloro-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
108 4-(4-methoxyphenyl)-8-methyl-7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy}-2H-chromen-2-one 
109 4-ethyl-8-methyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
110 4-phenyl-7-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-2H-chromen-2-one 
111 3-methyl-1-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
112 7-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-1H,2H,3H,4H-
cyclopenta[c]chromen-4-one 
113 4-methyl-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6H-
benzo[c]chromen-6-one 
114 4-(4-methoxyphenyl)-7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
115 4-ethyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2H-
chromen-2-one 
116 3-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-6H-benzo[c]chromen-6-one 
117 2,2-dimethyl-12-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2,3,4,6,7,8,9,10-octahydro-1,11-dioxatetraphen-10-one 
118 7-methyl-9-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
1H,2H,3H,4H-cyclopenta[c]chromen-4-one 
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119 6-methyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
1H,2H,3H,4H-cyclopenta[c]chromen-4-one 
120 8-methyl-4-phenyl-7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
121 8-methyl-4-propyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
122 4-phenyl-7-{[(2S,3S,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-2H-chromen-2-one 
123 2,2-dimethyl-12-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2,3,4,6,7,8,9,10-octahydro-1,11-dioxatetraphen-10-one 
124 3-methyl-1-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
125 7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
1H,2H,3H,4H-cyclopenta[c]chromen-4-one 
126 3,4,8-trimethyl-7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
127 8-methyl-4-phenyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2H-chromen-2-one 
128 3-{[(2S,3S,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-6H-benzo[c]chromen-6-one 
129 2,2-dimethyl-12-{[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-
yl]oxy}-2,3,4,6,7,8,9,10-octahydro-1,11-dioxatetraphen-10-one 
130 3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H,11H-cyclohepta[c]chromen-6-one 
131 3-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
6H,7H,8H,9H,10H-cyclohexa[c]chromen-6-one 
132 3,4-dimethyl-7-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-
2H-chromen-2-one 
133 4-phenyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2H-
chromen-2-one 
134 7-{[(2S,3S,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-1H,2H,3H,4H-
cyclopenta[c]chromen-4-one 
135 4-propyl-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2H-
chromen-2-one 
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5.2. SUPPORTING INFORMATION FOR SUBCHAPTER 3.2 
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Figure S1. Thermal cis-trans relaxation of glycodendrimers A) Man(3,5)8 1, B) Man(3,5)2Et8 
2, C) Man(3,5)12 3 and D) Man(3,4,5)2Et8 4 (0.05 mM in Milli-Q water) at 20°C. 
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Figure S2. Thermal cis-trans relaxation of glycodendrimers A) Man(3,5)8 1, B) Man(3,5)2Et8 
2, C) Man(3,5)12 3 and D) Man(3,4,5)2Et8 4 (0.05 mM in Milli-Q water) at 37°C. 
 
 
 
Figure S3. Time dependence of the absorbance changes at 325 nm for thermal cis-to-trans 
isomerization of glycodendrimers 1–4 in the dark in Milli-Q water at 20ºC and 37ºC. 
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Figure S4. 1H NMR spectra of Man(3,5)8 1 before UV photoirradiation (top), after UV 
photoirradiation (middle), and after blue light photoirradiation (bottom). 
 
 
Figure S5. 1H NMR spectra of Man(3,5)2Et8 2 before UV photoirradiation (top), after UV 
photoirradiation (middle), and after blue light photoirradiation (bottom). 
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Figure S6. 1H NMR spectra of Man(3,5)12 3 before UV photoirradiation (top), after UV 
photoirradiation (middle), and after blue light photoirradiation (bottom). 
 
Figure S7. 1H NMR spectra of Man(3,4,5)2Et8 4 before UV photoirradiation (top), after UV 
photoirradiation (middle), and after blue light photoirradiation (bottom)  
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Figure S8. UV-vis absorbance of A) Man(3,5)8 1, B) Man(3,5)2Et8 2, C) Man(3,5)12 3 and 
D) Man(3,4,5)2Et8 4 in Milli-Q water at 20°C under different concentrations. (Insets) Plots of 
the UV-vis absorbance measured at 325 nm as a function of concentration. 
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Figure S9. SANS data (symbols) and model fits (lines) for glycodendrimers 1–12 in the trans-
dominated PSS at a concentration of 0.1 mM in D2O. 
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Figure S10. SANS data (symbols) and model fits (lines) for glycodendrimer A) Man(3,5)8 1, 
B) Man(3,5)2Et8 2, C) Man(3,5)12 3 and D) Man(3,4,5)2Et8 4 in the trans PSS and cis PSS at 
a concentration of 0.1 mM in D2O. 
 
 
 
Figure S11. Representative example of the fluorescence polarization-based competitive 
binding assay of LecA with compounds 5–8 or methyl α-D-galactoside. 
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Figure S12. Representative example of the fluorescence polarization-based competitive 
binding assay of LecB with compounds 1–4 or methyl α-D-mannoside. 
 
 
 
Figure S13. Representative example of the fluorescence polarization-based competitive 
binding assay of LecB with compounds 9-12 or methyl α-L-fucoside. 
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Table S1. CAC values, DLS results, SANS fitting parameters and lectin binding results of 
glycodendrimer 1–12. 
 
Name CAC/mMa Naggb Ahgc/nm2 
Eff. Diam./nm (PDI)d SANSe 
Before UV After UV Radius/Å Length/Å 
1 0.0086 138 1.07 112(0.21) 199(0.17) 34 104 
2 0.0046 128 1.07 149 (0.23) 226 (0.15) 32 104 
3 0.0023 918 0.79 109 (0.24) 109 (0.39) 39 550 
4 0.0086 795 0.87 105 (0.25) 111 (0.24) 36 574 
5 0.0085 162 0.98 110 (0.20) 138 (0.18) 35 109 
6 0.0092 149 1.01 138 (0.26) 147 (0.20) 33 112 
7 0.0080 1424 0.79 114 (0.23) 102 (0.18) 38 903 
8 0.0100 536 0.90 102 (0.23) 91 (0.19) 35 406 
9 0.0200 182 0.97 110 (0.29) 159 (0.24) 37 115 
10 0.0085 1603 0.71 183 (0.21) 119 (0.25) 38 921 
11 0.0048 799 0.78 123 (0.17) 129 (0.18) 41 441 
12 0.0054 996 0.96 134 (0.17) 138 (0.19) 32 915 
 
a Measured in ultrapure water at 20°C; b Nagg = aggregation number; c Ahg = area per headgroup; 
d DLS samples were prepared at 0.1 mM; e SANS samples were dissolved in D2O at 0.1 mM, 
and were all fitted to cylindrical shaped structure.  
 
 
Analytical data 
Man(3,5)8 1: This compound was prepared from 27 and 31 according to general procedure 3 
and isolated as an orange solid (Yield: 45%). Mp = 212.4°C; [α]D20 111.6 (c, 0.06 in CH3OH); 
FT-IR: νmax/cm-1 3413, 2922, 1735, 1593, 1348, 1092, 840, 674; 1H NMR (400 MHz, 10% 
CD3OD in CDCl3) δ 7.93 (d, J = 8.85 Hz, 2H, 2×ArH), 7.84 (d, J = 8.42 Hz, 2H, 2×ArH), 7.71–
7.70 (m, 2H, 2×ArH), 7.55 (d, J = 8.55 Hz, 2H, 2×ArH), 7.30–7.24 (m, 4H, 2×ArH, 2×CH 
(triazole)), 6.65 (t, J = 2.23 Hz, 1H, ArH), 5.46 (s, 1H, CH), 4.78–4.44 (m, 14H), 4.18–3.56 (m, 
54H), 3.02–2.99 (m, 2H), 2.59 (s, 8H, 4×CH2), 1.75–1.68 (m, 4H, 2×CH2), 1.40–1.21 (m, 20H, 
10×CH2), 0.80 (t, J = 6.72 Hz, 6H, 2×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) δ 
172.4, 172.1, 160.3, 144.8, 126.9, 124.1, 122.7, 122.4, 108.2, 99.9, 72.8, 71.1, 70.3, 69.6, 69.4, 
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68.9, 68.4, 65.4, 64.2, 63.9, 49.9, 49.1, 48.9, 37.2, 31.7, 29.2, 29.1, 28.9, 28.8, 25.9, 22.6, 13.9; 
ESI-HRMS (m/z) calculated for C83H122N8O32 = 1765.8057 [M + Na]+, found 1765.8063 [M + 
Na]+. 
 
Man(3,5)2Et8 2: This compound was prepared from 28 and 31 according to general procedure 
3 and isolated as an orange solid (Yield: 42%). Mp = 203.7°C; [α]D20 103.0 (c, 0.065 in 
CH3OH); FT-IR: νmax/cm-1 3395, 2925, 1735, 1595, 1347, 1030, 841, 673; 1H NMR (400 MHz, 
10% CD3OD in CDCl3) δ 7.93 (d, J = 7.53 Hz, 2H, 2×ArH), 7.84 (d, J = 7.41 Hz, 2H, 2×ArH), 
7.72 (s, 2H, 2×ArH), 7.55 (d, J = 7.56 Hz, 2H, 2×ArH), 7.31–7.24 (m, 4H, 2×ArH, 2×CH 
(triazole)), 6.66 (s, 1H, ArH), 5.46 (s, 1H, CH), 4.69–4.44 (m, 14H), 4.16–3.49 (m, 54H), 3.01–
2.99 (m, 2H), 2.59 (s, 8H, 4×CH2), 1.68–1.63 (m, 2H, 2×CH), 1.49–1.25 (m, 16H, 8×CH2), 
0.88–0.83 (m, 12H, 4×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) δ 172.4, 172.1, 
160.5, 144.7, 126.9, 124.2, 124.1, 122.7, 122.4, 108.2, 99.8, 72.7, 70.8, 70.3, 69.6, 69.4, 68.9, 
65.4, 64.2, 63.9, 60.9, 49.9, 49.3, 49.1, 48.9, 48.7, 39.3, 37.2, 30.4, 29.0, 28.8, 23.8, 22.9, 13.9, 
11.0; ESI-HRMS (m/z) calculated for C83H122N8O32 = 1765.8057 [M + Na]+, found m/2z 
894.3980 [M + 2Na]+. 
 
Man(3,5)12 3: This compound was prepared from 29 and 31 according to general procedure 3 
and isolated as an orange solid (Yield: 49%). Mp = 189.9°C; [α]D20 105.4 (c, 0.055 in CH3OH); 
FT-IR: νmax/cm-1 3396, 2921, 1736, 1591, 1351, 1094, 841; 1H NMR (400 MHz, 10% CD3OD 
in CDCl3) δ 7.96 (d, J = 8.28 Hz, 2H, 2×ArH), 7.87 (d, J = 8.01 Hz, 2H, 2×ArH), 7.76 (s, 2H, 
2×ArH), 7.58 (d, J = 8.01 Hz, 2H, 2×ArH), 7.33–7.20 (m, 4H, 2×ArH, 2×CH (triazole)), 6.68 
(s, 1H, ArH), 5.48 (s, 1H, CH), 4.73–4.47 (m, 14H), 4.19–3.59 (m, 54H), 3.05–3.03 (m, 2H), 
2.62 (s, 8H, 4×CH2), 1.76–1.71 (m, 4H, 2×CH2), 1.42–1.21 (m, 32H, 16×CH2), 0.84–0.81 (m, 
6H, 2×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) δ 172.4, 172.1, 160.3, 144.7, 126.9, 
124.1, 122.7, 122.4, 108.2, 99.8, 70.3, 69.6, 68.9, 68.4, 65.4, 64.1, 63.8, 49.9, 49.3, 49.1, 48.9, 
37.2, 31.8, 29.5, 29.3, 29.1, 28.9, 28.8, 25.9, 22.6, 13.9; ESI-HRMS (m/z) calculated for 
C91H138N8O32 = 1877.9309 [M + Na]+, found m/2z 950.9617 [M + 2Na]+. 
 
Man(3,4,5)2Et8 4: This compound was prepared from 30 and 31 according to general procedure 
3 and isolated as an orange solid (Yield: 51%). Mp = 233.8°C; [α]D20 80.0 (c, 0.08 in CH3OH); 
FT-IR: νmax/cm-1 3395, 2928, 1735, 1331, 1094, 837; 1H NMR (400 MHz, 10% CD3OD in 
CDCl3) δ 7.93 (d, J = 8.68 Hz, 2H, 2×ArH), 7.84 (d, J = 8.21 Hz, 2H, 2×ArH), 7.73 (s, 2H, 
2×ArH), 7.55 (d, J = 8.21 Hz, 2H, 2×ArH), 7.34–7.27 (m, 4H, 2×ArH, 2×CH (triazole)), 5.46 
  126 
SUPPORTING INFORMATION 
  
S12 
 
(s, 1H, CH), 4.78–4.43 (m, 14H), 4.17–3.56 (m, 56H), 3.02–3.00 (m, 2H), 2.59 (s, 8H, 4×CH2), 
1.71–1.25 (m, 27H, 3×CH, 12×CH2), 0.88–0.82 (m, 18H, 6×CH3); 13C NMR (100 MHz, 10% 
CD3OD in CDCl3) δ 172.4, 172.1, 153.1, 150.1, 144.7, 143.1, 126.9, 124.2, 124.1, 123.3, 122.7, 
122.5, 108.0, 99.8, 71.3, 71.0, 70.3, 69.6, 69.4, 68.9, 66.5, 65.4, 64.1, 63.8, 60.9, 49.9, 49.2, 
49.0, 48.8, 48.6, 40.6, 39.5, 37.2, 30.4, 30.3, 29.2, 29.0, 28.9, 28.8, 23.8, 23.6, 23.0, 22.9, 13.9, 
11.0; ESI-HRMS (m/z) calculated for C91H138N8O33 = 1893.9259 [M + Na]+, found 1893.9246 
[M + Na]+. 
 
Gal(3,5)8 5: This compound was prepared from 27 and 32 according to general procedure 3 
and isolated as an orange solid (Yield: 44%). Mp = 205.3°C; [α]D20 148.6 (c, 0.055 in CH3OH); 
FT-IR: νmax/cm-1 3395, 2923, 1734, 1893, 1350, 1038, 840; 1H NMR (400 MHz, 10% CD3OD 
in CDCl3) δ 7.96–7.83 (m, 6H, 4×ArH, 2×CH (triazole)), 7.58–7.55 (m, 2H, 2×ArH), 7.35–
7.25 (m, 4H, 4×ArH), 6.68–6.63 (m, 1H, ArH), 5.48–5.46 (m, 1H, CH), 4.58–4.44 (m, 10H), 
4.17–4.06 (m, 10H), 3.97–3.84 (m, 10H), 3.69–3.29 (m, 40H), 2.61–2.59 (m, 8H, 4×CH2), 
1.76–1.69 (m, 4H, 2×CH2), 1.41–1.22 (m, 20H, 10×CH2), 0.82–0.79 (m, 6H, 2×CH3); 13C NMR 
(100 MHz, 10% CD3OD in CDCl3) δ 172.4, 160.3, 144.5, 126.9, 124.6, 124.1, 122.7, 122.4, 
108.2, 103.4, 74.7, 73.3, 70.9, 70.3, 69.5, 68.9, 68.4, 67.8, 64.2, 63.8, 61.2, 50.3, 49.3, 49.1, 
48.9, 31.7, 29.2, 29.1, 28.9, 28.8, 25.9, 22.5, 13.9; ESI-HRMS (m/z) calculated for 
C83H122N8O32 = 1765.8057 [M + Na]+, found m/2z 894.3968 [M + 2Na]+. 
 
Gal(3,5)2Et8 6: This compound was prepared from 28 and 32 according to general procedure 
3 and isolated as an orange solid (Yield: 54%). Mp = 201.1°C; [α]D20 175.7 (c, 0.05 in CH3OH); 
FT-IR: νmax/cm-1 3395, 2928, 1734, 1595, 1347, 1035, 843, 756; 1H NMR (400 MHz, 10% 
CD3OD in CDCl3) δ 8.16 (d, J = 8.75 Hz, 2H, 2×ArH), 8.10–8.07 (m, 4H, 2×ArH, 2×CH 
(triazole)), 7.78 (d, J = 8.29 Hz, 2H, 2×ArH), 7.53 (d, J = 8.54 Hz, 2H, 2×ArH), 7.48 (s, 2H, 
2×ArH), 6.89 (s, 1H, ArH), 5.69 (s, 1H, CH), 4.79–4.67 (m, 10H), 4.39–4.29 (m, 10H), 4.11–
4.03 (m, 12H), 3.90–3.66 (m, 34H), 2.83 (s, 8H, 4×CH2), 1.91–1.88 (m, 2H, 2×CH), 1.68–1.48 
(m, 16H, 8×CH2), 1.11–1.06 (m, 12H, 4×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) 
δ 172.5, 172.1, 160.5, 153.1, 144.5, 126.9, 124.6, 124.2, 122.7, 122.4, 108.2, 70.8, 70.3, 69.5, 
68.9, 64.2, 63.8, 49.6, 49.4, 49.2, 48.9, 39.3, 37.2, 30.5, 29.0, 28.8, 23.8, 22.9, 13.9, 11.0. ESI-
HRMS (m/z) calculated for C83H122N8O32 = 1765.8057 [M + Na]+, found m/2z 894.3987 [M + 
2Na]+. 
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Gal(3,5)12 7: This compound was prepared from 29 and 32 according to general procedure 3 
and isolated as an orange solid (Yield: 42%). Mp = 187.5°C; [α]D20 156.7 (c, 0.065 in CH3OH); 
FT-IR: νmax/cm-1 3395, 2921, 1732, 1592, 1350, 1037, 840, 754; 1H NMR (400 MHz, 10% 
CD3OD in CDCl3) δ 8.21 (d, J = 8.70 Hz, 2H, 2×ArH), 8.15–8.12 (m, 4H, 2×ArH, 2×CH 
(triazole)), 7.84 (d, J = 8.44 Hz, 2H, 2×ArH), 7.76 (s, 2H, 2×ArH), 7.58 (d, J = 8.82 Hz, 2H, 
2×ArH), 7.53–7.52 (m, 4H, 2×ArH), 6.94 (s, 1H, ArH), 5.74 (s, 1H, CH), 4.85–4.72 (m, 10H), 
4.45–4.35 (m, 10H), 4.23–4.09 (m, 12H), 3.95–3.69 (m, 34H), 2.88 (s, 8H, 4×CH2), 2.02–1.97 
(m, 4H, 2×CH2), 1.69–1.64 (m, 4H, 2×CH2), 1.47 (s, 28H, 14×CH2), 1.09–1.06 (m, 6H, 
2×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) δ 160.3, 144.5, 126.9, 124.6, 124.2, 
122.7, 122.4, 108.3, 74.7, 70.3, 69.6, 68.9, 68.4, 64.2, 63.8, 49.4, 49.2, 48.9, 31.8, 29.6, 29.5, 
29.3, 29.1, 28.9, 25.9, 22.6, 13.9. ESI-HRMS (m/z) calculated for C91H138N8O32 = 1877.9309 
[M + Na]+, found 1877.9312 [M + Na]+. 
 
Gal(3,4,5)2Et8 8: This compound was prepared from 30 and 32 according to general procedure 
3 and isolated as an orange solid (Yield: 40%). Mp = 223.7°C; [α]D20 62.6 (c, 0.075 in CH3OH); 
FT-IR: νmax/cm-1 3400, 2922, 1731, 1585, 1331, 1093, 839, 751; 1H NMR (400 MHz, 10% 
CD3OD in CDCl3) δ 8.16–8.14 (m, 2H, 2×ArH), 8.09–8.05 (m, 4H, 2×ArH, 2×CH (triazole)), 
7.78–7.76 (m, 2H, 2×ArH), 7.56–7.47 (m, 4H, 4×ArH), 5.68 (s, 1H, CH), 4.78–4.66 (m, 10H), 
4.38–4.28 (m, 10H), 4.14–4.04 (m, 12H), 3.89–3.65 (m, 34H), 2.81 (s, 8H, 4×CH2), 1.94–1.47 
(m, 27H, 3×CH, 12×CH2), 1.10–1.04 (m, 18H, 6×CH3); 13C NMR (100 MHz, 10% CD3OD in 
CDCl3) δ 172.5, 172.2, 164.9, 153.1, 144.5, 126.9, 124.1, 122.7, 122.5, 108.0, 103.4, 74.6, 71.3, 
70.3, 69.5, 68.9, 67.8, 64.2, 63.9, 50.3, 49.3, 49.2, 48.9, 40.6, 39.5, 37.2, 30.5, 30.3, 29.2, 29.0, 
28.9, 23.8, 23.6, 23.0, 22.9, 14.0, 13.9, 11.0. ESI-HRMS (m/z) calculated for C91H138N8O33 = 
1893.9259 [M + Na]+, found m/2z 958.9582 [M + 2Na]+. 
 
Fuc(3,5)8 9: This compound was prepared from 27 and 33 according to general procedure 3 
and isolated as an orange solid (Yield: 46%). Mp = 153.8°C; [α]D20 66.6 (c, 0.085 in CH3OH); 
FT-IR: νmax/cm-1 3409, 2921, 1735, 1595, 1348, 1032, 841, 754; 1H NMR (400 MHz, 10% 
CD3OD in CDCl3) δ 7.94–7.74 (m, 6H, 4×ArH, 2×CH (triazole)), 7.56–7.54 (m, 2H, 2×ArH), 
7.33–7.17 (m, 4H, 4×ArH), 6.65–6.64 (m, 1H, ArH), 5.46 (m, 1H, CH), 4.71–4.43 (m, 12H), 
4.16–4.06 (m, 8H), 3.95–3.83 (m, 10H), 3.66–3.41 (m, 34H), 2.60 (s, 8H, 4×CH2), 1.72–1.70 
(m, 4H, 2×CH2), 1.39–1.37 (m, 4H, 2×CH2), 1.21 (s, 18H, 6×CH2, 2×CH3), 1.09–0.79 (m, 4H, 
2×CH2), 0.80–0.79 (m, 6H, 2×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) δ 172.4, 
172.0, 160.3, 153.0, 152.8, 126.9, 124.1, 122.7, 122.3, 108.2, 101.4, 98.9, 71.7, 70.3, 69.5, 69.3, 
  128 
SUPPORTING INFORMATION 
  
S14 
 
68.9, 68.5, 68.4, 66.3, 65.8, 63.8, 49.4, 49.2, 48.9, 48.7, 48.5, 37.2, 31.7, 29.2, 29.1, 29.0, 28.9, 
28.7, 25.9, 22.5, 15.9, 13.9. ESI-HRMS (m/z) calculated for C83H122N8O30 = 1733.8159 [M + 
Na]+, found 1733.8152 [M + Na]+. 
 
Fuc(3,5)2Et8 10: This compound was prepared from 28 and 33 according to general procedure 
3 and isolated as an orange wax (Yield: 34%). [α]D20 78.7 (c, 0.07 in CH3OH); FT-IR: νmax/cm-
1 3438, 2925, 1735, 1592, 1350, 1092, 843, 754; 1H NMR (400 MHz, 10% CD3OD in CDCl3) 
δ 7.94 (d, J = 8.68 Hz, 2H, 2×ArH), 7.86–7.83 (m, 4H, 2×ArH, 2×CH (triazole)), 7.56 (d, J = 
8.37 Hz, 2H, 2×ArH), 7.30 (d, J = 8.68 Hz, 2H, 2×ArH), 7.25–7.24 (m, 2H, 2×ArH), 6.67–6.66 
(m, 1H, ArH), 5.46–5.44 (s, 1H, CH), 4.72–4.36 (m, 12H), 4.18–4.06 (m, 10H), 3.89–3.79 (m, 
14H), 3.62–3.41 (m, 28H), 2.60 (s, 8H, 4×CH2), 1.69–1.62 (m, 2H, 2×CH), 1.39–1.25 (m, 14H, 
7×CH2), 1.10–1.08 (m, 2H, CH2), 0.88–0.81 (m, 18H, 6×CH3); 13C NMR (100 MHz, 10% 
CD3OD in CDCl3) δ 172.4, 164.9, 160.5, 126.9, 124.1, 122.7, 122.4, 108.2, 70.8, 70.4, 69.6, 
69.4, 68.9, 66.3, 65.9, 64.3, 63.8, 49.9, 49.5, 49.2, 49.0, 48.8, 39.3, 37.2, 30.4, 28.9, 28.8, 23.8, 
22.9, 15.9, 13.9, 10.9. ESI-HRMS (m/z) calculated for C83H122N8O30 = 1733.8159 [M + Na]+, 
found m/2z 878.4021 [M + 2Na]+. 
 
Fuc(3,5)12 11: This compound was prepared from 29 and 33 according to general procedure 3 
and isolated as an orange solid (Yield: 47%). Mp = 146.4°C; [α]D20 76.5 (c, 0.065 in CH3OH); 
FT-IR: νmax/cm-1 3413, 2923, 1735, 1592, 1348, 1091, 842, 754; 1H NMR (400 MHz, 10% 
CD3OD in CDCl3) δ 7.94–7.84 (m, 6H, 4×ArH, 2×CH (triazole)), 7.57–7.55 (m, 2H, 2×ArH), 
7.31–7.17 (m, 4H, 4×ArH), 6.66–6.65 (m, 1H, ArH), 5.46 (s, 1H, CH), 4.72–4.39 (m, 12H), 
4.17–4.06 (m, 8H), 3.97–3.83 (m, 12H), 3.65–3.36 (m, 32H), 2.60 (s, 8H, 4×CH2), 1.72–1.71 
(m, 4H, 2×CH2), 1.39–1.38 (m, 4H, 2×CH2), 1.19 (s, 30H, 2×CH3, 12×CH2), 1.09–1.08 (m, 4H, 
2×CH2), 0.81–0.78 (m, 6H, 2×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) δ 172.4, 
160.3, 126.9, 124.4, 124.1, 122.7, 122.3, 108.2, 98.9, 71.7, 70.3, 69.5, 69.4, 68.9, 68.5, 68.4, 
66.3, 65.9, 64.3, 63.8, 49.9, 49.4, 49.2, 49.0, 48.8, 37.2, 31.8, 29.5, 29.2, 29.0, 28.8, 25.9, 22.6, 
15.9, 13.9. ESI-HRMS (m/z) calculated for C91H138N8O30 = 1845.9411 [M + Na]+, found m/2z 
934.9670 [M + 2Na]+. 
 
Fuc(3,4,5)2Et8 12: This compound was prepared from 30 and 33 according to general 
procedure 3 and isolated as an orange wax (Yield: 37%). [α]D20 130.0 (c, 0.03 in CH3OH); FT-
IR: νmax/cm-1 3407, 2922, 1731, 1331, 1093, 840; 1H NMR (400 MHz, 10% CD3OD in CDCl3) 
δ 7.95–7.93 (m, 2H, 2×ArH), 7.86–7.84 (m, 2H, 2×ArH), 7.57–7.55 (m, 2H, 2×ArH), 7.35–
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7.27 (m, 4H, 4×ArH), 5.47 (s, 1H, CH), 4.83–4.44 (m, 10H), 4.18–4.06 (m, 10H), 3.89–3.34 
(m, 46H), 2.61 (s, 8H, 4×CH2), 1.71–1.64 (m, 3H, 3×CH), 1.52–1.09 (m, 30H, 2×CH3, 
12×CH2), 0.89–0.83 (m, 18H, 6×CH3); 13C NMR (100 MHz, 10% CD3OD in CDCl3) δ 172.4, 
172.1, 172.0, 164.9, 153.2, 153.1, 152.8, 150.1, 143.1, 140.1, 126.9, 124.1, 123.3, 122.7, 122.5, 
108.0, 101.4, 71.3, 70.3, 69.4, 68.9, 63.8, 63.4, 62.7, 40.6, 39.5, 37.2, 30.5, 30.3, 29.2, 29.0, 
28.9, 28.8, 23.8, 23.6, 23.0, 22.9, 16.0, 13.9, 11.0. ESI-HRMS (m/z) calculated for 
C91H138N8O31 = 1861.9360 [M + Na]+, found m/2z 942.9638 [M + 2Na]+. 
 
3,5-dialkyloxybenzoic acid 13: This compound was prepared from methyl 3,5-
dihydroxybenzoate and 1-bromooctane according to general procedure 4, and was isolated as 
white solid (quantitative yield). Mp = 58.0°C; FT-IR: νmax/cm-1 2917, 1559, 1388, 1264, 1154, 
1015, 855, 720; 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 2.32 Hz, 2H, 2×ArH), 6.69 (t, J = 
2.37 Hz, 1H, ArH), 3.98 (t, J = 6.59 Hz, 4H, 2×CH2), 1.80–1.75 (m, 4H, 2×CH2), 1.48–1.28 
(m, 20H, 10×CH2), 0.91–0.87 (m, 6H, 2×CH3); 13C NMR (100 MHz, CDCl3) δ171.9, 160.2, 
130.9, 108.2, 107.5, 68.4, 31.8, 29.3, 29.2, 26.0, 22.7, 14.1; ESI-HRMS (m/z) calculated for 
C23H38O4=377.2697 [M - H]-, found 377.2697 [M - H]-. 
 
3,5-bis((2-ethylhexyl)oxy)benzoic acid 14: This compound was prepared from methyl 3,5-
dihydroxybenzoate and 2-ethylhexyl bromide according to general procedure 4, and was 
isolated as colorless liquid (quantitative yield). FT-IR: νmax/cm-1 2926, 1689, 1592, 1444, 1296, 
1166, 1053, 735; 1H NMR (400MHz, CDCl3) 7.23 (2H, d, J = 2.36 Hz), 6.69 (1H, t, J = 2.26 
Hz), 3.91–3.84 (4H, m), 1.77–1.68 (2H, m), 1.56–1.26 (16H, m), 0.96–0.88 (12H, m); 13C NMR 
(100 MHz, CDCl3) δ 172.2, 160.5, 131.0, 108.1, 107.5, 70.8, 39.4, 30.5, 29.1, 23.9, 23.3, 23.1, 
14.1, 11.1; ESI-HRMS (m/z) calculated for C23H38O4=377.2697 [M - H]-, found 377.2697 [M - 
H]-. 
 
3,5-bis(dodecayloxy)benzoic acid 15: This compound was prepared from methyl 3,5-
dihydroxybenzoate and 1-bromododecane according to general procedure 4, and was isolated 
as white solid (quantitative yield). Mp = 67.6°C; FT-IR: νmax/cm-1 2916, 1686, 1596, 1394, 
1316, 1161, 1058, 857, 669; 1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 2.33 Hz, 2H, 2×ArH), 
6.69 (t, J = 2.31 Hz, 1H, ArH), 3.98 (t, J = 6.50 Hz, 4H, 2×CH2), 1.80–1.77 (m, 4H, 2×CH2), 
1.47–1.44 (m, 4H, 2×CH2), 1.36–1.28 (m, 32H, 16×CH2), 0.88 (t, J = 7.06 Hz, 6H, 2×CH3); 
13C NMR (100 MHz, CDCl3) δ 171.7, 160.2, 130.9, 108.2, 107.5, 68.4, 31.9, 29.7, 29.6, 29.4, 
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29.2, 26.0, 22.7, 14.1; ESI-HRMS (m/z) calculated for C31H54O4=489.3949 [M - H]-, found 
489.3945 [M - H]-. 
 
3,4,5-tris((2-ethylhexyl)oxy)benzoic acid 16: This compound was prepared from methyl 3,4,5-
dihydrobenzoate and 2-ethylhexyl bromide according to general procedure 4, and was isolated 
as colorless liquid (quantitative yield). FT-IR: νmax/cm-1 2914, 1685, 1590, 1395, 1317, 1163, 
1059, 858, 669; 1H NMR (400 MHz, CDCl3) δ 7.33 (s, 2H, 2×ArH), 3.96–3.87 (m, 6H, 3×CH2), 
1.80–1.26 (m, 27H, 3×CH, 12×CH2), 0.96–0.89 (m, 18H, 4×CH3); 13C NMR (100 MHz, 
CDCl3) δ 171.7, 153.1, 143.2, 123.4, 108.1, 71.4, 40.6, 39.6, 30.5, 30.4, 29.3, 29.1, 23.8, 23.7, 
23.1, 14.1, 11.2, 11.1; ESI-HRMS (m/z) calculated for C31H54O5=505.3898 [M - H]-, found 
505.3892 [M - H]-. 
 
4-hydroxy-4’-formylazobenzene 171: A suspension of 2 g 4-aminobenzaldehyde  was prepared 
at 0°C in 11 mL water. At the same temperature was separately dissolved 1.1 g sodium nitrite 
in 8 mL water. To the suspension of 4-aminobenzaldehyde was simultaneously added at 
vigorous stirring the solution of sodium nitrite and 8 mL of 24% HCl solution. After 1 hour, a 
cooled to 0°C solution of 1.6 g phenol in 10 mL 6% NaOH solution was added to the reaction 
mixture. The end of the azo coupling was checked by TLC and the precipitate was filtered off 
to afford the final compound as brown-red solid (1.2g, 32%). Mp = 210°C; FT-IR: νmax /cm-1 
3308, 1670, 1584, 1281, 1128, 834; 1H NMR (400MHz, C3D6O) 10.07 (1H, s), 8.01 (2H, d, J 
= 8.53 Hz), 7.92 (2H, d, J = 8.53 Hz), 7.79 (2H, d, J = 8.91 Hz), 6.79 (2H, d, J = 8.88 Hz); 13C 
NMR (100 MHz, (CD3)2SO) δ 192.4, 177.7, 158.1, 140.7, 134.2, 131.2, 121.5, 120.6; ESI-
HRMS (m/z) calculated for C13H10N2O2=225.0669 [M - H]-, found 225.0670 [M - H]-. 
 
Compound 18: This compound was prepared from 13 and 17 according to general procedure 1 
and was isolated as an orange solid (Yield: 60%). Mp = 44.1°C; FT-IR: νmax/cm-1 2917, 1702, 
1594, 1444, 1295, 1161, 1053, 839, 752; 1H NMR (400 MHz, CDCl3) δ 10.10 (s, 1H, CHO), 
8.06–8.03 (m, 6H, 6×ArH), 7.40 (d, J = 8.89 Hz, 2H, 2×ArH), 7.33 (d, J = 2.35 Hz, 2H, 2×ArH), 
6.73 (t, J = 2.33 Hz, 1H, ArH), 4.01 (t, J = 6.60 Hz, 4H, 2×CH2), 1.84–1.77 (m, 4H, 2×CH2), 
1.49–1.44 (m, 4H, 2×CH2), 1.38–1.29 (m, 16H, 8×CH2), 0.89 (t, J = 6.95 Hz, 6H, 2×CH3). 13C 
NMR (100 MHz, CDCl3) δ 191.6 (CHO), 164.7 (C=O), 160.4, 155.8, 153.8, 150.2, 137.5, 
130.7, 124.6, 123.4, 122.6, 108.3, 107.4, 68.5 (CH2), 31.8 (CH2), 29.4 (CH2), 29.3 (CH2), 29.2 
(CH2), 26.0 (CH2), 22.7 (CH2), 14.1 (CH3). ESI-HRMS (m/z) calculated for 
C36H46N2O5=586.7730 [M + H]+, found 586.4662 [M + H]+. 
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Compound 19: This compound was prepared from 14 and 17 according to general procedure 1 
and was isolated as an orange wax (Yield: 56%). FT-IR: νmax/cm-1 2925, 1701, 1444, 1189, 
1034, 754; 1H NMR (400 MHz, CDCl3) δ 10.01 (s, 1H, CHO), 7.98–7.95 (m, 6H, 6×ArH), 7.32 
(d, J = 8.84 Hz, 2H, 2×ArH), 7.25 (d, J = 2.36 Hz, 2H, 2×ArH), 6.66 (t, J = 2.29 Hz, 1H, ArH), 
3.83-3.80 (m, 4H, 2×CH2), 1.67–1.64 (m, 4H, 2×CH), 1.46–1.23 (m, 16H, 8×CH2), 0.88–0.81 
(m, 12H, 4×CH3); 13C NMR (100 MHz, CDCl3) δ 191.6 (CHO), 164.8 (C=O), 160.6, 155.8, 
153.8, 150.2, 137.5, 130.7, 124.6, 123.4, 122.6, 108.3, 107.3, 70.8, 70.7, 39.4, 30.6, 29.1, 23.9, 
23.1, 14.1, 11.2 (CH3). ESI-HRMS (m/z) calculated for C36H46N2O5=587.3479 [M + H]+, found 
587.3477 [M + H]+. 
 
Compound 20: This compound was prepared from 15 and 17 according to general procedure 1 
and was isolated as an orange solid (Yield: 51%). Mp = 58.5°C; FT-IR: νmax/cm-1 2917, 1702, 
1594, 1347, 1165, 1046, 838, 752; 1H NMR (400 MHz, CDCl3) δ 10.01 (s, 1H, CHO), 7.97–
7.95 (m, 6H, 6×ArH), 7.31 (d, J = 8.73 Hz, 2H, 2×ArH), 7.24 (d, J = 2.04 Hz, 2H, 2×ArH), 
6.64 (s, 1H, ArH), 3.92 (t, J = 6.74 Hz, 4H, 2×CH2), 1.73–1.68 (m, 4H, 2×CH2), 1.39–1.35 (m, 
4H, 2×CH2), 1.18 (br s, 32H, 16×CH2), 0.79 (t, J = 6.49 Hz, 6H, 2×CH3); 13C NMR (100 MHz, 
CDCl3) δ 191.5 (CHO), 164.7 (C=O), 160.4, 155.8, 153.8, 150.2, 137.5, 130.7, 124.6, 123.4, 
122.6, 108.3, 107.4, 68.4, 31.9, 29.7, 29.6, 29.4, 29.2, 26.1, 22.7. ESI-HRMS (m/z) calculated 
for C44H62N2O5=697.4585 [M - H]-, found 697.5886 [M - H]-. 
 
Compound 21: This compound was prepared from 16 and 17 according to general procedure 1 
and was isolated as an orange wax (Yield: 61%). FT-IR: νmax/cm-1 2929, 1701, 1428, 1330, 
1180, 937, 752; 1H NMR (400 MHz, CDCl3) δ 10.14 (s, 1H, CHO), 8.10–8.08 (m, 6H, 6×ArH), 
7.46–7.43 (m, 4H, 4×ArH), 4.01–3.94 (m, 6H, 3×CH2), 1.83–1.36 (m, 27H, 3×CH, 12×CH2), 
0.99–0.94 (m, 18H, 6×CH3); 13C NMR (100 MHz, CDCl3) δ 191.6 (CHO), 164.8 (C=O), 155.8, 
153.9, 153.2, 150.2, 143.3, 137.5, 130.7, 124.6, 123.3, 122.7, 108.1, 71.4, 40.7, 39.6, 30.6, 29.1, 
23.9, 23.1, 14.1, 11.2. ESI-HRMS (m/z) calculated for C44H62N2O6=714.4602, found 714.5860. 
 
Compound 22: This compound was prepared from 18 according to general procedure 2 and was 
isolated as an orange solid (Yield: 61%). Mp = 139.4°C; FT-IR: νmax/cm-1 2923, 1739, 1590, 
1297, 1161, 1034, 754; 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J = 8.81 Hz, 2H, 2×ArH), 7.85 
(d, J = 8.27 Hz, 2H, 2×ArH), 7.55 (d, J = 8.36 Hz, 2H, 2×ArH), 7.29–7.25 (m, 4H, 4×ArH), 
6.65 (s, 1H, ArH), 5.41 (s, 1H, CH), 4.13–4.05 (m, 4H), 3.93 (t, J = 6.53 Hz, 4H, 2×CH2), 3.70 
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(d, J = 11.6Hz, 2H), 3.46 (s, 2H), 1.76–1.69 (m, 4H, 2×CH2), 1.39–1.35 (m, 4H, 2×CH2), 1.25–
1.18 (m, 16H, 8×CH2), 0.83–0.79 (m, 6H, 2×CH3); 13C NMR (100 MHz, CDCl3) δ 164.8 
(C=O), 160.4, 153.1, 152.8, 150.3, 140.6, 130.8, 126.9, 124.2, 122.9, 122.4, 108.3, 107.4, 
101.4, 70.1, 68.5, 65.4, 63.9, 38.9, 31.8, 29.4, 29.3, 29.2, 26.0, 14.1. ESI-HRMS (m/z) 
calculated for C41H56N2O8=705.4109 [M + H]+ 727.3928 [M + Na]+, found 705.4114 [M + H]+, 
727.3935 [M + Na]+. 
 
Compound 23: This compound was prepared from 19 according to general procedure 2 and was 
isolated as an orange solid (Yield: 53%). Mp = 123.6°C; FT-IR: νmax/cm-1 2927, 1743, 1592, 
1298, 1168, 1037, 752; 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.90 Hz, 2H, 2×ArH), 7.93 
(d, J = 8.68 Hz, 2H, 2×ArH), 7.63 (d, J = 8.41 Hz, 2H, 2×ArH), 7.37 (d, J = 8.84 Hz, 2H, 
2×ArH), 7.34 (d, J = 2.44 Hz, 2H, 2×ArH), 6.74 (t, J = 2.30 Hz, 1H, ArH), 5.49 (s, 1H, CH), 
4.18 (d, J = 11.76 Hz, 2H), 4.12 (s, 2H), 3.93–3.89 (m, 4H), 3.78 (d, J = 12.05 Hz, 2H), 3.54 
(s, 2H), 1.76–1.71 (m, 2H, 2×CH), 1.55–1.29 (m, 16H, 8×CH2), 0.97–0.89 (m, 12H, 4×CH3); 
13C NMR (100 MHz, CDCl3) δ 164.9 (C=O), 160.6, 153.1, 152.8, 150.3, 140.6, 130.8, 126.9, 
124.2, 122.9, 122.4, 108.2, 107.3, 101.4, 70.9, 70.0, 65.4, 63.9, 39.4, 38.9, 30.5, 29.1, 23.9, 
23.1, 14.1, 11.2. ESI-HRMS (m/z) calculated for C41H56N2O8= 705.4109 [M + H]+ 727.3928 
[M + Na]+, found 705.4113 [M + H]+, 727.3930 [M + Na]+. 
 
Compound 24: This compound was prepared from 20 according to general procedure 2 and was 
isolated as an orange solid (Yield: 57%). Mp = 132.0°C; FT-IR: νmax/cm-1 2919, 1747, 1595, 
1446, 1296, 1167, 1037, 754; 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.83 Hz, 2H, 2×ArH), 
7.93 (d, J = 8.66 Hz, 2H, 2×ArH), 7.63 (d, J = 8.41 Hz, 2H, 2×ArH), 7.37 (d, J = 8.90 Hz, 2H, 
2×ArH), 7.33 (d, J = 2.33 Hz, 2H, 2×ArH), 6.73 (t, J = 2.33 Hz, 1H, ArH), 5.49 (s, 1H, CH), 
4.19 (d, J = 11.87 Hz, 2H), 4.12 (s, 2H), 4.01 (t, J = 6.50 Hz, 4H), 3.78 (d, J = 11.87 Hz, 2H), 
3.53 (s, 2H), 1.82–1.78 (m, 4H, 2×CH2), 1.49–1.45 (m, 4H, 2×CH2), 1.37–1.27 (m, 32H, 
16×CH2), 0.88 (t, J = 6.65 Hz, 6H, 2×CH3); 13C NMR (100 MHz, CDCl3) δ 164.8 (C=O), 160.4, 
153.1, 152.8, 150.3, 140.6, 130.8, 126.9, 124.2, 122.9, 122.4, 108.3, 107.4, 101.4, 70.0, 68.5, 
65.4, 63.9, 38.9, 31.9, 29.7, 29.6, 29.4, 29.2, 26.0, 22.7, 14.1. ESI-HRMS (m/z) calculated for 
C49H72N2O8=817.5361 [M + H]+ 839.5180 [M + Na]+, found 817.5365 [M + H]+, 839.5185 [M 
+ Na]+. 
 
Compound 25: This compound was prepared from 21 according to general procedure 2 and was 
isolated as an orange solid (Yield: 46%). Mp = 92.5°C; FT-IR: νmax/cm-1 2925, 1735, 1584, 
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1428, 1332, 1182, 1093, 1008, 753; 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.84 Hz, 2H, 
2×ArH), 7.93 (d, J = 8.54 Hz, 2H, 2×ArH), 7.63 (d, J = 8.46 Hz, 2H, 2×ArH), 7.43 (s, 2H, 
2×ArH), 7.37 (d, J = 8.89 Hz, 2H, 2×ArH), 5.49 (s, 1H, CH), 4.20–4.12 (m, 4H), 3.98–3.93 (m, 
6H), 3.78 (d, J = 12.06 Hz, 2H), 3.53 (s, 2H), 2.64–2.61 (m, 2H), 1.80–1.32 (m, 27H, 3×CH, 
12×CH2), 0.98–0.89 (m, 18H, 6×CH3); 13C NMR (100 MHz, CDCl3) δ 164.9 (C=O), 153.2, 
152.8, 150.3, 143.2, 140.7, 126.9, 124.2, 123.4, 122.8, 122.6, 108.1, 101.4, 76.1, 71.4, 70.0, 
65.4, 63.9, 40.7, 39.6, 38.9, 30.6, 29.1, 23.9, 23.2, 14.1, 11.2. ESI-HRMS (m/z) calculated for 
C49H72N2O9=833.5810 [M + H]+ 855.5130 [M + Na]+, found 833.5314 [M + H]+, 855.5127 [M 
+ Na]+. 
 
14-oxo-4,7,10,13-tetraoxaheptadec-1-yn-17-oic acid 26: This compound was prepared 
according to literature procedure over two steps.2 Sodium hydride (2.6g, 65 mmol, 65 equiv. 
60% disperse in mineral oil) was slowly added to a solution of triethyleneglycol  (15.02g, 100 
mmol, 100 equiv.) in dry THF (75 mL) and the mixture stirred for 30 min at 0°C under N2. 
Propargyl bromide (5.4 mL, 50 mmol, 50 equiv.) was slowly injected to the reaction mixture, 
followed by stirring at 0°C for 2 hours and at room temperature for 20 hours. The mixture was 
poured into water, extracted with DCM, dried over Na2SO4 and purified by flash 
chromatography using EtOAc:hexane (3:2) as the eluent to afford the intermediate as pale 
yellow oil (3.95g, 43%). FT-IR: νmax/cm-1 2921, 2852, 1736, 1457, 1069; 1H NMR (400MHz, 
CDCl3) δ 5.15 (s, 1H, OH), 4.29–4.09 (m, 4H, 2×CH2), 3.68–3.54 (m, 10H, 5×CH2), 2.43–2.42 
(m, 1H, CH); 13C NMR (100 MHz, CDCl3) δ 79.5, 74.9, 72.4, 70.3, 70.2, 68.8, 61.2, 58.1; 
LCMS  (m/z) calculated for C9H16O4=189.1 [M + H]+, found 189.1 [M + H]+. The synthetic 
intermediate (2 g, 10.6 mmol, 1 equiv.) and succinic anhydride (1.28 g, 12.8 mmol, 1.2 equiv.) 
were dissolved in anhydrous DCM (10 mL) under N2. To this reaction mixture, triethylamine 
(1.48 mL, 10.6 mmol, 1 equiv.) was added dropwise. The reaction mixture was then stirred at 
room temperature for 24 hours under N2, before poured into water (60 mL) and neutralized with 
1N HCl. The organic layer was then washed with brine, dried over Na2SO4, concentrated under 
reduced pressure and purified by flash chromatography to afford the final product as pale yellow 
oil (2.02g, 68.3%). FT-IR: νmax/cm-1 1728, 1349, 1088, 834, 635; 1H NMR (400 MHz, CDCl3) 
δ 4.25–4.23 (m, 2H, CH2), 4.18 (d, J = 2.40 Hz, 2H, CH2), 3.69–3.64 (m, 11H, 5×CH2, CH), 
2.64 (s, 4H, CH2); 13C NMR (100 MHz, CDCl3) δ 176.2, 172.1, 79.6, 79.5, 74.9, 70.3, 70.2, 
70.1, 68.8, 63.7, 58.1, 28.8, 28.7; ESI-HRMS (m/z) calculated for C13H20O7=287.1136 [M - H]-
, found 287.1133 [M - H]-. 
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Compound 27: This compound was prepared from 22 and 26 according to general procedure 1 
and was isolated as an orange wax (Yield: 67%). FT-IR: νmax/cm-1 2923, 1735, 1592, 1348, 
1095, 843, 755; 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.92 Hz, 2H, 2×ArH), 7.91 (d, J = 
8.49 Hz, 2H, 2×ArH), 7.61 (d, J = 8.58 Hz, 2H, 2×ArH), 7.35 (d, J = 8.87 Hz, 2H, 2×ArH), 
7.31 (d, J = 2.24 Hz, 2H, 2×ArH), 6.70 (t, J = 2.27 Hz, 1H, ArH), 5.50 (s, 1H, CH), 4.51 (s, 
2H), 4.26–4.12 (m, 10H), 4.00–3.95 (m, 6H), 3.89–3.86 (m, 2H), 3.69–3.63 (m, 20H), 2.66 (s, 
8H, 4×CH2), 2.44–2.42 (m, 2H, 2×CH), 1.81–1.74 (m, 4H, 2×CH2), 1.47–1.41 (m, 4H, 2×CH2), 
1.36–1.27 (m, 16H, 8×CH2), 0.89–0.85 (m, 6H, 2×CH3); 13C NMR (100 MHz, CDCl3) δ 172.2, 
171.9, 164.7, 160.3, 153.1, 152.9, 150.2, 140.2, 130.9, 127.0, 124.2, 122.8, 122.4, 108.2, 101.5, 
79.7, 74.6, 70.6, 70.4, 69.5, 69.1, 69.0, 68.4, 63.9, 63.4, 62.7, 58.4, 37.3, 31.8, 29.3, 29.2, 29.1, 
29.0, 28.9, 26.0, 22.7, 14.1; ESI-HRMS (m/z) calculated for C67H92N2O20=1245.6316 [M + H]+ 
1267.6135 [M + Na]+, found 1245.6305 [M + H]+, 1267.6129 [M + Na]+. 
 
Compound 28: This compound was prepared from 23 and 26 according to general procedure 1 
and was isolated as an orange wax (Yield: 63%). FT-IR: νmax/cm-1 2929, 1734, 1592, 1347, 
1096, 841; 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.88 Hz, 2H, 2×ArH), 7.92 (d, J = 8.44 
Hz, 2H, 2×ArH), 7.63 (d, J = 8.49 Hz, 2H, 2×ArH), 7.37 (d, J = 8.84 Hz, 2H, 2×ArH), 7.32 (d, 
J = 2.33 Hz, 2H, 2×ArH), 6.73 (t, J = 2.30 Hz, 1H, ArH), 5.52 (s, 1H, CH), 4.52 (s, 2H), 4.27–
4.13 (m, 10H), 3.97–3.88 (m, 8H), 3.72–3.63 (m, 20H), 2.68 (s, 8H, 4×CH2), 2.44–2.42 (m, 2H, 
2×CH), 1.75–1.72 (m, 2H, 2×CH), 1.52–1.25 (m, 16H, 8×CH2), 0.95–0.89 (m, 12H, 4×CH3); 
13C NMR (100 MHz, CDCl3) δ 172.2, 171.1, 164.8, 160.6, 153.1, 152.9, 150.3, 140.2, 130.8, 
127.0, 124.4, 122.8, 122.4, 108.2, 101.5, 79.7, 74.6, 70.8, 70.6, 70.4, 69.5, 69.1, 63.9, 63.4, 
58.4, 39.4, 37.3, 33.9, 30.5, 29.1, 29.0, 28.9, 24.9, 23.9, 23.0, 14.1, 11.1; ESI-HRMS (m/z) 
calculated for C67H92N2O20=1245.6316 [M + H]+ 1267.6135 [M + Na]+, found 1245.6294 [M + 
H]+, 1267.6130 [M + Na]+. 
 
Compound 29: This compound was prepared from 24 and 26 according to general procedure 1 
and was isolated as an orange wax (Yield: 57%). FT-IR: νmax/cm-1 2926, 1735, 1593, 1348, 
1097, 841; 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.73 Hz, 2H, 2×ArH), 7.91 (d, J = 8.34 
Hz, 2H, 2×ArH), 7.62 (d, J = 8.35 Hz, 2H, 2×ArH), 7.37–7.31 (m, 4H, 4×ArH), 6.71 (s, 1H, 
ArH), 5.51 (s, 1H, CH), 4.51 (s, 2H), 4.27–4.13 (m, 10H), 4.01–3.87 (m, 8H), 3.71–3.63 (m, 
20H), 2.67 (s, 8H, 4×CH2), 2.44–2.42 (m, 2H, 2×CH), 1.86–1.75 (m, 4H, 4×CH2), 1.45–1.42 
(m, 4H, 2×CH2), 1.33–1.25 (m, 32H, 16×CH2), 0.88–0.85 (m, 6H, 2×CH3); 13C NMR (100 
MHz, CDCl3) δ 172.2, 171.9, 164.7, 160.4, 153.1, 152.9, 150.3, 140.2, 130.9, 127.0, 124.2, 
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122.8, 122.4, 108.2, 107.3, 101.5, 79.7, 74.6, 70.6, 70.5, 69.5, 69.1, 69.0, 68.4, 63.9, 63.4, 62.7, 
58.4, 37.3, 31.9, 29.7, 29.6, 29.4, 29.2, 29.0, 28.9, 26.0, 22.7, 14.1; ESI-HRMS (m/z) calculated 
for C75H108N2O20=1357.7568 [M + H]+ 1379.7387 [M + Na]+, found 1357.7605 [M + H]+, 
1379.7400 [M + Na]+. 
 
Compound 30: This compound was prepared from 25 and 26 according to general procedure 1 
and was isolated as an orange wax (Yield: 46%). FT-IR: νmax/cm-1 2932, 1731, 1333, 1183, 
1095, 1009, 938, 840, 755; 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.90 Hz, 2H, 2×ArH), 
7.92 (d, J = 8.44 Hz, 2H, 2×ArH), 7.62 (d, J = 8.48 Hz, 2H, 2×ArH), 7.41 (s, 2H, 2×ArH), 7.36 
(d, J = 8.93 Hz, 2H, 2×ArH), 5.51 (s, 1H, CH), 4.51 (s, 2H), 4.27–4.13 (m, 10H), 3.96–3.87 
(m, 8H), 3.71–3.63 (m, 20H), 2.67 (s, 8H, 4×CH2), 2.44–2.42 (m, 2H, 2×CH), 1.88–1.30 (m, 
27H, 3×CH, 12×CH2), 0.95–0.87 (m, 18H, 6×CH3); 13C NMR (100 MHz, CDCl3) δ 172.2, 
171.9, 164.8, 153.3, 153.2, 152.9, 150.2, 143.1, 140.2, 127.0, 124.2, 123.4, 122.8, 122.5, 108.1, 
101.5, 79.7, 74.6, 71.4, 70.6, 70.4, 69.5, 69.1, 69.0, 63.9, 63.4, 62.7, 58.4, 40.7, 39.6, 37.3, 
30.5,30.4, 29.3, 29.1, 29.0, 28.9, 23.9, 23.7, 23.1, 14.2, 14.1, 11.2; ESI-HRMS (m/z) calculated 
for C75H108N2O21=1373.7517 [M + H]+ 1395.7336 [M + Na]+, found 1373.7531 [M + H]+, 
1395.7316 [M + Na]+. 
 
2-azidoethyl α-D-mannopyranoside 31: This compound was prepared from α-D-mannose 
pentaacetate according to general procedure 5 and was isolated as white solid (Yield: 74%). Mp 
= 132.8°C; [α]D20 125.0 (c, 0.06 in CH3OH); FT-IR: νmax/cm-1 2922, 2100, 1559, 1406, 1287, 
1056, 648; 1H NMR (400 MHz, CD3OD) δ 4.85 (d, J = 1.48 Hz, 1H, H-1), 3.96–3.84 (m, 3H, 
H-2, H-3, H-4), 3.78–3.73 (m, 2H, H-6), 3.69–3.57 (m, 3H, H-5, CH2CH2N3), 3.45–3.42 (m, 
2H, CH2N3); 13C NMR (100 MHz, CD3OD) δ 100.4, 73.4, 71.0, 70.6, 67.1, 66.3, 61.3, 50.4; 
LCMS: m/z calculated for C8H15N3O6 = 272.1 [M + Na]+, found 272.1 [M + Na]+. 
 
2-azidoethyl β-D-galactopyranoside 32: This compound was prepared from β-D-galactose 
pentaacetate according to general procedure 5 and was isolated as colorless wax (Yield: 77%). 
[α]D20 18.9 (c, 0.19 in CH3OH); FT-IR: νmax/cm-1 2102, 1580, 1369, 1047; 1H NMR (400 MHz, 
CD3OD) δ 4.30 (d, J = 7.36 Hz, 1H, H-1), 4.07–4.01 (m, 1H, OCH), 3.89–3.88 (m, 1H, H-4), 
3.79–3.74 (m, 3H, H-2, H-3, OCH), 3.59–3.49 (m, 5H, H-5, CH2CH2N3, CH2N3); 13C NMR 
(100 MHz, CD3OD) δ 103.7, 75.3, 73.5, 71.1, 68.9, 67.8, 61.0, 50.7; LCMS (m/z) calculated 
for C8H15N3O6 = 272.1 [M + Na]+, found 272.1 [M + Na]+. 
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1H-NMR, 13C-NMR and 19F-NMR traces of synthesized compounds
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Table S1: Calculation of inhibition constants (Ki) from IC50 values
Kd (tracer 3) [µM]
concentration of 3 [µM]
compound
1
5
10
11
12
14
15
20
21
22
25
26
3.1
0.01
IC50 [µM] Ki [µM]
10.8 10.8
498 496.4
13 13.0
2.9 2.9
7.0 7.0
14.5 14.5
7.4 7.4
116 115.6
104 103.7
64 63.8
19 18.9
13.8 13.8
Calculation performed using the Cheng-Prusoff equation initially developed for competitive inhibition of 
enzymes (Cheng, Y.C. and Prusoff, W.H. Biochem. Pharm.,1973, 22:3099-108).
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1H-NMR trace of 35
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Figure S1. LecA heterologs found in a BLAST search using protein blast BLASTP 2.6.0+ and the 
sequence of LecA from P. aeruginosa PAO1 (GenBank AAG05958.1) against the non redundant 
nucleotide collection while excluding the genus Pseudomonas.
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Figure S2. Calibration of the size-exclusion chromatography column using 4 known proteins as 
molecular mass standards. The elution volume of PllA was 95 mL (see Figure 2).
Figure S3. Dynamic light scattering of (A) PllA and (B) LecA a suggested tetramer formation of both lectins 
in aqueous solution. 
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Scheme S1: Synthesis of allyl α-D-galactoside and methylation in position 3.
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Glu44
Asp103
Asp96
Gln57
Thr100
Figure S8. Molecular docking of D-galactosamine (10) in the PllA binding pocket. Interactions 
between ligand and protein or protein-bound calcium are indicated as dashed lines. The 
carbohydrate recognition domain of PllA is presented as cartoon with transparent surface. Ligand 
and amino acids forming interaction with the ligand are depicted as sticks colored by elements (N: 
blue, O: red, C: grey). The Ca2+-ion is shown as green sphere. 
Figure S9. (left) Molecular docking of methyl glycoside of Gal-α-1,3-Gal (20) in the PllA binding 
pocket. (right) Crystal structure of GS-IB4 in complex with methyl glycoside of 20 (pdb code: 
1HQL); Interactions between ligand and protein or protein-bound calcium are indicated as dashed 
lines. The carbohydrate recognition domain of PllA or GS-IB4 is presented as cartoon with 
transparent surface. Ligand and amino acids forming interaction with the ligand are depicted as 
sticks colored by elements (N: blue, O: red, C: grey). The Ca2+-ion is shown as green sphere.
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Figure S10. PllA bound to 1, additional angle of view. No interactions with the protein are observed 
beyond the carbohydrate moiety. The fluorescein can only  be observed as the result of fortuitous 
crystal contacts in half of the monomers in the asymmetric unit. PllA is shown as a yellow cartoon/
surface representation, ligand as grey sticks and the Ca2+ ion as green spheres.
                                                                                7
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Figure S11. Superposition of PllA (yellow) and LecA (PDB ID 4LKD, orange). Ca2+ ions are 
coloured to match proteins. 
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